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BACKGROUND AND RATIONALE OF THE STUDY 
Introduction 
This introductory chapter aims at providing the reader with the basic knowledge 
and background of what is known so far about monolithic columns in HPLC and their 
chromatographic retention mechanisms. Also, this chapter introduces the reader to the 
prefractionation and concentration methodologies of complex proteomics samples prior 
to their analysis by LC/MS-MS. 
 
Monolithic columns for HPLC 
Introductory remarks 
Monolithic stationary phases are “continuous separation media” that do not 
contain interstitial space (i.e., interparticle space). Two decades ago (year 1991), Hjerten 
and co-workers introduced monolithic stationary phases in which one piece of porous 
organic polymer filled the cylindrical column [1]. Five years later (year 1996), Minakuchi 
et al. developed monolithic columns based on inorganic silica matrices. The silica 
columns gave plate heights of 10-20 m for aromatic hydrocarbons. It was observed that 
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the performance of silica rods was better than particle columns for high molecular weight 
species [2].  Even though, they have been introduced recently, monolithic columns have 
rapidly become popular in HPLC due to their advantages of low back pressure drop, fast 
mass-transfer and simple preparation [3].   They possess good flow through pores that 
yield good permeability and enable separation at high flow rate, withstand pressure while 
generating good separation efficiency. Monolithic columns possess higher porosity than 
densely packed particle columns. This higher porosity leads to higher permeability and 
lower pressure drop [4]. Due to their small sized skeletons, high separation efficiency can 
be expected using monolithic columns. Monoliths can be molded into disks, tubes, 
microfluidic channels, capillary columns or regular sized columns [5, 6]. In developing 
monoliths one can tailor the surface interactive sites according to the solutes to be 
separated. Today, organic, inorganic and hybrid monolithic separation media are 
primarily used in HPLC. These monoliths have their own advantages and disadvantages.  
Organic polymer monoliths can be made out of organic polymer matrices such as 
polystyrenes, polymethacrylate esters, polyacrylamides and others [7-9]. Inorganic 
monoliths are mainly made out of silica polymers [10]. In addition to the monoliths 
mentioned above, nanotubes incorporated monoliths are also being developed for the 
rapid separations of a wide spectrum of analytes [11].  
Organic polymer monoliths are basically suited for separations of large molecules 
such as peptides and proteins and also they withstand high temperatures and a wide range 
of pH [9], while silica based monoliths show high separation efficiency towards small 
molecules [12]. Before monolithic columns gained popularity as stationary phases in 
HPLC, particulate columns were used. Particulate columns attempt to optimize the Eddy 
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diffusion term (A) and longitudinal molecular diffusion term (B) constants in the Van 
Deemter equation, but they are unable to address the mass transfer kinetics [13, 14]. 
Since in monolithic columns the mobile phase flowing through the stationary phase is the 
driving force for the mass transfer, the macropores enable a substantial increase in the 
separation speed of large molecules such as proteins [15, 16].  
This overview attempts to summarize the types of monolithic stationary phases 
used in HPLC and their applications. Each section explains the monomers and 
crosslinkers used in the column fabrication, any new techniques used in the column 
development, types of the solutes analyzed and polarity of the stationary phases.  
Although the emphasis of this dissertation is the development of non-polar monoliths that 
are primarily used in RPC, for the sake of completeness polar as well as other monoliths 
are being overviewed in this chapter. 
 
Organic polymer monoliths  
Nonpolar organic monoliths. Organic polymer-based monoliths are becoming 
increasingly popular due to the fact that they show good stability towards all pH values, 
temperatures and easy surface modification. These features have proven advantageous for 
the separation conditions of macromolecules such as proteins and relatively small 
carbohydrates and nucleotides under gradient elution conditions [17, 18].  
Organic polymer-based monoliths are usually fabricated via radical 
polymerization of crosslinking and functional monomers in the presence of a well-chosen 
porogenic solvent. The polymerization reaction is initiated with decomposition of a 
radical initiator, usually 2,2′-azobisisobutyronitrile (AIBN), and is facilitated with the 
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thermal initiation at a constant temperature using a water bath or a GC oven [19-21].  The 
polymerization begins with the formation of the nuclei, then the cross linking monomer 
starts to incorporate around the nuclei and gradually a heterogeneous polymer material 
fills the tubular column. Once the polymerization is completed, the monolith is washed 
extensively with organic solvent such as acetonitrile (ACN) or methanol (MeOH) to 
remove porogen and unreacted monomers.  
Polymer monoliths can be prepared from styrene, methacrylate, acrylate, 
acrylamide or using cyclic monomers e.g., cyclic olefin copolymers and cyclic norborn-
2-ene [8, 22, 23].  Alkyl methacrylate-based monolithic stationary phases of different 
hydrophobicity were constructed for reversed-phase chromatography (RPC) by thermally 
initiated radical polymerization. This involved the use of a series of alkyl methacrylates 
such as ethyl methacrylate (EMA), n-butyl methacrylate (BMA), n-hexyl methacrylate 
(HMA), n-lauryl methacrylate (LMA) and n-octadecyl methacrylate (ODMA), and the 
retention of alkyl benzenes were evaluated and found out that the ODMA-based column 
shows enhanced retention towards alkyl benzenes [24]. Another monolith was fabricated 
using the radical polymerization of ethylene dimethacrylate (EDMA) and BMA in the 
presence of porogenic solvent mixtures containing various concentration ratios of 1-
propanol, 1, 4-butanediol, and water with AIBN as the initiator. The RPC retention of the 
column thus obtained was evaluated using some benzene derivatives [25]. In another 
investigation, a series of monoliths was fabricated via a radical polymerization using 
alkyl methacrylate based monomers and EDMA as a cross linker, with different 
compositions of the porogens. Hydrodynamic and chromatographic properties of these 
monoliths were studied. Among the prepared monoliths, BMA yielded rigid macroporous 
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morphology and excellent hydrodynamic characteristics (flow rate up to 5 mL min
–1
). 
The monolith was evaluated using a mixture of benzene and its derivatives in the RPC 
mode. The separation efficiency was shown to increase with the addition of a lauryl 
methacrylate additive (LMA) in the polymerization mixture. The maximum separation 
efficiency achieved was 35 000 plates/meter for the monolith based on BMA with 7% 
LMA in the reaction mixture [26].   Construction of large volume monolithic columns 
was described using GMA-EDMA monolith.  Due to the exothermic nature of the 
polymerization reaction, the evolved heat affected the nature of the monolith. The 
temperature increase depends on the thickness of the monolith. This study has analyzed 
the heat released during the polymerization and derived a mathematical model for the 
prediction of the maximal thickness of the monolithic having a uniform structure [27]. 
A monolith fabricated using bisphenol A epoxy vinyl ester resin as the functional 
monomer and EDMA as the cross-linker was used as the stationary phase for HPLC. The 
column showed good reproducibility and efficiency for the baseline separation of 
benzene derivatives and halogenated derivatives using isocratic elution. The column 
showed a good reproducibility in terms of relative standard deviation (RSD) for the 
retention times from run-to-run, column-to-column and batch-to-batch (n=3) with RSD of 
0.98, 1.68, and 5.48, respectively [3]. Macroporous polymer monoliths based on 
poly(styrene-co-divinylbenzene) with varied styrene/divinylbenzene ratios have been 
prepared. The separation efficiency of small molecules (e.g., alkyl benzenes) was 
evaluated by HPLC under isocratic RPC mode. The use of tetrahydrofuran as a 
macroporogen and decanol as a microporogen for the fabrication of 
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poly(styrene/divinylbenzene) monolith yielded a column that enabled separation of 
peptides and proteins by the RPC mode [28].  
Monolithic columns were prepared via ring-opening metathesis polymerization 
(ROMP) within silanized fused silica capillaries with an internal diameter of 200 μm by 
in situ grafting using the polymerization of norborn-2-ene (NBE) and 1,4,4a,5,8,8a-
hexahydro-1,4,5,8-exo,endo-dimethanonaphthalene (DMN-H6) in a porogenic system 
ROMP initiator.  The column thus obtained was suitable for the separation of peptides 
[29].  
Polar organic monolithic stationary phases.  Polar organic polymer-based 
monolithic columns for hydrophilic interaction liquid chromatography (HILIC) can be 
fabricated by incorporating hydrophilic moieties in the polymer matrix. Monolithic 
columns were developed by an in situ reaction of tris (2, 3-epoxypropyl) isocyanurate 
with 4-[(4-aminocyclohexyl) methyl] cyclohexylamine in the presence of polyethylene 
glycol (PEG). The column thus obtained proved useful for the separation of nucleic bases 
and nucleosides [30]. In another report, a polar acrylamide based monolith was developed 
using in situ polymerization of piperazine, diacrylamide and methacrylamide with the 
addition of N-isopropyl acrylamide or a mixture of 2-hydroxymethacrylate and 
vinylsufonic acid, and the resulting monolith was evaluated with some aromatic polar 
compounds such as pyridine, 4-pyridylmethanol, 4-methoxyphenol, 2-naphthol, catechol, 
hydroquinone, resorcinol, 2,7-dihydroxynaphthalene [31].  
In a study by Foo et al. [32], a novel stationary phase for HILIC was reported. It 
involved the co-polymerization of zwitterionic N, N’-dimethyl-N-methacryloxyethyl-N-
(3-sulfopropyl) ammonium betaine (SPE) and the crosslinker 1, 2-bis (p-vinylphenyl) 
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ethane (BVPE). The chromatographic properties of the optimized poly (SPEco-BVPE) 
monolithic column were evaluated. Triplicate injections of the compounds thiourea, 
toluene and acrylamide were carried out with an average separation efficiency in the 
range of 26,888 to 35,930 [32].  
Chemical modification is another way to increase the number of binding sites for 
the desired analytes. These chemical modifications are easily achieved using the 
monomers such as chloromethyl styrene and divinylbenzene. Reaction of poly 
(chloromethylstyrene-co-divinylbenzene) with ethylenediamine followed by -
gluconolactone leads to a porous medium that has highly hydrophilic surface 
functionalities. The monolith thus obtained was tested with alkyl benzenes in the RPC 
mode and large proteins in the hydrophobic adsorption and ion exchange modes. The 
authors claimed that the modified monolith possessed a sufficient hydrophobicity that 
seems comparable to some of the existing hydrophilic HPLC packings [33]. 
Zwitterionic hydrophilic porous poly (SPV-co-MBA) monolithic column was 
fabricated by the thermal co-polymerization of 1-(3-sulphopropyl)-4-
vinylpyridiniumbetaine (4-SPV) and N, N’-methylenebisacrylamide (MBA). An 
HILIC/RPC dual separation mechanism was observed on this optimized poly (SPV-co-
MBA) monolithic column. The monolith yielded the baseline separation of nine benzoic 
acid derivatives using ACN gradient [34]. 
Some highlights of applications of organic polymer monoliths. Organic polymer 
monoliths are most suitable in the separation of relatively large molecules using linear 
gradient elution. The RPC separations of standard proteins have been investigated using 
commercial poly(styrene-co-divinylbenzene) monolithic columns (Dionex ProSwift™ 
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RP-2H and RP-4H) [35]. Alternative solvents to acetonitrile, such as 2-propanol and 
methanol, coupled with elevated temperatures demonstrated complementary approaches 
to adjusting separation selectivity and reducing organic solvent consumption.  
Measurements of peak area at increasing isothermal temperature intervals indicated that 
only minor (<5%) decreases in detectable protein recovery occurred between 40 and 100° 
on the timescale of separation (2-5 min). The reduced viscosity of a 2-propanol/water 
eluent at elevated temperatures permitted coupling of three columns to increase peak 
production (defined as number of peaks/min) by 16.5%.  Finally, narrow-bore (1 mm i.d.) 
columns were found to provide a more suitable avenue to fast, high temperature (up to 
140°) separations. 
A novel monolith was fabricated using the copolymerization of bis (p-
vinylbenzyl) dimethylsilane (BVBDMS) with p-methylstyrene (MS) in the presence of 2-
propanol and toluene, using AIBN as the radical initiator.  The resulting monolith was 
used to separate proteins, peptides and oligonucleotides. Also, monolithic columns as 
applied to clinical analysis in the areas of  monitoring of therapeutic drug and drug abuse 
and trace compound analysis have been reviewed recently [13]. Furthermore, organic 
polymer monoliths have recently been applied to the analysis of peptides, proteins and 
trace contaminants in food samples, and the field has been reviewed very recently [36]. A 
sensitive chromatographic method utilizing a monolithic column of the poly (glycidyl 
methacrylate-co-ethylene dimethacrylate) type, which was further modified with 
quaternary amine groups, were developed for the determination of trace level bromate in 
food and drinking water. GMA/EDMA type prepared using in situ polymerization and 
further modified with quaternary amine, have been used in the analysis of bromates in 
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drinking water. Bromate was detected after post-column reaction with potassium iodide 
at 352 nm.  The parameters affecting the detection limit of bromate were studied in detail. 
This method showed good linearity over the concentration range 5.0-30 μg/L, short 
analysis time (8.5 min), and satisfactory relative standard deviation of the replicate 
analyses (n = 6, 0.043 %) with detection limit for bromate of 1.5 μg/L [37] .  
 
Inorganic monoliths  
Nonpolar inorganic monoliths. Besides silica- [10], zirconia- [38] and titania-
based monoliths  [39] have been recently developed. Among these materials, silica is an 
ideal support due to its favorable characteristics, such as good mechanical strength, high 
chemical and thermal stability, controllable pore structure and surface area, surface rich 
in silanol groups that can be modified, and non-swelling property [10]. Since it is the 
most widely used approach to prepare silica-based monoliths, the sol-gel method is 
described in next section.  
In the sol-gel process, the silica monolith is usually fabricated by utilizing 
tetramethoxysilane (TMOS) as a silica precursor and polyethylene oxide (PEO) as a pore-
forming agent [40]. The two components TMOS and PEO are dissolved under slightly 
acidic conditions and the resulting solution is filled into a suitable gelation tubes and 
heated at moderate temperature. These reaction conditions initiate the hydrolysis and 
polycondensation of the TMOS in the presence of the PEO.  Transfer of the sol to the gel 
state forming the silica and the phase separation of the silica-rich phase and the solvent-
rich phase happens simultaneously. The following two processes then take place in 
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parallel and compete with each other. The phase separation process that occurs after a 
specified reaction time determines the macroporous structure of the silica. In this stage, 
the silica-rich phase separates from the solvent-rich phase, building up the silica skeleton. 
Elimination of the solvent by drying in the solvent-rich phase then leads to the formation 
of the macropores. Further polycondensation reactions cause shrinkage of the rod, which 
then detaches from the inner surface of the gelation tube, allowing its removal. The 
polycondensation of the TMOS starts along the PEO chains forming H-bonds with the 
polymer and building up the silica consecutively. During this reaction, methanol is 
introduced to accumulate in "vacuoles" within the co-continuous silica-forming network. 
These "vacuoles" form the resulting macropores. Their size is determined by the 
concentration of the PEO added to the starting solution.  An increasing amount of PEO 
will lead to silica monoliths with decreasing macropore sizes [10].  
Recently, monolithic silica columns whose skeletons contained weakly connected 
porous silica microspheres were prepared [41]. The aging temperature was selected in the 
range of 25–30
 o
C, the mass ratio of PEG to TMOS in the range 0.10–0.20 and mass ratio 
of TMOS to H2O less than 0.5. Then, dispersed porous silica spheres were obtained by 
gentle grinding of the monolithic column using a mortar. After surface modification with 
C18, the silica microspheres with an average diameter of 5.4 m were packed and used 
for the HPLC of neutral, acidic, and basic compounds. The retention behavior was similar 
to that obtained on the commercially available 5 m C18 silica particles but the 5.4 m 
grounded silica microspheres showed better separation efficiency [41].  
Novel silica-based monolithic columns have been produced recently to achieve 
fast separation with low backpressure and good resolution. Although silica monoliths are 
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favored over polymeric monoliths due to their chemical/mechanical stability and non-
swelling property, the monolithic columns with randomly distributed pore structures were 
used so far, leading to eddy diffusion and peak broadening.  To overcome this drawback, 
a directional freezing and freeze drying method was used for the first time to produce 
aligned porous silica monoliths in a silica capillary from commercially available silica 
colloidal suspension.  Both silica and silica-polymer composite monoliths are produced 
and the full pore characterizations were performed.  These monoliths contain parallel 
microchannels and thus minimize eddy diffusion.  The HPLC tests on these monoliths 
under both normal phase and reversed phase conditions demonstrated the feasibility for 
use in chromatography.  The aligned microchannel structures of the monoliths can 
achieve efficient separation with significantly low backpressure, compared to 
conventional porous monoliths [42].  
In another development simple and comprehensive two-dimensional (2D)-HPLC 
was studied in a reversed-phase mode using monolithic silica columns for second-
dimension (2nd-D) separation [43]. Every fraction from the first column, 15 cm x 4.6-
mm i.d., packed with fluoroalkylsilyl-bonded (FR) silica particles, was subjected to the 
separation in the 2nd-D using one or two C18 monolithic silica columns (3 cm x 4.6-mm 
i.d.). Monolithic silica columns in the 2nd-D were eluted at a flow rate of up to 10 
mL/min with separation time of 30 s that meets the fractionation every 15-30 s at the first 
dimension (1st-D) operated at a flow rate of 0.4-0.8 mL/min. Three cases were studied. 
(1) In the simplest scheme of 2D-HPLC, effluent of the 1st-D was directly loaded into an 
injector loop of 2nd-D HPLC for 28 s, and 2 s was allowed for injection. (2) Two six-port 
valves each having a sample loops were used to hold the effluent of the 1st-D alternately 
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for 30 s for one 2nd-D column to affect comprehensive 2D-HPLC without the loss of 1st-
D effluent. (3) Two monolithic silica columns were used for 2nd-D by using a switching 
valve and two sets of 2nd-D chromatographs separating each fraction of the 1st-D 
effluent with the two 2nd-D columns alternately. In this case, two columns of the same 
C18 stationary phase or different phases, C18 and (pentabromobenzyloxy) propylsilyl-
bonded (PBB), could be employed at the 2nd-D, although the latter needed two 
complementary runs. The systems produced peak capacity of approximately 1000 in 
approximately 60 min in cases 1 and 2 and in approximately 30 min in case 3. The three 
stationary phases, FR, C18 and PBB, showed widely different selectivity from each other, 
making 2D separations possible. The simple and comprehensive 2D-HPLC utilizes the 
stability and high efficiency at high linear velocities of monolithic silica columns [43]. 
Recently, the chromatographic properties of a new type of monolithic silica rod 
columns were examined [44].  In this study, silica rod columns were prepared from 
tetramethoxysilane, modified with octadecylsilyl moieties, and encased in a stainless-
steel protective column with two polymer layers between the silica and the stainless-steel 
tubing.  A 25 cm column provided up to 45,000 theoretical plates for aromatic 
hydrocarbons, or a minimum plate height of about 5.5 μm, at optimum linear velocity of 
about 2.3 mm/s and back pressure of 7.5 MPa in an ACN-water (80/20, v/v) mobile phase 
at 40 ˚C.  The permeability of the column was similar to that of a column packed with 5 
μm particles, while the plate height value equivalent to that of a column packed with 2.5 
μm particles.  Generation of 80,000-120,000 theoretical plates was feasible with 
backpressure <30 MPa by employing two or three 25 cm columns connected in series.  
The use of the long columns enabled facile generation of large numbers of theoretical 
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plates in comparison with conventional monolithic silica columns or particulate columns 
[44].   
Polar inorganic monoliths.  HILIC is a valuable alternative to RPC separations for 
polar, weakly acidic or basic samples. The retention mechanism is based on the 
competition between the sample and the mobile phase for localized polar adsorption 
centers on the adsorbent surface, such as silanol groups on the surface of silica gel [45].  
Monolithic Titania columns were prepared by Randon et al. for the separation of 
naphthalene, caffeine, 7-(β-hydroxyethyl) theophylline and theophylline in HILIC. 
Titania monoliths were prepared from a mixture of titanium propoxide, hydrochloric 
acid, formamide and water. In order to obtain the macroporous titania monolith, synthesis 
parameters such as hydrolysis ratio, porogen type, precursor concentration, and drying 
step have been identified.  Standard xanthines were separated successfully in HLIC using 
the titania monolith thus prepared [46].  
Zirconia monolithic silica columns were fabricated to achieve a higher efficiency 
with a lower backpressure than traditional monoliths. In addition, zirconia has a higher 
thermal and chemical stability and specific surface properties. The monolith was able to 
separate mixture of amines, naphthalene, orthotoluidine, aniline and an alkoxybenzene 
mixture [47]. 
Highlights of applications of inorganic polymer monoliths. Inorganic polymer 
monoliths are useful for the high efficiency separation of small molecules. Especially, 
monolithic columns were used in the separation of biologically important compounds and 
pharmaceuticals. An HPLC method using fluorescence detection was developed for the 
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simultaneous determination of 21 derivatized 4-fluoro-7-nitro-2, 1, 3-benzoxadiazole 
(NBD-F) amino acids. The NBD-F derivatized amino acids were separated on a 
monolithic silica column (MonoClad C18-HS, 150 mm × 3 mm i.d.) [48]. Monolithic 
silica columns were used to separate mixtures of hydrophobic naturally occurring 
metabolites. These monolithic silica columns were able to separate polyprenols [49, 50]. 
Benzoic acid is a preservative and vanillin is a flavoring agent added to the food to 
enhance flavor. But adding synthetic vanillin to the food is illegal. Using titania based 
monolith, a simple and reliable method was developed to determine the benzoic acid and 
vanillin in food stuff [39].  
 
Hybrid monolithic stationary phases  
Monolithic columns made out of organic polymers such as polymethacrylates, 
polyacrylamides and polystyrenes, and the silica-based inorganic polymers were 
described in the above sections. These monoliths have their own advantages and 
disadvantages. The former monoliths can be generally prepared by in situ polymerization 
of organic monomers and crosslinkers in the presence of porogenic solvents while the 
latter is fabricated via a sol–gel process followed by a chemical modification of the 
matrix with different sialylation reagents. Organic polymer monoliths exhibit swelling or 
shrinkage while silica monoliths involve tedious fabrication procedures. An alternative to 
address these drawbacks is organic-silica hybrid monolithic column, which is receiving 
more and more attention as it possesses the advantages of easy fabrication, more pH 
stability, and less shrinkage. The field has been reviewed very recently [51]. 
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Very recently, hybrid monoliths synthesized via a sol-gel process have been reviewed in 
Ref. [51]. According to a recent review article, hybrid monoliths can be classified into 
two classes [52]  depending on the nature of the interface between the organic and 
inorganic moiety. Hybrid monoliths class I are based on weak interactions such as van 
der Waals forces, hydrogen bonding or electrostatic interactions between organic and 
inorganic parts, and obtained by the methods of impregnation, doping, or physical 
entrapment of organic species into sol–gel matrices. Hybrid monoliths of class II refer to 
monoliths possessing organic components strongly attached to the siloxane network via 
covalent bonds, and are typically prepared via co-condensation of alkoxysilane and 
organosilane reagents [53].  There are several chemical routes to synthesize these 
monoliths including (a) the encapsulation of organic components into silica monolith via 
sol–gel process, (b) the attachment of the desired organic functionality to sol–gel 
matrices by covalent bond formation and (c) direct synthesis into the final hybrid 
monoliths by using a functional organosilane. A detailed description of these routes can 
be found in a recent review [53].  
Monolith fabricated via sol-gel process consisting of hydrolysis and condensation 
reactions of tetraalkoxysilanes such as tetramethoxysilanes or tetraethoxysilanes are 
commonly used in research. A novel hydroxyl functionalized organic–inorganic hybrid 
monolithic column was fabricated via free radical copolymerization with sonication-
assisted] to decrease the time of the sol–gel process. Vinyltrimethoxysilane (VTMS) was 
used as the monomer and vinyl ester resin was used as both the monomer and crosslinker. 
The obtained column showed high permeability and low backpressure. The column was 
used to analyze lysozyme from egg white, and benzene derivatives [54]. In another 
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report, a hybrid monolith was fabricated using polycondensation of alkoxysilanes and in 




-deoxy)-Ph-β-CD and vinyl group on 
the pre-condensed siloxanes yielding the hybrid monolithic column of 
perphenylcarbamoylated β-cyclodextrin-silica (Ph-β-CD-silica), and the column was used 
for the enantioseperation of 13 different racemates [55]. In a more recent report, an 
epoxy-based organic–inorganic hybrid monolithic column was used to monitor the beta-
lactam antibiotics such as amoxicillin, cephradine, and cefazolin sodium in aquatic 
environment and milk using online solid phase extraction-HPLC [56]. Hybrid C8-silica 
monoliths functionalized with octyl groups was synthesized in a capillary column for 
nano-LC separations in the RPC mode. The resulting hybrid monoliths yielded retention 
factors comparable to those obtained on a C18 grafted silica monoliths for the nano-LC 
separation of alkyl benzenes. The authors reported separation efficiencies for alkyl 
benzenes that were the best ever recorded in nano-LC with hybrid monoliths [57]. Two 
zwitterionic organic-silica hybrid monolithic columns were successfully synthesized 
using [2-(methacryloyloxy)ethyl]dimethyl-(3-sulfopropyl)ammonium hydroxide (MSA) 
and 2-methacryloyloxyethyl phosphorylcholine (MPC) as the organic monomers. Polar 
compounds as well as neutral, acidic and basic analytes and small peptides were analyzed 
in the HILIC mode [58] on these columns.  
 
Highlights of the use of monolithic stationary phases in affinity chromatography 
Affinity monolith chromatography (AMC) is a type of liquid chromatography that 
uses a monolithic support having surface bound biologically active compounds as the 
stationary phase ligands. The field has been reviewed by Pfaunmiller et al. [59] and 
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Malik and Luke [60]. The retention mechanism is based on the specific and reversible 
interactions found in the biological systems, such as binding of an enzyme with a 
substrate, an antibody with an antigen, or binding of a glycoproteins with lectins [60]. In 
AMC the affinity columns can be fabricated using the monolithic materials such as 
organic polymers, silica, agarose and cryogels [59]. Stationary phase ligands used in 
AMC are antibodies, enzymes, proteins, lectins, immobilized metal ions and dyes [59]. In 
general, affinity columns whether made of monoliths or particulate materials are used 
extensively in many fields such as protein isolation, biomarker discovery, biochemical 
and chemical research, molecular biology, clinical testing, biotechnology, environmental 
analysis and biophysical measurements [61-65]. Monoliths used in affinity 
chromatography should exhibit high porosity, high permeability and low backpressure. 
Monoliths fabricated using glycidyl methacrylate (GMA) and ethylene glycol 
dimethacrylate (EDMA) are the most commonly used organic based affinity monoliths, 
and have been used in many applications. GMA/EDMA monolith is used in affinity 
chromatography due to several important characteristics of the monolith. The monolith is 
relatively easy to fabricate and hydrophilic in nature, thus eliminating nonspecific 
binding for most of the solutes [66]. The monolith can be easily modified to make it 
suitable for ligand attachment. By changing the porogen content, the monolith can be 
developed in various pore sizes, surface areas and shapes. The GMA/ EDMA monolith 
has been used in the identification of glycoprotein biomarkers from human breast cancer 
serum [67]. A multicolumn based fluidic system comprising GMA/EDMA monolithic 
micro columns with immobilized protein A, protein G′, and antibodies was used for the 
depletion of high abundance proteins in human serum [68].  Using metal ions as ligands 
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GMA/EDMA monolith was used in metal ion affinity chromatography for the 
simultaneous depletion and prefractionation of human serum prior to 2-DE for facilitating 
in-depth serum profiling [69]. GMM/ PETA monolith with specific immobilized lectins 
is emerging as a novel affinity monolith and was used in this dissertation for the 
capturing of sialylated glycoproteins from human serum. The GMM/PETA monolith was 
used for the capturing of human fucome form the breast cancer serum [67] . 
Affinity monoliths can also be prepared from cryogels, and the preparation of 
such monolithic matrices has been recently reviewed [60].  Briefly, a mixture of 
acrylamide, allyl glycidyl ether and N,N’-methylene bis-(acrylamide) is used in making 
the polymer. Affinity cryogel monolith with immobilized concavalin A (Con A) was used 
for the chromatographic separation of the cells mixture of Saccharomyces cerevisiae and 
Escherichia coli [70]. The bio particle such as cells capturing properties and detaching 
them from the stationary phase by deforming the monolith was studied by the different 
ligand–receptor pairs ( IgG–protein A, sugar–Con A, metal ion–chelating ligand) using 
cryogel monolith [71]. 
 
Nanotube incorporated monolithic columns 
Carbon nanotubes (CNT) have been recognized for having high strength and 
unique electronic properties. The unique physicochemical properties of CNT such as 
large surface –to –volume ratio, porous nature, low density, high strength, good thermal 
stability have made them very attractive for use in developing novel stationary phases for 
HPLC. Boron nitride nanotubes functionalized via quinuclidine-3-thiol with gold 
nanoparticles were incorporated into monolithic columns and enhanced separation was 
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achieved for benzene derivatives, naphthalene derivatives and alkyl parabens [11]. 
Increased separation of alkyl benzenes and uracil was observed with MWCNTs 
incorporated into GMM/EDMA monolith [72]. Also, (MWCNTs were incorporated into 
a mixture containing benzyl methacrylate (BMA) and ethylene dimethacrylate (EDMA) 
as co-monomers. The optimized porogenic mixture was a ternary solution composed of 
cyclohexanol, 1,4-butandiol and butanol, which resulted in a stable and homogeneous 
suspension. Six capillary columns with increasing amounts of MWCNT, from 0 to 0.4 
mg/mL, were prepared by thermal polymerization in 0.32 mm (i.d.) and 150 mm length 
fused silica tubing. The chromatographic evaluation showed that the synthesized 
monolithic beds were mechanically stable while their porosity and permeability increased 
with the MWCNTs content. The prepared capillary columns were tested for the 
separation of mixtures of ketones and phenols at an optimum flow rate of 2 μL/min. The 
results showed that incorporation of MWCNT slightly affected the retention while it 
enhanced the column efficiency by increasing the column efficiency by a factor of up to 
9. This effect corresponded also to an improved resolution and full separation of the 
solutes [73]. Recently, fast enantiomeric separation of underivatized amino acids was 
achieved with silica based carbon nanotube (CNT) monolithic columns coated with a 
pyrenyl derivative as chiral selector. This column was applied to the chiral separation of 
underivatized amino acids. As well, ultra-fast separations in the range of seconds were 




Strategies for prefractionation and concentration of proteomic samples prior to their 
analysis by LC/MS-MS 
Introductory remarks 
Proteomics is the study of protein structures and functions, for recent review on 
this topic, see Ref. [75]. Proteins are important indicators of physiological or pathological 
states of an individual and contribute to the early diagnosis of disease, which may help 
for identifying the underlying mechanism of disease development. Differentially 
expressed proteins in serum have become an important event to monitoring the state of a 
certain disease(s). These differentially expressed proteins can be identified as candidate 
biomarkers for specific diseases. Protein biomarkers can assist in diagnosing a disease at 
the biochemical level or discriminating the responses of different patients to the same 
medical treatment, for review see [76]. Recent advances in proteomic techniques give the 
opportunity in biomarker research in which serum is considered as an excellent 
diagnostic medium for the detection of disease. Diseases are often discovered in an 
advanced stage because of the lack of specific biomarkers. Therefore, early detection of 
biomarkers is vital in disease diagnosis and reduces the severity of its impact on the 
patient’s life or prevents and/or delay subsequent complications.  
In proteomic analysis of serum, it is vital to reduce the complexity of serum 
sample. Several techniques have been suggested and employed to reduce the complexity 
of the plasma proteome, including depletion of high abundance proteins [67], nonspecific 
enrichment of low abundance proteins via combinatorial peptide ligand libraries (CPLL) 
from human serum and venom [77, 78] and specific enrichment of targeted peptides after 
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enzymatic digestion [79]. Also, the serum complexity can be reduced using the traditional 
methods such as centrifugation or extraction with organic solvents [80] or by immuno-
depletion [68, 81]. Precipitation of high abundance proteins using organic solvents is 
another method to reduce the complexity of the serum sample. The simple organic 
precipitation is suitable for large scale studies as they are inexpensive, scalable, 
potentially robust and reproducible [82]. In this overview, an explanation of depletion 
methods to remove high abundance proteins from the serum sample as well as 
equalization of protein concentration will be provided. Furthermore, chromatographic 
fractionation prior to LC-MS/MS and capturing of specific proteome by lectin affinity 
chromatography will be discussed with some emphasis of the capturing of specific sub-
glycoproteome. 
 
Methodologies used to reduce the complexity of proteomic samples 
Depletion methods. The wide range in protein abundance poses a tremendous 
challenge for plasma proteomics. However, as a relatively small number of proteins make 
up most of the total protein pool, the concentration range can be compressed by depletion 
of abundant proteins, such as albumin. To reduce sample complexity and increase the 
detection of low abundance proteins, the depletion methods can be applied [68, 81-87].  
Solvent solubalization and precipitation methods. The main goal of proteomics 
is to discover disease biomarkers, which helps to identify physiological changes of cells, 
tissue or organisms compared to the control sample and helping to diagnose the diseases 
and pharmaceuticals design. Many of the abundant proteins in plasma have molecular 
weights exceeding 60 kDa (e.g. albumin, transferrin, and fibrinogen, IgA, α-2- 
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antitrypsin, apolipoproteins, and -1-acid glycoprotein). The depletion of many of these 
large and highly abundant plasma proteins is possible by precipitation using organic 
solvents such as acetonitrile, acetone, trichloroacetic acid (TCA). To reduce sample 
complexity and increase the protein identification coverage, organic precipitation 
methods have been developed.  High abundance proteins were removed using organic 
solvents such as acetonitrile. Authors state that up to 90% of albumin and other abundant 
proteins were removed by adding an equal volume of acetonitrile to the blood plasma 
samples adjusted to pH 5 [82].  Solubility of proteins is also affected by pH, ionic 
strength and temperature [88], and by adjusting one or more of these parameters, the 
precipitation may be optimized to efficiently remove as much as possible of the abundant 
proteins such as albumin in a single step, while maintaining low-abundant proteins in 
solution. Alternatively, several precipitation steps can be combined for a more efficient 
depletion of abundant proteins and increased recovery of low abundant proteins. Albumin 
is the highest abundance protein in serum. Albumin-TCA complex is soluble in organic 
solvents such as acetone. In the study carried out by Fattahi et al., acetone was added to 
15 mL of serum sample and incubated at 20 
0
C for 90 min and then centrifuged at 4 
o
C. 
The albumin in the serum sample remains in the supernatant phase binding to TCA and 
other proteins were precipitated and used for proteomic analysis [89]. For protein 
precipitation, acetonitrile was mixed with the serum samples in 1:1 (v/v) ratio and the 
samples were vortexed, and then incubated in an ultrasonic bath at room temperature. 
These steps were repeated twice and incubated in ultrasonic bath for 10 min and 
centrifuged. The high abundance proteins were precipitated and low abundance proteins 
were collected from the precipitate [82]. Sequential depletion of osteoarthritis disease 
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serum was performed using two different chemical depletion methods, using acetonitrile 
and dithiothreitol (DTT), for the mass spectrometry analysis of human serum proteins. 
Records showed that ACN depletion was efficient for depleting high molecular weight 
proteins (over 75 kDa), whereas DTT depletion primarily promotes the precipitation of 
proteins rich in disulphide bonds (mainly albumin). The study combined these two 
chemical depletions in a sequential way with the intention of reducing the complexity of 
serum protein profile while removing high abundant proteins. First, the serum sample 
was incubated for 1 h at room temperature with DDT, and after centrifugation of these 
samples the supernatant was vortexed and supernatant was subjected to 2D gel followed 
by MALDI-TOF [83]. In order to find the candidate proteomic biomarkers in the serum 
of ankylosing spondylitis diseased serum were precipitated using chloroform and 
methanol. The serum was depleted from IgGs and albumin. The depleted serum was 
subjected to nano liquid chromatography and mass spectrometry analysis to detect and 
quantify proteins. A total of 316 proteins were identified with 22 showed significant up 
or down regulation [90]. 
  Immunoaffinity depletion methods. Immunoaffinity depletion methods involve 
the use of immobilized antibodies to capture one or more of the high abundance proteins. 
This is another approach to decrease the complexity of the serum sample before 
proteomic analysis. There are numerous immunodepletion methods available which were 
reviewed recently by Selvaraju and El Rassi [91]. Holewinski et al. has conducted a study 
to find fast and reproducible method for albumin depletion from serum and cerebrospinal 
fluid. In this study, commercially available albumin depletion methods were compared in 
terms of their reproducibility and efficiency. Albumin and IgG were depleted from 
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pooled human serum samples and cerebrospinal fluid using commercially available 
immunoaffnity kits including ProteaPrep HSA spins columns, ProteaPrep HSA 96-well 
plate, ProteaPrep HSA/IgG depletion column, Vivapure anti-HSA/IgG depletion kit, and 
Sigma antiHSA/IgG depletion columns. Two depletion methods (e.g., Sigma and 
Proteaprep) showed albumin depletion of 97% or greater for both serum and 
cerebrospinal fluid [84]. Tan et al. used the chicken host to produce polyclonal 
antibodies IgY against complex mammalian antigens. The ability of chicken IgY 
antibody to deplete six high abundance proteins including 1-antitrypsin, albumin, 
transferrin, haptoglobin, IgG and IgA from serum was studied. The authors concluded 
that the polyclonal IgY antibodies were suited for the depletion of serum from high 
abundance proteins and to consequently identifying novel biomarkers [92].  Janecki et al. 
conducted a study using liquid chromatography setup for automated serum/plasma 
depletion with two immunoaffinity columns.  The first column was the Seppro IgY14 for 
the depletion of the 14 most abundant proteins followed by the second column Seppro 
SuperMix to deplete the next 200-300 proteins. The authors processed nine serum 
samples of 1 mL each within 24 h period with excellent reproducibility. The proposed 
automated serum depletion setup can be used for the faster depletion of a large number of 
biological samples [85]. Yu at al. conducted the study for the depletion of albumin and 
IgG for the quantification of human serum transferrin, which is the principal ion 
transporter for the body. Briefly, serum was depleted using the ProteoPrep® Blue 
Albumin and IgG Depletion Kit according to the manufacture’s protocol. The author 
believed this methodology can be applied to the clinical monitoring of human transferrin 
which is a potential biomarker for certain cancers [93]. Abundant proteins were depleted 
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from the serum in the process of quantifying target proteins using protein standard 
absolute quantification (PSAQ) method, which uses full-length isotope labeled protein 
standards to quantify proteins. Serum samples were depleted of the six most abundant 
proteins using the human Multiple Affinity Removal Spin cartridge (MARS6) in the 
study of quantification of cardiovascular biomarkers from serum. The authors were able 
to quantify six biomarkers from the serum including LDH-B, total LDH, creatine kinase 
B, creatine kinase M, myoglobin, and troponin 1. The authors believed that PSAQ will be 
a major contributor to efficiently quantify biomarkers [94]. Maternal serum proteome 
changes during pregnancy were studied with the intention of developing new gestational 
biomarkers. Serum (50 μL) was depleted from albumin, immunoglobulin IgA, IgG, -
antitrypsin, transferrin and haptoglobin using a multiple affinity removal column with the 
size of 100 x 4.6 mm I.D. and subjected the depleted serum to the LC-MS/MS analysis. 
Mass spectrometric analysis detected 38 known proteins during pregnancy and identified 
one novel protein the beta 1 glycoprotein 4, which is a pregnancy specific protein. 
Further isotope labeling studies detected four new proteins. The authors concluded that 
measurement of changes in maternal serum proteome may be useful to identify birth 
defects, preterm delivery and reproductive health [95].  
Supermacroporous cryogels are good alternative to traditional protein-binding 
stationary phase matrices due to many advantages such as large pores, short diffusion 
path, low-pressure drop, and very short residence times for both adsorption and elution. 
Macroporous cryogels imprinted with human serum albumin (HSA) was fabricated by 
copolymerization of 2-hydroxyethyl methacrylate with a functional co-monomer of N-
methacryloyl-l-phenylalanine and used for the depletion of albumin from human serum. 
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The cryogel was first equilibrated with passing pH 6.0 phosphate buffer solution and 
then, human serum was injected [96].  
Immunoaffinity fractionation of highly abundant proteins has proven to be one of 
the most effective approaches for overcoming the wide dynamic range of protein 
concentration, as well as enabling the detection of low abundance proteins. Janecki et al. 
developed fully integrated multi column system for the depletion of abundant proteins 
from plasma. The serum sample was loaded onto an immunoaffinity depletion column 
SepproTM IgY14 LC10 and Seppro SuperMix LC5 columns. The samples were serially 
depleted from 14 high abundance proteins first by SepproTM IgY14 LC10 column 
followed by Seppro SuperMix LC5 column [85].  Commercially available Seppro IgY14 
LC10 column and SuperMix LC5 column were used to remove fourteen high abundance 
proteins from human serum samples including albumin, α1-antitrypsin, IgM, haptoglobin, 
fibrinogen, α1-acid glycoprotein, HDL, LDL, IgG, IgA, transferrin, α2-macroglobulin, 
and complement C3. Serum samples were diluted 6-fold with the dilution buffer, passed 
through a 0.45 μm spin filter, and centrifuged for 1 min at 9,200 × g to remove any 
particulate materials present in the sample [97].  In another investigation, novel HSA and 
IgG affinity sorbents were developed using epitope-imprinted polymers as artificial 
antibodies to deplete human serum. Acrylic acid, acrylamide, and N-acryl tyramide were 
used as monomers, N,N’-ehtylene bisacrylamide was the cross linker and cellulosic fibers 
were the supporting matrix. The adsorption capacity of these artificial antibodies were 
found to be 15.2 mg, 10 mg and 15 g for human serum albumin, IgG and human serum, 
respectively. The authors state that rapid production, high specificity efficient depletion 
make them attractive for the serum depletion [87]. In the work conducted by Selvaraju 
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and El Rassi to identify differentially expressed fucosylated glycoproteins by lectin 
affinity chromatography, albumin and Igs were depleted using GMM/PETA monolithic 
columns with immobilized protein G’, protein A and anti-human albumin [67]. 
Highlights of protein equalization method in proteomics.  The few high-
abundance proteins make up 99% of the serum, thus making it difficult to identify low-
abundance proteins and protein alterations with different physiological conditions. It is 
important to reduce the concentration of high abundance proteins in serum to discover the 
low-abundance ones. One main approach to decrease the high abundance proteins are 
depletion methods, which are described above in this chapter.  The other main approach 
is protein equalization [98]. The concept of combinatorial peptide ligand libraries (CPLL) 
combined with other fractionation methods such differential gel electrophoresis and off 
gel fractionation was recently reported to identify a large number of low abundance 
proteins in some extracts [91]. Righetti et al. have introduced CPLL for the equalization 
of proteins and conducted proteomics analyses for many fluids and matrices including 
human serum, plant and animal tissues [99-107]. Each CPLL consists of millions of baits 
on beads or in columns, which bind proteins to the peptide ligands of the beads. The high 
abundance proteins saturate the binding sites of CPLL and the remaining molecules of 
these proteins are washed away. This results in enrichment of low abundance proteins 
and in turn it reduces the concentration of high abundance proteins. CPLL approach has 
been applied for the quantitative comparison of the proteomic in multiple cell extracts. In 
one study, the reproducibility of CPLL was assessed by capturing the whole range of 
protein abundances from the proteome of Saccharomyces cerevisiae. For the quantitative 
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evaluation of the performance of CPLLs, the selected reaction monitoring (SRM) 
approach has been used in which mass spectrometric tool is employed for quantitative 
protein analysis [99]. Proteomic characterizations of venoms of rattlesnakes were 
conducted using CPLL. Captured protein fractions were subjected to the N-terminal 
sequence analysis using Procise instrument according to the manufactures protocol. 
Peptides were identified and subjected to SDS-PAGE and analyzed with tandem mass 
spectrometry [77]. The proteome of untreated white wines was explored via capture 
CPLL at four different pH values: pH 2.2, 3.8, 7.2, and 9.3. The study revealed the 
identification of 106 unique gene products belonging to Vitis vinifera as well as of an 
additional 11 proteins released by the S. cerevisiae used in the fermentation process 
[108].  Righetti et al. conducted an in depth analysis of proteome in banana fruit with the 
focus of identifying the metabolite composition and proteins causing food allergies and 
low abundance proteins in banana using CPLL. They were able to identify 1131 proteins, 
and food allergens such as mus a 1, pectinesterase, superoxide dismutase, and potentially 
new allergens. The authors believed that this is the first in-depth exploration of the 
banana fruit proteome and one of the largest descriptions of the proteome of any 
vegetable system [101]. In this study, CPLL has been used as a two-dimensional (2D) 
method for proteome analysis in which proteins capture under conditions favoring ionic 
interactions vs. environments inducing hydrophobic interactions. Briefly, the 2D 
orthogonal mode that utilizes the affinity of the multiple ligands, serum proteins were 
captured at physiological pH either at low ionic strength (25 mM NaCl) or at high 
concentrations of lyotropic salts which favor hydrophobic interaction. By comparison of 
the two modes the authors reported that 52% of the captured proteins are common to the 
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two capture modes, 20% are unique to the “ionic” interaction mode and 28% are unique 
to the hydrophobic mode. This orthogonal method overcome the major drawbacks of 
CPLL in which it diminishes the loss of protein up to 5% in ionic capture, whereas the 
hydrophobically engendered  capture is loss-free [109]. Recently, CPLL was used in the 
enrichment of low abundance glycoproteins [102]. To reduce the high abundance protein 
concentration in swine plasma, CPLL has been used with dual-enzyme, dual-activation 
strategy to achieve high proteomic coverage. The CPLL treatment enriched the lower 
abundance proteins by >100-fold and a total of 3421 unique proteins spanning a 
concentration range of 9–10 orders of magnitude were identified [110].  To identify the 
proteins in the development of chick embryos, hen egg white proteins were analyzed by 
CPLL. Briefly, this method used ProteoMiner protein enrichment kits to enrich low 
abundance and identify the low abundance proteins in hen egg white samples. The study 
identified 30 proteins in five protein families including transferrin, protease inhibitor, 
clusterin, serpin and lipocalin family [111]. Ovarian cancer serum was equalized using 
CPLL, and the concentration of the most abundant serum proteins was reduced using the 
ProteoMiner Enrichment Kit and then submitted to 2-D gel electrophoresis followed by 
identifying proteins using MALDI-TOF. To identify new proteins with potential 
diagnostic or prognostic value for the therapy of ovarian cancer comparative proteomic 
analysis of sera from ovarian cancer patients and healthy women was performed [112].  
In this investigation, serum samples from 10 patients diagnosed with epithelial ovarian 
cancer and 10 age-matched healthy women were analyzed.  To decrease the extremely 
wide dynamic range of protein concentration in serum CPLL was used.  Serum samples 
were then subjected to proteomic 2-DE analysis. Three proteins with differential 
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abundance were found and identified by mass spectrometry: α-1-antitrypsin, 
apolipoprotein A-IV and retinol-binding protein 4.  Identification of α-1-antitrypsin and 
apolipoprotein A-IV confirms previous studies but the identification of significantly 
decreased levels of RBP4 in ovarian cancer patients represents a novel observation. The 
decrease of RBP4 levels in ovarian cancer patient sera was verified by two independent 
methods and determined absolute RBP4 concentrations in patients and healthy women.  
The possible non-cancer factors that could be responsible for the observed RBP4 
decrease could be excluded, and consequently, a connection of RBP4 with epithelial 
ovarian was proposed and the potential of RBP4 as a candidate biomarker was advocated 
by the authors [112]. Human serum from osteoarthritis patients were subjected to   
protein equalization using ProteoMiner kit [83]. Serum from patients with gastric 
precancerous lesions, were equalized using ProteoMiner kit. The study identified altered 
O-glycosylation using simple mucin type carbohydrate antigen STn and T antigens in the 
serum from patients with gastritis and IM in opposition to minor or no reactivity in the 
same proteins of healthy individuals without any gastric disease [113].  
A single chain variable fragment (scFv) displaying M13 phage library covalently 
immobilized onto magnetic microspheres was used to equalize human serum proteins. In 
this method, the phage library with magnetic microspheres was incubated with serum 
sample, eluted captured proteins on the library using eluting mobile phase, and tightly 
bound proteins were released with treatment of thrombin. The eluted proteins were 
analyzed with SDS-PAGE followed by the 2D strong cation exchange RPLC-ESI-
MS/MS.  The authors state that the number of proteins identified from scFv M13 treated 
human serum sample was improved by 100% compared with that from the untreated 
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sample. The spectral count of 10 high abundance proteins (serum albumin, 
serotransferrin, α-2-macroglobulin, α-1-antitrypsin, apolipoprotein B-100, Ig γ-2 chain C 
region, haptoglobin, hemopexin, α-1-acid glycoprotein 1, and α-2-HS-glycoprotein) was 
significantly reduced, which resulted in more protein identification. The phage library 
was compared to the peptide library and it shows strong binding capacity and high 
specificity toward proteins and also can be reproduced to obtain enough ligands for 
sample preparation [98].  
Enrichment of proteins via immobilized metal ion affinity chromatography (IMAC)    
IMAC is a protein purification and enrichment technique. Its applications include the 
purification of histidine-tagged proteins, natural metal-binding proteins, and antibodies. 
The underlying mechanism of IMAC is the adsorption of proteins due to the   interactions 
between an immobilized metal ion and electron donor groups located on the surface of 
proteins. Most commonly used metals are Cu(II), Ni(II), Zn(II), Co(II), TI(II) and IV  and 
Fe(III) ions, for review see [114].  
Enrichment of phosphoproteome Yue et al. developed an optimized method for 
the IMAC enrichment of the phosphoproteome of the human mammary cell line, MCF-
10A, using both SCX-IMAC and optimized multistep IMAC enrichment followed by the 
high-pH RP fractionation method (multi-IMAC-HLB). 5519 unique phosphopeptides 
were identified in 13 fractions using the SCX-IMAC method from 15 mg of starting 
material. 8969 unique phosphopeptides were identified in 12 multi-IMAC-HLB, (HLB 
means hydrophilic–lipophilic-balanced reversed-phase cartridge) fractions from 3 mg of 
starting material. The efficiency of the SCX-IMAC method and the multistep IMAC-
HLB method was compared using the number of identified unique phosphopeptides, the 
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phosphopeptide ratios, and the numbers of singly and multiply phosphorylated peptides. 
The authors concluded that multi-IMAC-HLB is a robust and efficient method of 
phophoproteome research [115]. In another very recent report, a novel material for IMAC 
for phosphoproteome research was designed using polydopamine coated on the graphene 
surface and functionalized with titanium ions (denoted as Ti
4+-
G@PD). The above 
monolith with enhanced hydrophobicity and biological compatibility was evaluated using 
scanning electron microscopy (SEM), transmission electron microscopy (TEM), and 
infrared (IR). The performance for effective enrichment of phosphopeptides was 
evaluated with both standard peptide mixtures and human serum. The authors believed 
that there will be a possibility to design an efficient and sensitive tool for 
phosphoproteome analysis [116]. Sun et al. evaluated sequential IMAC using gallium 
based IMAC in conjunction with titanium dioxide based metal affinity chromatography 
for the enrichment of  phosphopeptides. The quantitative performance of this approach 
was evaluated using tryptic peptides from casein, bovine serum albumin and standard 
phosphopeptides.  This study evaluated the repeatability, dynamic range, and linearity of 
IMAC for large scale quantitative phosphoproteomics applications [117]. Zeng et al. 
conducted a study with immobilized TiO2 onto poly(acrylic acid)-functionalized 
magnetic carbon-encapsulated iron nanoparticles as affinity probes for efficient 
enrichment of phosphopeptides. To evaluate the performance of magnetic TiO2 affinity 
probes, tryptic digests of -casein and BSA were used. Using the magnetic TiO2 affinity 
probes to isolate the phosphopeptides from 200-mg equivalent of HeLa cell lysates from 
bovine fetal serum, 1415 unique phosphopeptides and 1093 phosphorylation sites were 
identified [118]. Zhou et al. conducted their investigation for enrichment of specific 
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phosphopeptides with immobilized titanium IMAC with the polymeric column chelated 
with Ti
4+
. Briefly, phosphate polymer was prepared by direct polymerization of 
monomers containing phosphate groups through immobilize TI
4+
 through chelating 
interactions between phosphate groups on the polymer and Ti
4+
. Ti-IMAC resin isolated 
phosphopeptides from digest mixture of standard phosphopeptides and BSA.  The Ti-
IMAC was also used to isolate phosphopeptides from mouse liver. The authors state that 
this method is highly specific to isolate phosphopeptides due to the specific interaction 
between immobilized Ti
4+
 ion and phosphate group on the phosphopeptides
 
[119].  
Enrichment of histidine-tagged proteins.  The histidine-tag is today the most 
commonly used tag for recombinant proteins. It is used for the purification of 
recombinant expressed proteins and detection purposes [120]. Lee et al. developed a 
novel magnetic mesoporous silica (MMS) material with high magnetic strength for the 
selective His-tagged enzyme enrichment. The efficiency was compared with nickel-based 
MMS materials, such as Ni
2+
-MMS and Ni-MMS, and nickel ion doped silica-coated 
magnetic nanoparticles (Ni
2+
-MNPs). The efficiency was calculated to be 100 ± 1.93%, 
70.94 ± 1.95%, and 37.03 ± 5.93% for Ni
2+
-MMS, Ni-MMS, and Ni
2+
-MNPs, 
respectively and identified Ni2+-MMS as the suitable material for the enrichment of 
histidine tagged proteins. This method enables a high-throughput and advanced 
systematic approach for the separation and immobilization of proteins which cover a 
broad spectrum of polyhistidine-tagged proteins [121]. For the enrichment of histidine 
tagged peptides, silicon nanostructured (NanoSi) surface functionalized with an organic 
layer of nitrotriacetic acid (NTA) was used as an affinity surface-assisted laser 
desorption/ionization mass spectrometry (SALDI-MS) interface for histidine-tagged 
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peptide enrichment and mass spectrometry analysis. The developed platform has shown 
good selectivity toward His-tagged peptide and permits its enrichment from an artificial 
mixture of both tagged and untagged peptides and the mass spectrometry detection was 
obtained with good signal/noise ratio [122]. 
Enrichment of other subproteomes. Recently, in our laboratory Jmeian and El 
Rassi introduced an integrated fluidic platform with tandem affinity columns for the 
depletion of high abundance proteins followed by online fractionation and concentration 
by immobilized metal affinity chromatography (IMAC) [69]. The IMAC columns were 
fabricated using GMA/ EDMA monolithic columns with surface bound iminodiacetic 




, and Cu 
2+
.  The captured fractions 
were analyzed by 2-DE and analyzed with MALDI-TOF and LC-MS/MS and 295 
proteins were identified.  While Cu
2+
-IMAC column can bind to proteins having cysteine 





- IMAC columns require two histidine  residues in  particular 
position on the protein surface [69]. Wang et al. developed an IMAC method with an 










, and Cu 
2+
. 
After analyzing the eluted fractions of each metal column by the LC-MS/MS, the 
identified proteins were compared with the published literature and observed there are 
published proteins as well as novel proteomic biomarkers [123].  
Miscellaneous affinity for protein enrichment Boronate-affinity chromatography 
(BAC) is another tool for specific isolation and enrichment of cis-diol compounds. The 
boronic acid monoliths can be prepared by directly precipitate boronic-acid ligands with 
active groups (e.g., vinyl and amino group) or by immobilized boronic-acid ligands on a 
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monolithic column. Recent review by Li et al. has reviewed the advances in boronate 
affinity chromatography, see ref. [124].  
Enrichment of peptides. Antibody free peptide enrichment platform was 
developed by Shi et al. for targeting specific peptides. A high-pressure, high-resolution 
separation with intelligent selection and multiplexing (PRISM) is a highly efficient 
method for quantification of target peptides. Application of this strategy to enrichment of 
human plasma demonstrated that the method was able to accurately and reproducibly 
quantitate peptides at the concentration ranges from the 50-100 pg/mL. The PRISM 
reduces background interferences and result in high sensitivity in quantification of low-
abundance proteins in clinical serum samples [125]. Hydrophilic interaction liquid 
chromatography (HILIC) is a common approach for non-destructive method for 
glycopeptide enrichment. Kuo et al. compared HILIC methods for the enrichment of 
glycopeptides from serum using amine-derivatized Fe3O4 nanoparticles and Sepharose 
CL-4B resin.  Glycopeptides were enriched from uterine luminal fluid of mice.  67 N-
glycosylated peptides were identified with amine-derivatized Fe3O4 nanoparticles and 55 
N-glycosylated peptides were identified with Sepharose CL-4B resin. The authors 
concluded that NH2 functionalized nanoparticles are very useful for enrichment of N-
glycosylated peptides [126].  Specific and sensitive immunoaffinity LC-MS/MS assay for 
quantification of low abundance cytokine of human and cynomologus monkey 
interleukin 21 was developed. Briefly, the peptide immunoaffinity enrichment of 
plasma/tissue extract was carried out using 96-well microtiter plate with the addition of 
monoclonal anti-IL 21. The cytokines were eluted and subjected to LC-MS/MS analysis.   
The authors state that the immunoaffinity LC-MS/MS approach is a selective and 
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sensitive strategy for pharmacological and clinical biomarker investigation [127]. Stable 
isotope standards and capture by anti-peptide antibodies (SISCAPA) is an 
immunoaffinity enrichment method for capturing of targeted peptides from digested 
tissue or bio-fluids. In the method of SISCAPA, peptide immunoaffinity enrichment of 
plasma was carried out using 96-well microtiter plate in triplicate. The bulk mixture of all 
eight anti-peptide antibodies was prepared and sixteen microliters of 1m protein G 
magnetic beads (Invitrogen) were added to each sample and mixed briefly. The plates 
were sealed with further processed according to the manufactures procedure and 
subjected for LC analysis. The authors state that the developed SISCAPA method is a 
valuable technology that bridges the gap between discovery and clinical validation of 
candidate protein biomarkers [128] .   
Serum fractionation methods. Serum fractionation has been proposed as a 
promising method to measure low-abundance proteins. There are several approaches to 
fractionate the serum that can be performed according to the size, polarity and the 
differences in the isoelectric points (pI values) of serum proteins. 
Chromatographic fractionation. RPC columns have been used in the 
fractionation of serum samples. Selvaraju and El Rassi used proSwift
TM 
RP-1S column 
for the fractionation of fucosylated proteins captured from disease free and breast cancer 
sera. Two lectins namely Lotus tetragonolobus agglutinin (LTA) and Aleuria aurentia 
(AAL) lectin were used to capture the fucome. The collected RPC fractions were 
subjected to the LC-MS/MS analysis that led to the identification of a 35 broad panel of 
differentially expressed proteins (DEP) in the breast cancer serum relative to disease free 
serum and an eight narrower panel of DEP from both LTA and AAL captured protein 
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fractions [67]. Zhu et al. has developed two dimensional method with strong anion 
exchange (SAX) combined with RPC column to deplete high abundance proteins in 
human plasma and identification of low abundance proteins. Plasma was fractionated 
onto the SAX column producing 67 fractions. All the SAX fractions were reconstituted 
with suitable mobile phase and subjected to high pH RPC fractionation using a Jupiter C4 
column and a linear gradient of 158 min with high UV absorption at 215 nm. The 
collected fractions were subjected to LC-MS/MS analysis for protein identification.  Out 
of the 83 proteins that were identified, 68 were reported to be of the high- or middle-
abundance proteins in plasma [129]. Kimura et al. used RPC in search for novel 
biomarkers for hepatocellular carcinoma (HCC). In this method, serum was subjected to 
immunoaffinity depletion to remove 10 high abundance proteins from the serum using 
Proteome Lab IgY-12HC LC10 column according to the manufacturer’s instructions. The 
depleted serum was then loaded onto the Intrada WP-RP column and separation was 
performed using multi-segment elution gradient. The chromatograms were monitored at 
218 nm and 40 fractions were collected each at 50 sec intervals. Fractions were analyzed 
with SDS-PAGE followed by in gel digestion and subjected to LC-MS/MS. 83 protein 
bands were found to be up regulated in HCC. Among the 83 protein bands clusterin was 
significantly overexpressed and the authors concluded that clusterin is a novel biomarker 
for HCC [130]. Comparison of two prefractionation methods based on RPC and SAX 
were carried out for the proteomic analysis of Saccharomyces cerevisiae. The first 
prefractionation separation was performed using SAX on Water BioSuite Q SAX at  50 
˚C using a gradient of ammonium acetate and 20 fractions were collected. The second 
prefractionation of proteins was performed by RPC on a PLRP-S column heated at 80 °C. 
38 
 
Fractions were collected using ACN gradient. In this study, more proteins were identified 
by RPC prefractionation than by SAX.  The study concluded that RPC fractionation 
provides wider coverage than the SAX method [131]. 
Prefractionation by RPC was also used for peptides before subjecting them to LC-
MS/MS. Ma et al. reported the RPC fractionation of peptides in the search of N-linked 
glycoproteome profiling of human serum. The serum was subjected to immunoaffinity 
depletion and the collected proteins were tryptically digested yielding peptides. N-linked 
peptides were captured with WGA, Con A, and RCA lectins. These enriched N-linked 
glycopeptides were fractionated using Durashell RP analytical column packed with 5 m 
particles. The fractionation was carried out with high pH linear ACN gradient and 36 
fractions were collected. The tandem enrichment methods, followed by high-pH 
reversed-phase prefractionation, enhanced the level of N-glycoproteome analysis from 
312 N-glycosites to 615 N-glycosites using high-accuracy mass spectrometry [132]. 
Multidimensional separation of tryptic peptides from human serum proteins using RPC 
fractionation was done on an XBridge column [133]. Capillary reversed phase column of 
the dimension 200 μm inner diameter (i.d.) × 50 cm long, were packed in-house with 3 
μm Jupiter C18 bonded particles to fractionate the non-depleted human serum [134]. In 
the search of cardiovascular biomarkers using nano-LC, depleted serum was subjected to 
tryptic digestion and fractionated using 300-μm x 5-mm PepMap C18 column at 
300nL/min flow rate with a linear gradient for 60 min. The study was able to identify 




Anion exchange chromatography is another technique for the fractionation of 
biological fluids including serum and cerebral spinal fluid (SPF). Ovarian cancer serum 
was fractionated using anion exchange chromatography for finding the highly 
glycosylated subproteome. A Mono Q 4.6/100 PE Tricorn high performance column 
connected to an HPLC system was used for the serum fractionation and four fractions of 
500 L were collected into glass vials containing 100 L of 6% BSA [135]. With the 
intention of identifying breast cancer biomarkers, serum was fractionated by SAX 
chromatography. Six fractions were collected, based on differences in isoelectric point 
(pI) of the proteins. In the process of serum fractionation high-abundance proteins are 
segregated into a limited number of fractions, which reduces the signal suppression 
effects on proteins of lower abundance in the other fractions [136]. Multidimensional 
separation of tryptic peptides from human serum using strong cation exchange on 
PolySulfoethyl A column and serum protein profiling by nanoChip-LC–MS/MS resulted 
in the identification of 208 proteins and 1088 peptides with the lowest reported 
concentration of 11 ng/mL for heat shock protein 74 [133].  
In this dissertation, RPC columns were used to fractionate disease free and breast 
cancer serum. In chapter 4, RPC columns were fabricated with ODA/TRIM monolith. 
Depleted serums as well as non-depleted serum were fractionated using linear ACN 
gradient. In chapter 5, RPC column was developed with different composition of 
ODA/TRM but incorporated with MWCNTs into the polymerization mixture. The data 
showed that the ODA/TRIM column incorporated with MWCNTs captured higher 
number of proteins than the blank ODA/TRIM column. 
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Capturing various glycoproteome by lectin affinity chromatography (LAC). 
Lectins are capable of recognizing specific glycan structures and serve as invaluable tools 
for the separation of glycosylated proteins (i.e., glycoproteome) from non-glycosylated 
proteins in biological samples [137]. Lectins can be considered as ideal reagents for 
protein-carbohydrate recognition since they can detect cell surface glycolipids and 
glycoproteins. They can be employed to identify minor variations in protein glycosylation 
including changes in the content of sialic acid and fucosyl residues present in serum 
glycoproteins [138]. There are around 60 commercially available lectins, which has the 
ability to recognize the diverse sugar structures, some are highly specific while others 
having overlapping selectivity for particular carbohydrate structures. Concanavalin A 
(Con A) is the best known plant lectin having very broad specificity while sambucus 
nigra (SNA) lectin has the specificity for sialic acid linked to -2,6 galactose containing 
structures [139]. There are several formats of LAC used in glycoproteome research. 
While single LAC enriches limited number of glycoproteins, serial-LAC and multi- LAC 
allow capturing of large number of glycoproteins. In serial-LAC fraction from one lectin 
column is collected, dialyzed, dried and reconstituted and then transferred to a second 
lectin. This generates excessive discontinuous sample manipulation, which causes sample 
loss and propagation of experimental biases from column to column. M-LAC refers to 
using a mixture of immobilized lectins having complementary specificities in a given 
column (i.e., mixed bed column). After loading the sample onto the column, the M-LAC 
column is eluted sequentially using a specific haptenic sugar for each lectin. In this 
process, sequential elution may not be a clear cut, and some glycoproteins captured by 
another lectin may be concurrently eluted. It has been reported that serial-LAC resulted in 
41 
 
the identification of a higher number of proteins than M-LAC [140]. Recently, in our 
laboratory Selvaraju and El Rassi introduced tandem lectin affinity column using 
different lectin columns operating independently with switching valves whereby the 
sample is loaded onto the tandem columns and the pass through fraction of the first 
column is moved to the second column and so on by the mobile phase so that there is no 
need for collection, and fraction processing between columns, thus eliminating 
experimental biases and propagation of errors [140]. The study with the tandem lectin 
affinity monolithic column platform with surface immobilized Con A, wheat germ 
agglutinin (WGA) and Ricinus communis agglutinin (RCA) for identifying captured 
proteins from breast cancer and disease free human sera. According to the authors the 
suitable order of the lectin affinity columns were WGA, Con A and RCA. This tandem 
column format was able to capture 113 and 112 proteins from disease free and breast 
cancer sera, respectively, with 75 and 65 non redundant proteins, respectively [140].  A 
fully integrated platform comprised of a multicolumn operated by HPLC pumps and 
independent switching valves for the online depletion of high abundance proteins and 
capturing fucosylated glycoproteins via immobilized Aleuria aurentia (AAL) and Lotus 
tetragonolobus lectins (LTA) followed by fractionation of captured glycoproteins by 
RPC, was introduced by Selvaraju and El Rassi [67]. This investigation revealed a wide 
panel of 35 differentially proteins (DEP) and 8 narrow panel of DEP common to both 
LTA and AAL fractions which is a good representative of cancer altered fucome [67]. M-
LAC methods was developed for the identification of cellular glycoproteins from MCF-7 
breast cancer lysate combining three agarose bound lectins, namely, Con A, jacalin, and 
WGA and the captured lectin fractions were analyzed using nano LC-MS/MS.  This 
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study revealed that M-LAC can be extended to total cell lysate to investigate the cellular 
proteomics [137]. With the intention of increasing the efficiency of the chromatographic 
process and selectivity of glyco-compounds separation, two stationary phases were 
compared. Con A lectin was immobilized on different macroporous stationary phase 
matrices of silica coated with poly vinyl alcohol (PVA), silica coated with cationic PVA 
(DEAE-PVA) and cellulose were compared. The authors concluded that in silica based 
monoliths higher flow rate and higher sorption parameters can be obtained [141]. The 
selectivity of recombinant forms of Aleuria aurentia lectin using weak-LAC on a 
commercial HPLC system was reported. Briefly, four different variants of Aleuria 
aurentia (AAL) which are native AAL purified from Aleuria aurentia mushrooms (n-
AAL), recombinant AAL dimer (r-AAL), recombinant AAL monomer (m-AAL) and 
AAL site 2 protein (S2-AAL) were evaluate for the capturing of fucosylated 
glycoproteins. The study revealed that r-AAL forms show similar affinities toward 
glycoproteins but S2-AAL form has lower affinity to glycoproteins having sialic acid 
containing fucosylated saccharides [142]. Serial lectin affinity chromatography was 
performed for pooled human serum with four different types of affinity columns which 
are agarose-bound Lycopersicon esculentum lectin (LEL), agarose-bound Helix pomatia 
agglutinin (HPA), agarose-conjugated anti-Lewis x and anti-sialyl Lewis x IgM were 
used in serial-LAC. The numbers of glycoproteins identified were studied with columns 
attached in different orders. The authors believed that serial-LAC is a valuable tool in 
recognizing diversity in protein glycosylation, especially when the order of the columns 
in the serial-LAC is varied. [143]. In-depth analysis of the salivary proteome for the early 
diagnosis to identify disease biomarkers in different pathophysiological conditions were 
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conducted by Yates et al. The study utilized Con A, RCA-1, and ulex europaeus (UEA-1) 
lectins in lectin affinity chromatography. The captured glycoproteins were subjected to 
LC-MS/MS analysis and identified a total of 262 of O- and N-linked glycoproteins 
among them 224 were unique N-linked glycoproteins. It is believed that the glycoproteins 
identified in this study provide valuable information for more accurate diagnosis, 
prognosis, and treatment of local and systematic diseases [144].  Macroporous silica 
particles of 2-m size, were used in LAC for the enrichment of glycoproteins. Briefly, 
AAL and Con A lectins were immobilized on the silica particles and tested for their 
binding properties with standard glycoproteins. The study revealed that the columns 
exhibited excellent binding capacities for microaffinity enrichment where Con A was 
able to bind 75 μg of a standard glycoprotein in a 50 × 1 mm column. The authors 
believed that 2 m silica particles are excellent for chromatographic applications, owing 
to their rigidity, high surface area, large pores, and small particle diameter [145]. Hess et 
al. conducted a study to characterize Mycobacterium tuberculosis proteome using LCA 
and mass spectrometry based proteomic techniques. This study used WGA lectin and 
captured 1051 M. tuberculosis protein groups including 183 transmembrane proteins as 
identified by LC-MS/MS analysis. The authors state that the data set will serve as a 
valuable resource for M. tuberculosis proteome research [146]. Xu et al. conducted lectin 
affinity based approach to enrich and increase the number of secreted proteins detected in 
the media of cultured tissues of colorectal cancer patients. For the enrichment of 
glycoproteins, Con A and WGA lectins were used. The captured proteins were analyzed 
by one-dimensional gel electrophoresis coupled to LC-MS/MS and identified 123 
differentially expressed secreted proteins with 68 of the differentially expressed proteins 
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were up-regulated in colorectal cancer tissues. EFEMP2 protein is one of the top 10 up-
regulated differentially expressed proteins and the study indicated that EFEMP2 is a 
promising serum biomarker for the early detection of colorectal cancer [147]. The 
determination of glycoproteins in barley malt was conducted due to its importance in beer 
production. The aim of this study was to optimize separation and enrichment of 
individual modified proteins on a monolithic Con A affinity HPLC column and identified 
10 bound protein fractions and their possible N-glycosylation sites [148]. 
Lectin affinity chromatography can also be employed as a fractionation method. 
This approach is widely used to fractionate protein glycoforms that have a specific glycan 
structure with binding affinity to lectin. It is becoming very attractive as a mode of 
fractionation to observe the difference between protein glycoforms. A number of lectins 
has been used to fractionate specific protein glycoforms from complex glycoproteome 
[129]. A pair of pooled serum samples was fractionated using phytohemagglutinin-L (L-
PHA) lectin immobilized on biotin−streptavidin conjugated to magnetic beads specific 
for capturing of tissue inhibitor of metalloproteinase 1 (TIMP1) known to be aberrantly 
glycosylated in patients with colorectal cancer (CRC).  Each captured glycoform was 
digested and enriched using a stable isotope standard and captured by the antipeptide 








Rationale and scope of the study 
Despite the progress made in the fabrication of monoliths, which was overviewed 
in the first part of this chapter, there is still need for monolithic columns well suited for 
the separation of small molecules as well as proteins by HPLC. Therefore, it is the aim of 
this dissertation to develop nonpolar organic polymer monoliths for RPC of small 
molecules that exhibit unique selectivity (see Chapter II). In this regards, multiwalled 
carbon nanotubes (MWCNTs) were incorporated into the organic polymer based 
monolithic columns prepared via the copolymerization of GMM/EDMA monomers in the 
presence of MWCNTs in the polymerization mixture. The above GMM/EDMA monolith 
was relatively hydrophilic with little or no RPC characteristics.  The GMM/EDMA blank 
monolith when evaluated with alkyl benzenes did not show any retention but with the 
addition of MWCNTs, the monolith incorporating MWCNTs showed retention for alkyl 
benzenes and several other compounds such as toluene derivatives, anilines and 
herbicides.  Chiral separation of biologically and environmentally important compounds 
was achieved using the novel monolith. However, the GMM/EDMA column incorporated 
MWCNTs did not separate proteins, and consequently cannot be used for proteomic 
studies. Therefore, we continued our search to find the monolithic column suitable for the 
separation of proteins.  
In Chapter III, ODA/TRIM monolith was developed and the monolith was 
evaluated using alkyl benzenes and standard proteins. Although proteins exhibited good 
retention and separation on the ODA/TRIM monolithic column, the ODA/TRIM 
monolith was further optimized by incorporating in its texture small amount of 
MWCNTs.  Protein separation was improved in terms of peak shape and retention. The 
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ODA/TRIM incorporated with MWCNTs thus obtained was used for the RPC 
fractionation of sialylated glycoproteins captured by lectin affinity columns in a 
multicolumn liquid phase based platform described in Chapters IV and V. 
Although separation science in general and chromatography in particular have 
contributed extensively to advancing the field of proteomics, new approaches for the 
selective capturing of complex sub-glycoproteomics such as sialylated glycoproteins that 
are altered in cancers are badly needed. In this regards, a multi column liquid phase based 
platform was introduced for the online depletion of high abundance proteins and 
capturing of sialoglycoproteins. Thus, Chapters IV and V involved the development of 
monolithic columns with immobilized lectins for lectin affinity chromatography (LAC) 
enrichment of human serum sialoglycoproteins. To achieve this objective, Sambucus 
Nigra lectin (SNA) and Maakia amurensis lectin (MAL-II) were immobilized onto 
GMM/PETA monolithic columns for use in a multi column liquid phase based platform 
to capture sialoglycoproteins from disease free-human serum and from breast cancer 
serum for the identification of differentially expressed sialylated glycoproteins in breast 




This introductory chapter summarized the progress made in monolithic columns 
for HPLC. The overviewed monoliths included organic, inorganic, hybrid and 
nanoparticle incorporated monoliths. Also, the progress made so far in proteomics sample 
preparation approaches have been highlighted. This involved the description of the 
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methodological approaches developed so far for reducing the complexity of proteomics 
samples including the depletion of high abundance proteins from serum, the enrichment 
of specific subproteomes in serum and the fractionation of the various subproteomes by 
different chromatographic techniques. Finally, the rationale and scope of the dissertation 
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POLY (GLYCERYL METHACRYLATE – ETHYLENE GLYCOL 
DIMETHACRYLATE) COPOLYMER MONOLITH SUPPORTED  
MULTIWALL NANOTUBES FOR REVERSED 




Monolithic stationary phases have been used in CE, CEC, and HPLC. Monolithic 
stationary phases allow tailoring the surface of the material that best suits the separation 
of the solutes of interest since in many instances different kind of interactions could be 
used in the separation of compounds. Recently, great attention has been paid for using 
nanomaterials as chromatographic stationary phases. In this regard, nanotubes are 
emerging as chromatographic stationary phases due to their unique characteristics [1]. 
Nanoparticles, nanotubes, fullerenes and nano sized diamonds are widely used in 




chemical interactions, thermal conductivity, chemical and thermal stability and tensile 
strength.  Some of these properties have contributed to their rapid growth in separation  
sciences [2-4]. Nanotubes in general started emerging in nanostructures since 1980, and 
carbon nanotubes in particular gained popularity in research due to their unique chemical 
and physical properties [5].  Carbon possesses the ability to bind with various chemical 
compounds and create materials having diverse characteristics [6]. Carbon nanotubes 
belong to the fullerene family of carbon allotropes. It is tubular in shape and consists of 
covalently bonded carbon atoms [7]. A single-walled carbon nanotube (SWNT) can be 
described as a sheet of graphene rolled into a seamless cylinder and the ends capped with 
the hemispherical, fullerene like structures [5]. Multi-walled carbon nanotubes 
(MWCNTs) have relatively complex structure consisting of additional concentric 
cylindrical shells of graphene sheets coaxially arranged around the central core of the 




Figure 1. Schematic illustration of SWNT and MWNT (Adapted from Chem draw). 
The application of carbon nanotubes (CNT) as a chromatographic separation 




which is a well-known stationary phase in chromatography [8-10]. MWCNTs have been 
used as adsorbents for solid-phase extraction (SPE) of several compounds. The 
adsorptive potential of MWCNTs has been used in environmental analysis of several 
compounds e.g. pesticides and polyaromatic hydrocarbons [11-14]. Non-modified 
MWCNTs, activated carbon and graphitized carbon black (Carbopack B) have been used 
as column packing materials, and their separation ability has been shown in gas 
chromatography. It has been shown that MWCNTs are better packing material than 
activated charcoal and carbopack B for volatile compounds, especially with low boiling 
compounds [15]. In order to achieve high resolution and stability at high temperatures in 
gas chromatography CNTs have been immobilized onto the wall of GC capillary columns 
by chemical vapor deposition. By changing the thickness of CNT wall coatings different 
retention capabilities have been achieved [16, 17]. Covalently modified CNT also have 
been used in GC to enhance the dispersion of CNT and to increase the affinity of polar 
solutes [18]. Enhanced separation of alkanes and aromatic compounds was achieved by 
packing the GC column with MWCNT-COOH and MWCNT-CONH2 [19].    
Carbon nanotubes have also been tested as stationary phases for CEC. In CEC, 
open tubular columns as well as organic monolithic stationary phases incorporated with 
CNT have been used.  In one investigation, a fused-silica capillary was silanized and a 
carboxyl modified MNCNT was immobilized onto the capillary walls.  The columns thus 
obtained showed high resolution, high separation efficiency, good retention factors and 




poly(diallydimethylammonium chloride)-modified fused silica surface showed improved 
baseline separation of a mixture of seven nitrogen-containing aromatic compounds 
compared to capillary zone electrophoresis [21]. An organic monolithic stationary phase 
consisting of vinylbenzyl chloride (VBC) and ethylene dimethacrylate (EDMA) 
incorporated with SWCNT and without SWCNT has been tested with a mixture of 
peptides.  The organic monolith VBC-EDMA-SWCNT thus obtained showed better peak 
efficiency and good peak retention compared to the control column i.e. without SWCNTs 
[22]. More recently, a capillary column filled with carboxy functionalized nanotubes that 
were incorporated in the glycidyl methacrylate (GMA) and ethylene glycol 
dimethacrylate (EDMA) was used in the separation of small molecules in the reversed 
phase chromatography mode. Superior efficiency was achieved with a GMA/EDMA 
column with nanoparticles when compared to the control column, i.e. without SWCNT 
[23].  
The use of CNT as stationary phases in HPLC is a recent promising trend in 
separation science. Baseline separation of polycyclic aromatic hydrocarbons (PAHs) was 
achieved in HPLC with MWCNTs assembled layer by layer onto silica microspheres to 
form MWCNTs/SiO2 [8].  Other research reports have shown that silica HPLC columns 
incorporated with CNTs yielded high separation efficiency for peptides and small 
aromatic compounds [3, 24]. Although there have been  studies conducted in the field of 
incorporating CNT into monolithic stationary phases for HPLC, the full potentials of 




improved characteristics to produce columns with the best performance for the separation 
of a wide range of solutes.  
Thus, it is the aim of this study to develop MWCTs incorporated into a suitable 
organic polymer monolith for use as a novel stationary phase in HPLC. To achieve a 
column with best performance, several experiments were carried out by changing the 
amount and type of nanoparticles, the polymerization temperature of the monolith and the 
high power sonication time of nanotubes. As will be shown, the nanoparticle-
incorporated monolith is hydrophobic in nature and also has bonds. The optimized 
column was used for the reversed phase separation of small molecules, and offered good 




The HPLC setup consisted of a quaternary solvent delivery system Model Q-grad 
pump from Lab Alliance (State College, PA, USA), a solvent delivery system model 
CM4000  and a model 3100 UV-Vis variable wavelength detector from Milton Roy, LDC 
division (Riviera Beach, FL, USA) and a Rheodyne injector model 7010 (Cotati, CA, 
USA) equipped with a 20 L sample loop. A constant pressure air driven pump Model 
Shandon from Southern Products Limited (Cheshire, UK) was used for column packing. 




bath model 2100 and high power sonicator model sonic dismembrator 50 were from 
Thermo Fischer Scientific (Waltham, MA, USA).  
 
Reagents and Materials 
Multi-walled carbon nanotubes (MWCNTs) were purchased from Sun Innovation 
Inc. (Fremont, CA). Alkyl benzenes (ABs), phenoxy acid herbicides, cyanobenzene 
derivatives, benzonitrile, aniline derivatives, trifluoroacetic acid (TFA), 2,2’-
azobis(isobutyronitrile) (AIBN), pentaerithrytol triacrylate (PETA), butyl methacrylate 
(BMA), ethylene glycol dimethacrylate (EDMA), ethylenedimethacrylate (EMA), methyl 
methacrylate (MMA), chlorophenols, glycidyl methacrylate (GMA), 1-dodecanol, 
cyclohexanol, DL-dansyl (Dns) amino acids were purchased from Sigma Aldrich 
(Milwaukee, WI, USA).  Glyceryl monomethacrylate (GMM) was from Monomer-
Polymer and Dajac Labs (Trevose, PA, USA). HPLC grade acetonitrile and isopropyl 
alcohol were purchased from Pharmco Aaper (Brookfield, CT, USA). Stainless steel 
tubing of 4.6 mm id was obtained from Alltech Associates (Deerfield, IL, USA). 
 
Preparation of monolithic columns 
A polymerization mixture of 6g was prepared by weighing monomers and 
porogens according to the values listed in Table 1. All the mixtures were first vortexed 
for 1 min, sonicated at 40
 ˚
C for 15 min, purged with nitrogen for 5 min and then 




a mold for the monolith. Both column ends were plugged tightly with column end fittings 
and thereafter heated at 50 ˚C - 60 ˚C in a water bath for 15 -20h.  The monolithic 
columns thus obtained were washed with acetonitrile for 30 min followed by isopropyl 
alcohol for 30 min.  The monolith was transferred from the 25 cm mold to a shorter 
column of 10 cm x 4.6 mm id by connecting the two columns by a ¼ “-union and passing 
isopropanol (IPA) using constant pressure pump at 6000 psi until the monolith was 
completely transferred.  Thereafter, the column was washed with the running buffer and 
tested with standard solutes. A series of monolithic compositions were tested.  The 
GMM/EDMA monolith was found as a suitable monolith to incorporate nanoparticles. 
SN3251 was incorporated in different amounts in the GMM/EDMA monolith and 3 mg 
quantity was found as the best amount. In order to homogenize and break the nanotubes 
into smaller ones, the MWCNTs was dissolved in 1-dodecanol and subjected to high 
power sonication for 1 min, 15 min and 30 min while keeping the vial in ice to prevent 
evaporation and then added the monomer and the rest of the material. Once the 
polymerization solution was sonicated, the column was prepared similarly as above. 
 
Chromatographic conditions 
To achieve a good retention of small molecules, the polarity of the mobile phase 
must be adjusted.  Different compositions of ACN/H2O with 0.1% of TFA were used as 
the mobile phases. For the chiral separation of D and L Dns-amino acids, a mobile phase 




prepared by dissolving the solutes in the mobile phase and injected via a 20 L injection 
loop. Isocratic separation of small molecules and chiral compounds were carried out at a 
flow rate of 1 mL/min. 
 
Results and discussion 
 
Column optimization incorporating MWCNTs 
In order to find the monolithic stationary phase best suited to incorporate 
MWCNTs, a series of monolithic columns incorporating different nanotubes and 
monomer compositions were tested, see Table 1. These were compared with a blank 
monolith that would have the least hydrophobic character.  
The MN1 monolith (see Table 1 for composition) did not meet the criteria as a 
blank monolith, since it showed some retention toward alkyl benzenes and proteins. In 
other words, MN1 possessed RPC properties.  The addition of 12.5 mg of MWCNTs to 
MN1 yielded the MN1a monolith, which resulted in a moderate enhancement of protein 
retention as shown in Table 2, but the protein bands were broad. Since the aim was to 
achieve separation and retention solely via the incorporated MWCNTs, the search for an 
ideal blank monolith continued. In this regard, MMA has a smaller alkyl chain than 
BMA, and therefore, it might generate a less hydrophobic monolith (designated as MN2) 
than BMA. As expected, MN2 yielded less retention time than MN1, but it gave higher 




porous structure, the concentration of the crosslinker was increased. The resulting 
monolith (MN2) did show more permeability and in turn lower pressure (~2000 psi at 1 
mL/min). To further improve the monolith, a new cross linker e.g., TRIM, was evaluated. 
The resulting MN3 monolith did not separate alkyl benzenes and proteins indicating a 
suitable blank monolith. Then, 37.5 mg SN6957838 MWCNTs were incorporated into 
MN3 to increase the hydrophobic character of the stationary phase (denoted as MN3a) 
and in turn yield good separation and retention. However, the monolith MN3a, gave a 
high pressure and MWCNTs did not show a homogeneous dispersion in the monolith. 
This led to a monolith with low performance even after decreasing the amount of 
MWCNTs to 12.5 mg (MN3b). The monolith designated as MN4 was developed using 
GMM/PETA, see Table 1. This monolith (MN4) was not suitable as a blank because it 
produced high pressure. All of the above monoliths were unsatisfactory because they 
showed residual hydrophobicity or exhibited low permeability. Finally, the suitable blank 
monolith was achieved using the monomers GMM/EDMA and designated as MN5. As 
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Incorporating MWCNTs into the MN5 monolith.  
Nanotubes are inert, hydrophobic in nature and may undergo strong van der Walls 
and  interactions with the solutes. Due to these characteristics, the MWCNTs are 
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expected to achieve the desired retention for solutes under RPC mobile phase conditions; that 
is hydro-organic mobile phases. 
 
TABLE 2 
COMPARISON OF THE RETENTION TIMES OBTAINED WITH MN1 AND MN1a 
WITH AND WITHOUT NANOPARTICLES 
 
MN5 monolith with SN 6957838.  First, MWCNTs batch # SN 6957838 were 
selected and incorporated into the MN5 blank monolith. These nanotubes have an outer 
diameter of 20-30 nm, an internal diameter of 5-10 nm, and a length of 1-2 m.  With the 
addition of 12.5 mg of SN6957838 to the MN5 monolith to yield the monolith MN5a, which 
showed some retention towards ABs, see Fig. 3a. In order to enhance the separation and 
retention of ABs, the polymerization temperature was changed to 55 
o
C and 58 
o
C and the 
corresponding monoliths were designated as MN5b, and MN5c, respectively. The 
Protein Retention time (min) 
MN1 MN1a 






Ribonuclease A 5.51 5.78 6.06 6.16 
Cytochrome C 6.3 6.62 7.04 7.25 
Lysozyme 6.86 7.27 7.78 7.85 
BSA, Transferrin 7.39 7.93 8.42 8.53 
Carbonic anhydrase 8.05 8.6 9.04 9.15 




chromatograms of AB separations using MN5b and MN5c are shown in Fig. 3B and C. As 
shown in these Figures, an improved separation was achieved on MN5b at a polymerization 
temperature of 55˚C. The retention values of ABs are reported in Table 3. From these data, it 
is clear that the 55 
o
C was the best temperature and was used as the polymerization 








   
 
Figure  2. Chromatogram of a mixture of 7 ABs (toluene, ethyl benzene, propyl benzene, 
butyl benzene, amyl benzene, hexyl benzene and heptyl benzene) using MN5 monolith. 
Mobile phase, ACN: H2O (35:65 v/v) containing 0.1% TFA; column dimensions, 10 cm x 4.6 
mm I.D.; flow rate, 1 mL/min. 
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Figure 3. Chromatograms of ABs using (A) MN5a (50 
o
C) (B) MN5b (55 
o
C) and (C) MN5c 
(58 
o
C) monolithic columns prepared at different polymerization temperatures.  Mobile 
phase, ACN: H2O (35:65 v/v) containing 0.1% TFA. Other conditions are as in Fig.2. 






































































































































































































RETENTION TIMES OF ABS OBTAINED ON GMM/EDMA MONOLITH 
INCORPORATING MWCNTS PREPARED AT DIFFERENT POLYMERIZATION 
TEMPERATURES 
 







tR k’ log k’ tR k’ log k’ tR k’ log k’ 
Toluene 2.36 1.8 0.255 2.48 1.62 0.21 2.64 1.93 0.28 
Ethyl benzene 2.56 2.04 0.31 2.74 1.87 0.27 2.92 2.24 0.35 
Propyl benzene 2.88 2.43 0.38 3.1 2.59 0.41 3.32 2.68 0.43 
Butyl benzene 3.55 3.22 0.51 3.62 3.21 0.51 3.74 3.15 0.5 
Amyl benzene 4.12 3.9 0.58 4.44 4.16 0.62 4.33 3.81 0.58 
Phenyl hexane 5.25 5.25 0.72 5.76 5.67 0.75 5.6 5.22 0.72 
Phenyl heptane 7.29 7.67 0.88 8.4 8.76 0.94 8.25 7.25 0.86 
 
TABLE 4 
RETENTION TIMES OF ALKYL BENZENES AT DIFFERENT ACETONITRILE 
CONCENTRATIONS ON MN5e MONOLITH 
 35% ACN 40% ACN 45 % ACN 
 tR k’ log k’ tR k’ log k’ tR k’ log k’ 
Toluene 2.67 2.81 0.44 1.92 1.74 0.24 1.56 1.6 0.12 
Ethyl  benzene 3.08 3.28 0.52 2.08 1.97 0.29 1.61 1.69 0.14 
Propyl benzene 3.7 4.14 0.62 2.3 2.28 0.35 1.73 1.79 0.19 
Butyl benzene 4.55 5.32 0.73 2.65 2.78 0.44 1.84 2.19 0.24 
Amyl benzene 5.54 6.69 0.82 2.98 3.25 0.52 1.94 2.5 0.28 
Phenyl hexane 6.78 8.41 0.92 3.67 4.24 0.62 2.08 2.71 0.32 





MN5 monolith with SN 32547.  SN 32547 is OH-MWCNTs and has the following 
specifications: 10-20 nm OD, 5-10 nm ID, and 10-30 m length. The monolithic column 
prepared with OH-MWCNT (MN5e) showed good separation and retention, see Fig. 4. 
The monolith MN5e (see Table 1 for the composition) was further tested with the 
ABs test mixture while changing the composition of the mobile phase. The retention of ABs 
at different ACN concentration is shown in Table 4.  At 35% ACN concentration, the column 
shows the best retention. To obtain a column with optimized retention characteristics, the 
amount of OH-MWCNTs added to the polymerization mixture was varied. The ABs test 
mixture was injected onto all the columns (i.e., MN5d –MN5h columns) at different ACN 
concentrations. With increasing the ACN concentration the k’ values of ABs decreased, see 
Fig. 5. The monolithic composition and the amounts of nanotubes incorporated into MN5d-
MN5h columns are shown in Table 1. Out of these monoliths MN5g with 3 mg of OH-
MWCNTs showed the best retention and separation for ABs, see Fig. 4.  The column made 
with 1 mg of OH-MWCNTs, (MN5h) poorly separated ABs, a fact that indicates that the 
MWCNTs help in the separation of ABs. The k’ values of the solutes are linearly 
proportional to the amount of MWCNTs incorporated into the monolith. The hydrophobic 
character and  interactions of the column increased with an increased amount of OH-
MWCNTs in the polymerization mixture.  Fig. 5 shows the linear relationship of k’ values of 
ABs obtained on the monolithic columns vs. the amount of nanotubes incorporated in the 
columns MN5d –MN5h at different acetonitrile concentrations.  
Effect of high power sonication. Even though the above monolith gave better 
performance with ABs, it did not show improvement for protein, peptide or amino acid 




subjected to a high power sonication [25, 26] before incorporating the nanotubes in the 
monolith, and columns were prepared at varying time of the high power sonication. Both the 
1 min and 15 min sonication times resulted better peak shapes with latter resulted much 
better peak efficiency.  The column made using OH-MWCNTs at 30 min sonication did not 
show any improvement (see Fig. 6). This may be due to the fact that OH-MWCNTs may 
change their properties while subjecting them to high power sonication. Therefore, for the 
rest of the investigation, the 15 min sonicated column was used, and the MN5g column 
whose nanotubes were sonicated for 15 min was designated as MN5g-15. 
 
Chromatographic evaluation of the optimized MN5g-15 columns  
Based on the series of monolithic columns evaluated above, which involved 
optimizing different parameters such as polymerization temperatures, nature of the monolith, 
the amount and type of MWCNT and sonication time, the MN5g-15 column was identified 
as the best column. On this basis, the column was evaluated with different types of solutes. 
Aromatic compounds with different functional groups. Aromatic compounds with 
different substituents on the benzene ring were used as model solutes to characterize the 
chromatographic properties of the MN5g-15 column.  With the addition of OH-MWCNTs to 
the monolith, it is expected that the column would exhibit  interaction in addition to 
hydrophobic interaction. To analyze the hydrophobic and  interactions exhibited by the 
MN5g-15 stationary phase, aromatic compounds having different electron 
























































































































































Figure 4: Chromatograms of ABs obtained on GMM/EDMA columns with varying amounts 
of OH-MWCNTs. (A)MN5e,  (B) MN5f,  (C) MN5g, (D) MN5h.  Mobile phase, ACN: H2O 
(35:65 v/v) at 0.1% TFA. Other conditions as in Fig. 2. Solutes: 1, toluene; 2, ethylbenzene; 
3, propy benzene; 4,butylbenzene; 5,amylbenzene; 6, hexylbenzene; 7, heptylbenzene. 
Time (min)























































































































































































Amount of nanotubes (OH-MWCNTs) 






Figure 5. Retention factors of ABs at different acetonitrile concentration obtained on 
GMM/EDMA monolithic columns incorporating various amounts of OH-MWCNTs.  
 
Aromatic compounds with different functional groups. Aromatic compounds with 
different substituents on the benzene ring were used as model solutes to characterize the 
chromatographic properties of the MN5g-15 column.  With the addition of OH-MWCNTs to 
the monolith, it is expected that the column would exhibit  interaction in addition to 
hydrophobic interaction. To analyze the hydrophobic and  interactions exhibited by the 
MN5g-15 stationary phase, aromatic compounds having different electron 
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Figure 6.  Chromatograms of ABs obtained on the MN5g monolith with different times of 
high power sonication. A. 1 min, B. 15 min, C. 30 min. Mobile phase, ACN: H2O (35:65 v/v) 
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at 0.1% TFA. Other conditions as in Fig.2. Solutes 1, toluene; 2,ethylbenzene; 3, propyl 
benzene; 4, butylbenzene; 5, amylbenzene; 6, hexylbenzene; 7, heptylbenzene. 
 
TABLE 5 
COMPARISON OF THE k’ VALUES OF ABS OBTAINED ON MN5g COLUMN AT 
VARIOUS HIGH POWER SONICATION TIME 
 
Electron-donating substituents on the benzene ring make the ring more  donating 
than benzene. These groups are called benzene ring activating groups [25]. They increase the 
electron density on the benzene ring. Typical examples of strongly activating groups are – 
NH2, NHR, -NR2, OH and O
-
; while representative moderately activating groups are –
NHCOCH3, -NHCOR, -OCH3 and –OR and weakly activating substituents are –CH3, -C2H5, 
-R, and –C6H5. Electron-withdrawing groups decrease the electron density on the benzene 
ring by making the ring able to accept more  electrons. These are called deactivating groups 
 0 min 1 min 15 min 30 min 
Toluene 2.17 3.38 3.78 3.65 
Ethyl benzene 2.71 4.07 4.57 4.2 
Propyl benzene 3.44 5.05 6.65 5.19 
Butyl benzene 4.54 6.42 7.28 6.58 
Amyl benzene 5.77 8.11 9.15 8.26 
Phenyl hexane 7.3 10.22 11.46 10.29 




and are classified into (i) weakly deactivating groups such as –F, -Cl, -Br and  -I; (ii) 
moderately deactivating substituents such as  -CN, -SO3H, -COOH, -COOR, -CHO and  
-COR; and  (iii) strongly deactivating groups such as  -NO2, -NR3, -CF3, and CCl3[26].  
 
TABLE 6 
CHROMATOGRAPHIC BEHAVIOR OF PARA SUBSTITUTED TOLUENE 
COMPOUNDS. MOBILE PHASE, ACN:H2O (20:80 v/v) CONTAINING 0.1% TFA 
Compound tR k’ log k’ 
p-toluidine 1.11 0.44 -0.35 
p-tolualdehyde 2.068 1.68 0.22 
p-tolunitrie 2.24 1.91 0.28 
toluene 3.78 3.9 0.59 
 
Toluene derivatives. p-Toluidine, p-tolualdehyde, p-tolunitrile and toluene were used 
as model solutes. When the mixture of these solutes was injected onto the column, the 
observed elution order was p-toluidine, p-tolualdehyde, p-tolunitrile and toluene with the k’ 
values of 0.44, 1.68, 1.91 and 3.9, respectively, see Table 6.  Regarding hydrophobicity, 
toluene is more hydrophobic than the other 3 solutes. p-Toluidine, p-tolualdehyde and p-
tolunitrile eluted in the order of increasing deactivation of the benzene ring by their 
respective substituents which indicate π-π interactions in addition to nonpolar interactions 
with the nanotubes on the surface of the monolith, while toluene being the most hydrophobic 
and carrying the weakly activating methyl group was the last eluting compound, a fact that 




A mixture of m substituted toluene compounds including m-toluidine, m-
tolualdehyde, m-tolunitrile, toluene and m-nitrotoluene were separated on the column and the 
k’values for these compounds were 0.31, 2.42, 2.8, 3.9, 4.52 respectively, see Table 7. m-
Nitrotoluene is more retained on the column  than toluene. This gives the idea that the 
TABLE 7 
CHROMATOGRAPHIC BEHAVIOR OF META SUBSTITUTED TOLUENE 
COMPOUNDS. MOBILE PHASE, ACN:H2O (20:80 v/v) CONTAINING 0.1% TFA 
Compound tR k’ log k’ 
m-toluidine 1.05 0.31 -0.51 
m-tolualdehyde 2.74 2.42 0.38 
m-tolunitrile 3.04 2.8 0.45 
Toluene 3.78 3.9 0.59 
m-nitrotoluene 4.42 4.52 0.65 
 
retention mechanism is due to the hydrophobic interactions and interactions. The strong 
electron withdrawing group on m-nitrotoluene decreases the  electron density on the 
aromatic ring, making it a soft Lewis acid that can accept  electrons from OH-MWCNTs 
which is having high  electron density resulting in -donor--acceptor complexes. The  
interactions make the nitrotoluene more retained on the column than other solutes. 
Benzene derivatives. In addition to toluene derivatives, other compounds that show 




derivatives such as benzonitrile, benzaldehyde, nitrobenzene and toluene were injected onto 
MN5g-15 monolith using the mobile phase, ACN:H2O (30:70 v/v) containing 0.1% TFA. 
The elution order was observed as benzonitrile, benzaldehyde, nitrobenzene and toluene with 
the observed respective k’ values as 2.08, 3.44, 3.44 and 4.05, see Table 8. Toluene has a 
weakly 
TABLE 8 
CHROMATOGRAPHIC BEHAVIOR OF BENZENE DERIVATIVES  
Compound tR k’ log k’ 
Benzonitrile 2.5 2.08 0.31 
Benzaldehyde 3.6 3.44 0.53 
Nitrobenzene 3.65 3.45 0.54 
Toluene 4.05 4 0.602 
 
activating methyl group which weakly increases the electron donating density of the benzene 
ring but it has a relatively high hydrophobic character. The other three compounds have 
deactivating substituents with the strongest deactivator being the nitro group followed by 
moderate nitrile and then aldehyde. Nitro-substituted benzene is expected to have greater 
retention on the column because nitrobenzene has low  electron density and it has the ability 
to accept  electrons from the  electrons of OH-MWCNTs resulting in interactions that 
leads to -donor--acceptor complexes [25, 27]. But in this case toluene shows the higher 




 Anilines. The retentive character of the column was further studied using a mixture of 
anilines with ACN: H2O (20:80 v/v) containing 0.1% TFA as the mobile phase, see Fig. 7. 




Figure 7. Chromatogram of anilines obtained on MN5g-15 column. Solutes: (1), aniline; 
(2),4-ethylaniline; (3),4-bromoaniline; (4),2,4-dichloroaniline. Mobile phase, ACN:H2O 
(20:80 v/v) containing 0.1% TFA, Other conditions as in Fig.2. 
The retention shows the typical RPC characteristics where halogenated anilines were more 
retained than ethyl substituted anilines.  This demonstrates that hydrophobicity and  



































































Figure 8. Chromatogram of some phenolic compounds obtained on MN5g-15 column. 
Solutes: (1), phenol; (2), 2-chlorophenol; (3), 4-nitrophenol; (4), 2,4,5-trinitrophenol; (5), 
pentachlorophenol. Mobile phase, ACN:H2O (40:60 v/v) containing 0.1% TFA, Other 
conditions as in Fig.2. 
Phenolic compounds. In this section, some phenols were analyzed on the MN5g-15 
column using the mobile phase composed of ACN:H2O (40:60 v/v) containing 0.1% TFA.  
Fig. 8 shows the separation of some phenolic compounds using the MN5g-15 stationary 
phase. The observed elution order was phenol, 2-chlorophenol, 4-nitrophenol, 2, 4, 5-
trichlorophenol and pentachlorophenol with the k’ values of 1.14, 1.64, 2.76, 4.46, 7.78, 
respectively. Phenol eluted faster than the substituted phenols such as 2,4,5-trichlorophenol 
and pentachlorophenol, which yielded higher retention due to their hydrophobic and  
interactions.  It is observed that the degree of halogenation and the size of the solute control 
the retention. More halogenated phenols were retained for longer time on the stationary phase 
showing the RPC behavior for separation. 
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Herbicides. Herbicides are a group of highly toxic compounds that can accumulate in 
the environment or in drinking water resulting in serious damage to the human health. 
Therefore, it is important to develop a method to analyze for these compounds [28]. The 
chromatographic properties of the MN5g-15 column were further evaluated using phenoxy 
herbicides as model solutes, see Fig. 9.  Since they are polar solutes they can be ionized 








Figure 9. Chromatogram of some phenoxy herbicides obtained on MN5g-15 column. Mobile 
phase, ACN:H2O (40:60 v/v) at 0.1% TFA, Other conditions as in Fig.2. Solutes: (1), 2-
phenoxypropionic acid; (2), 2-(2-chloro) propionic acid; (3), methylchlorophenoxypropionic 
acid; (4), 2-(2,4,5-trichloropenoxy)-propionic acid.  
can be seen in Fig. 9, the column was able to separate 2-phenoxypropionic acid, 2-(2-chloro)- 
propionic acid, methyl chloro phenoxy propionic acid, 2-(2,4,5- trichlorophenoxy)propionic 
acid with the k’ values of 2.01, 3.93, 7.19, 11.74, respectively. These data illustrate the fact 
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that 2-(2,4,5-trichlorophenoxy)propionic acid with three chlorine atoms attached to the 
benzene ring exhibits a higher retention than 2-phenoxy propionic acid.  Similarly, 2-(2-
chloro) propionic acid is more retained on the column than 2-phenoxypropionic acid. This 
gives the idea that chloride substitution can induce  interactions with the stationary phase 
and increase solute retention. In addition, phenoxy herbicides show other interactions due to 
the polar groups such as -COOH, -OH. 
 
Separation of chiral compounds 
The analysis of enantiomers is an area of increasing importance in separation science. 
In HPLC, chiral separation is carried out using chiral additives in the mobile phase or using a 
chiral stationary phase [29]. Enantiomers are isomeric forms of the same compound, which 
differ only in their spatial orientation and have identical physical properties. In order to 
separate racemic mixtures, the two enantiomers should interact differently with the OH-
MWCNTs in the stationary phase. Due to their unique physical, chemical, and electrical 
properties, MWCNTs have been the subject of intense research as chiral selectors in CE but 
to a lesser extent in HPLC [7, 29-37].  The MWCNTs have large surface to volume, which in 
turn results in achieving a favorable mass transfer and thus enhanced chromatographic 
efficiency towards the separation of chiral compounds. The chirality of the MWCNTs arises 
from the arrangement of multiple walls around the central cylinder [38].  
   The MN5g-15 column was able to successfully separate five enantiomeric 
compounds including phenoxy herbicides such as phenoxypropionic acid, 2,4-dichloro- 





Dns-phenylalanine and the pharmaceutically important compound bupivacaine; for their 
structures see Fig. 10. 
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Figure 10. Chiral compounds separated on the MN5g-15 column (* indicates the 
stereocenters). 
Dansyl methionine 
Dansyl phenylalanine  
Bupivacaine 
2,4-dichloro phenoxy  propionic acid 





 To achieve an optimal enantioseparation, the column loading in nanotubes needs to 
be optimized.  This was carried out by varying the amount of OH-MWCNTs incorporated in 
the monolith.  The results are shown in Table 10 where it can be see that 3 mg of OH-
MWCNTs yielded enhanced performance for separating the chiral compounds under 
investigation. Enantiomeric phenoxypropionic acid and 2,4-dichlorophenylpropionic acid 
were separated using the mobile phase 50 mM sodium acetate 25% ACN, pH of 4.12, see 
Fig. 11.  Since the pKa value of phenoxy herbicides is around 4.14, these compounds are 
partially ionized at the pH of the mobile phase, a condition that favored separation. Also, 
Dns- methionine and Dns-phenylalanine were separated using 25 mM acetate buffer, 35% 
ACN, pH 4.12.  This shows that MWCNTs can function as a chiral stationary phase to 
separate enantiomeric compounds. 
TABLE 9 
ENATIOMERIC RESOLUTION SEPARATION OF COMPOUNDS USING  
 MN5g-15 COLUM 
PS: Partially resolved, see Fig.9 a 
Compound Name Resolution of chiral compounds with  varying amount of 
nanotubes 
2 mg 3 mg 4 mg 5 mg 
DNS methionine 0.42 1.35 0.24 0 
DNS Phenyl alanine 0.84 1.25 0.62 0 
Bupivacaine 0.7 1.02 0.5 0 
Phenoxy propionic acid 0 1.4 P.S. 0 0 
2,4-Dichloro phenyl propionic 
acid 






















Figure 11. Separation of raceimic phenoxy herbicides using MN5g-15 column. Mobile 
phase, ACN: H2O (40:60 v/v) at 50 mM sodium acetate, pH 4.12, Other conditions as in 
Fig.2.Solutes; A, 2,4-dichlorophenoxy propionic acid; B, phenoxy propionic acid.  
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Figure 12. Separation of Dns amino acids obtained on the MN5g-15 column. Mobile phase, 
ACN:H2O (35:65v/v) containing 25 mm mM sodium acetate, pH 4.1, Other conditions as in 
Fig.2 Solutes; A, Dns-methionine; B, Dns -phenylalanine.  
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Figure 13. Separation of racemic Bupivacaine obtained on the MN5g-15 column. Mobile 
phase, ACN:H2O (55:45v/v) containing 0.1% TFA.  Other conditions as in Fig.2. 
In this study, SN 32547 was identified as the optimum chiral selector. The chiral 
resolution is based on the inclusion complexation between the chiral selector e.g., OH-
MWCNTs and the enantiomer, which causes the selective retardation of the enantiomer [39, 
40].  When the racemic mixture is injected onto the column it forms an analyte–chiral 
selector complex. Two enantiomers have different affinity for the chiral selector and 
therefore the chromatographic retention of these enantiomers is different. By increasing the 
chiral selector concentration, resolution is increased up to a certain level. After the addition 
the 3 mg of MWCNTs there were no chiral separation is achieved. Here the chiral selector is 
OH-MWCNTs. Increasing OH-MWCNTs   prevents the free movement of the analyte in the 
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stationary phase. Therefore, with the addition of 5 mg of OH-MWCNTs, zero resolution is 
achieved. To provide a maximum resolution there is an optimum OH-MWCNTs  
concentration. By observing the enantiomeric resolution of Table 9, it can be seen that 2 mg 
of OH-MWCNTs are not sufficient for the  retention and consequently a good resolution of 
the racemic mixture. 3 mg OH-MWCNTs is the optimum chiral selector concentration. The 
columns made out of 4 mg and 5 mg of OH-MWCNTs show low resolution due to an 
increase in the retention time of the enantiomers causing increased band broadening and 




This study introduced a novel monolithic stationary phase for RPC separation by 
HPLC.  The monolith, which was designated as MN5g-15, allowed separation solely via 
differential interaction of the solutes with OH-MWCNTs (i.e., the carbon nanotubes). A wide 
range of aromatic compounds such as benzene derivatives, toluene derivatives, anilines and 
chlorophenols were resolved by the column. The separation of these compounds was mainly 
due to  interactions and hydrophobic interactions. The column proved useful for the 
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OCTADECYL MONOLITHIC COLUMNS FOR PROTEIN SEPARATION 
 
Introduction 
High performance liquid chromatography is a high efficiency separation 
technique for quantitative and qualitative analysis of a wide range of compounds. In 
HPLC, the column is the heart of the separation process. Columns packed with micro 
particulates have several limitations for the efficient separation such as slow diffusional 
mass transfer and large void volume between the packed particles [1-4].  Monolithic 
columns evolved significantly in last decades and have proven a very good alternative to 
particle packed columns due to their ability to separate a wide range of compounds [5, 6]. 
Higher separation efficiency could be achieved due to the small sized skeletons and wide 
flow-through pores of the monolithic columns [7, 8]. The monolithic column is a 
continuous rigid skeleton with uniform pore size and if necessary,  the surface can be 
functionalized to achieve the desired binding properties [9]. They can be developed using 
synthetic organic materials, natural polymers or inorganic materials and have specific 
hydrodynamic properties such as lower mass transfer resistance and pressure drop [10-




hydrophobic monoliths [15].   The advantages of monolithic columns are that they exhibit 
good flow profile, good permeability, withstand high pressure, allow tailor made surfaces 
and by selecting the appropriate monomers, one can control the interactions of the 
monolithic surface.  
One of the challenges in proteomic research is the separation and identification of 
compounds with very similar physicochemical properties [16, 17].  In RPC, proteins are 
bound to hydrophobic matrices. When the organic solvent interacts with the protein and 
the monolithic stationary phase it displaces the protein. Reports have shown that RPC has 
good resolving power for proteins [18-20]. Proteins differ in their size and they have 
different polarities, therefore they have different interactions with the monolithic surface. 
There have been several attempts to separate proteins using monolithic columns.  In the 
the first attempt, a single piece of cellulose sponge was used in separating proteins [21]. 
In another study,  proteins were separated on polyacrylamide based monolithic columns 
[14]. Similarly, norbornene based monoliths were also used in separating proteins [22, 
23]. In another study, macroporous poly(styrene–co-divinylbenzene) monolithic 
stationary phases have been prepared by free radical polymerization and were able to 
separate proteins and peptides in a relatively short time [24].  
Additions of nanotubes to monolithic stationary phases are gaining popularity due 
to their unique characteristics [25-27]. Svec at al. introduced carbon nanotubes in the 
polymerization mixture and achieved 44000 plates/m for benzene with monolithic 
capillary columns [28]. Guillaume et al. added  carbon nanotube (CNT) monolithic 
column coated with a pyrenyl derivative as the chiral selector. A solution of pyrenyl 




HPLC chiral separation of underivatized amino acids [29]. Multiwalled carbon nanotubes 
were incorporated into a polymethacrylate-based monolith made out of EDMA and GMA 
and used for separation of anions. The study analyzed the efficiency of separation with 
changing amounts of MWCNTs, and studied thermal stability and Raman characteristics 
of the polymer [30]. ODA/TRIM monolith (or ODM monolith) is an organic and neutral 
monolith showing RPC characteristics. Neutral monoliths, void of fixed charges, were 
introduced and tested in our laboratory. The first monolith was reported by Okanda and 
El Rassi [31] and another attempt was reported by Karenga and El Rassi [32]. In this 
investigation, the previously reported ODM monolith from our laboratory [32], originally  
for use in RP-CEC, was slightly altered to render it suitable for RPC separation by 
HPLC. The alteration was concerned with making the column operate at high mobile 
phase using flow velocity high precision HPLC pump. The original ODM monolith was 
ideal for CEC where the mobile phase was transported through the capillary column by 
electroosmotic flow (EOF). Therefore, it was necessary to optimize the composition of 
the monolith to yield a highly permeable column for use in HPLC, yet with good 
separation efficiency toward proteins.  The monolith was further evaluated for proteins 




The HPLC setup consisted of a quaternary solvent delivery system Model Q-grad 




CM4000, and a Model SpectroMonitor 3100 UV-Vis variable wavelength detector from 
Milton Roy, LDC division (Riviera Beach, FL, USA) and a Rheodyne injector Model 
7010 (Cotati, CA, USA) equipped with a 20 L loop. A constant pressure air-driven 
pump Model Shandon from Southern Products Limited (Cheshire, UK) was used for 
column packing. An ultrasonic cleaner, Model 1510 Branson was purchased from 
Emersion (Danbury, CT, USA). The water bath Model 2100 was obtained from Thermo 
Fischer Scientific (Waltham, MA, USA). 
 
Reagents and Materials 
Multiwalled carbon nanotubes were purchased from Sun Innovation Inc. 
(Fremont, CA). Alkyl benzenes (ABs), trifluoroacetic acid (TFA), 2,2’-
azobis(isobutyronitrile) (AIBN), octadecyl acrylate (ODA), trimethylolpropane 
trimethacrylate (TRIM), ethylene glycol dimethacrylate (EDMA), ethylene glycol and 
cyclohexane, were purchased from Sigma Aldrich (Milwaukee, WI, USA). Egg white 
lysozyme, bovine serum albumin, ribonuclease A, ovalbumin, horse heart cytochrome C, 
bovine erythrocytes carbonic anhydrase, bovine milk lactoglobulin A and B and 
bovine milk -lactalbumin were purchased from Sigma (St. Louis, MO, USA). Chicken 
white lysozyme were from Promega (Madison, WI, USA). HPLC grade acetonitrile and 
isopropyl alcohol purchased from Pharmco Aaper (Brookfield, CT, USA). Stainless steel 
tubing of 4.6 mm id was obtained from Alltech Associates (Deerfield, IL, USA). 
Preparation of monolithic columns 
A polymerization mixture consisting of 5.5 g was prepared by weighing 




composition was varied in the range of 50% - 54.2% and ethylene glycol was in the range 
of 20.9%-24.48%. All polymerization solutions for making the monoliths were vortexed 
for 1 min, sonicated at 40
 o
C for 15 min, purged with nitrogen for 5 min and introduced 
into stainless steel columns with dimensions of 25 cm x 4.6 mm id that function as a 
mold for the monolith. Both column ends were plugged tightly and heated at 60 ˚C in a 
water bath for 15 h.  The monolithic column was washed with acetonitrile for 30 min 
followed by isopropyl alcohol.  The monolith was transferred from the 25 cm mold to a 
shorter column of 10 cm x 4.6 mm id by connecting the two columns with a ¼ “-union 
and passing IPA using a constant pressure pump starting from the pressure of 6000 lb/ in
2
 
until the monolith was completely transferred.  The column was washed with the running 
buffer and tested with standard solutes.  
                            
 
Figure 1.  Chemical structures of the monomer (A) ODA, and  (B) the crosslinker TRIM. 
A series of ODA/TRIM monolithic compositions were tested and an optimized 
column suitable for the separation of alkyl benzene and proteins was identified. 
MWCNTs were added to the monolith which shows optimum performance for RPC of 
proteins. Different polymerization mixtures were prepared by changing the type and 
amount of nanotube added to the polymerization mixture. The monoliths were tested 







To achieve a good retention for small molecules, the polarity of the mobile phase 
must be adjusted by changing its composition.  Different compositions of ACN/H2O with 
0.1% of TFA were used for the reversed phase separation. The proteins were analyzed 
using linear gradient of ACN from 0% - 75 % within 12 min. The alkylbenzenes were 
analyzed on the series of ODA/TRIM RPC columns using isocratic elution. All samples 
were prepared by dissolving the solutes in the mobile phase and were injected via a 20 
L sample loop. Isocratic separation of small molecules and linear gradient for proteins 
were carried out at flow rate of 1 mL/min. 
TABLE 1 





Monomer (% w/w) / 
Cross-linker (% w/w) 

































































































































ODA   (7%) /TRIM (14.5 
%) 
     
SN 2302 
150 mg 
M8 SN 2302 
25 mg 
M9 SN 2302 
18 mg 
M10 SN 2302 
12 mg 




















Results and discussion  
Column fabrication and RPC characterization 
Porogens and monomer composition. The monolithic RPC column was developed 
by optimizing  previously developed and tested monolith in our laboratory for CEC [32]. 
This involved the adjustment of its characteristics to be suitable for use in HPLC. First, 
the original monolith was tested using the optimal composition described by Karenga and 
El Rassi [32].  This monolith was designated as M1column, see Table 1, which is the 
optimum column for CEC for the separation of proteins and alkyl benzenes, see Fig. 1. 
The M1 column which was fabricated in the presence of the porogens cyclohexanol and 
ethylene glycol at 54.2-wt % and 20.9-wt%, respectively, showed low permeability and 
in turn exhibited high pressure. The column did not show good separation efficiency for 
alkyl benzenes. This may be due to the high mass transfer resistance in small pores as it 
was manifested by the relatively high backpressure observed with the column. In order to 
increase the size of the pores, the porogen composition was changed as in M2, see Table 
1. This composition did not show much improvement in terms of protein or alkyl benzene 
separations. Therefore, further decrease in the cyclohexanol concentration and increase in 
the concentration of ethylene glycol were necessary. The M3 column showed narrower 
peaks for proteins than all other columns investigated, but was not the optimum for the 
AB separation. It yielded higher retention time for alkyl benzenes but did not show 
efficient peaks. Similarly, we tested the M4 and M5 columns. Proteins were separated 




alkylbenzenes. Since for this series of columns, the porogen composition was changed 
while keeping that of the monomer constant, the only change would be the morphology 
of the resulting monoliths. As a result, the monolithic columns yielded similar retention 
times for proteins. The M3 column showed enhanced separation of proteins, which 
indicates that it has a relatively larger pore size thus providing easy accessibility for 
proteins and consequently greater separation efficiency. The other monoliths M1, M2, 
M4 and M5 were identified as not suitable for the separation of proteins as they showed lower 
separation efficiency. The M4 column was ideal for the separation of alkyl benzenes. 
These results indicate that M4 column has narrower channels or smaller pores, and 
therefore, it easily accessible for small molecules such as alkyl benzenes. 
 
 



















































































































Figure 2. Chromatograms of standard proteins (A) and alkyl benzenes (B) injected on the 
M1 column. Proteins were analyzed using a linear ACN gradient while alkyl benzenes 
were analyzed using isocratic elution. (A) Linear ACN gradient was carried out by 
increasing ACN from 0-75% of mobile phase B in 12 min. Mobile phase A consisted of 
H2O/ ACN (95:5 v/v) containing  0.1% TFA and the mobile phase B consisted of 
ACN/H20 (95:5 v/v) containing 0.1% TFA (B): Mobile phase, ACN: H2O (65:35 v/v) 
containing 0.1% TFA.  Solutes in A: (1), ribonuclease A; (2), cytochrome C; (3), bovine 
serum albumin; (4), ovalbumin; Solutes in B: (1), toluene; (2), ethylbenzene; (3), 
propylbenzene; (4), butylbenzene; (5), amylbenzene; (6), hexylbenzene; 






























Figure 3. Chromatograms of standard proteins (A) and alkyl benzenes (B) obtained on 
the  M2 column. All other conditions are as in Fig.  2. 
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Figure 4. Chromatograms of standard proteins (A) and alkylbenzenes (B) obtained on 


































































































































Figure 5. Chromatograms of standard proteins (A) and alkylbenzenes (B) obtained on 













































































































































































Figure 6. Chromatograms of standard proteins (A) and alkylbenzenes (B) obtained on 
the M5 column. All other conditions are as in Fig. 2.  
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Alkyl benzenes. Alkyl benzenes were chromatographed on the series of 
ODA/TRIM RPC columns, namely the M1-M5 monoliths, and the retention behavior 
was evaluated, see Table 2. It was observed that the k’ values gradually increased from 
the M1 to the  M4 column while decreasing the cyclohexanol content from 54.2-wt%-
51.2-wt% and increasing the  ethylene glycol from 20.9-wt%-23.6-wt% in the porogen. 
For the M4 column, the k’ reached an optimum value and then decreased on the M5 
column, see Fig. 7. This may indicate that the M4 column contains an ideal pore sizes for 
the separation of alkyl benzenes. 
 
Figure 7. Retention behavior of alkylbenzenes on the series of the RPC columns 
Since the M4 column showed the best performance for alkylbenzenes, the retention 







































concentration in the mobile phase from 65% - 80% (v/v), see Fig. 8. It can be seen that 
while increasing the organic content of the mobile phase, the log k’ of ABs decreased. 
This indicates that upon decreasing the polarity of the mobile phase the k’ values 
decreased which is the normal RPC behavior. This data indicate that the M4 column is 
suitable for RPC of small molecules. 
Evaluation of ODA/TRIM RPC columns with proteins  
A mixture of four standard proteins was injected onto the series of RPC columns 
and the retention times were measured, see Fig. 9. Each proteins show relatively similar 
retention times on this series of RPC columns using a linear ACN gradient. 
TABLE 2 


















M1 tr 0.89 2.21 2.44 2.85 3.4 4.07 5.12 6.57 
 k’  1.45 1.71 2.16 2.78 3.5 4.7 5.67 
          
M2 tr 0.83 2.07 2.67 3.67 4.52 5.62 7.18 9.28 
 k’  1.49 2.21 3.39 3.69 5.7 7.65 10.18 
          
M3 tr 0.83 2.56 2.96 3.61 4.44 5.56 7.03 9.27 
 k’  2.08 2.56 3.35 4.34 5.79 7.75 10.16 
          
M4 tr 0.71 2.78 3.22 3.96 4.98 6.33 8.2 10.78 
 k’  2.86 3.47 4.5 5.91 7.79 10.39 13.97 
          
M5 tr 0.78 2.42 3.05 3.71 4.74 5.94 7.65 11.48 





The columns were generated from the polymerization mixtures with constant 
monomer composition but at different porogen content. Therefore, it is believed that it 
will affect only the size of the channels thus generating relatively similar retention time 
for proteins. 
Testing M3 column with proteins. The M3 column was further evaluated with 
several other standard proteins to explore its potentials in resolving complex protein 
mixtures using the linear ACN gradient. 
 
 




































       
 
Figure 9. Retention time of the standard proteins obtained on the RPC columns 
  As shown in Fig. 10,  the column was able to successfully separate 7 proteins 
including ribonuclease A, cytochrome C, lysozyme, transferrin, BSA, lactalbumin A and 
ovalbumin with the retention times of 6.8, 7.72, 8.14, 8.54, 8.82, 9.27 and 10.5 min, 
respectively. When comparing the elution order of the proteins in Fig. 10, the typical 
RPC behavior was obtained on the M3 column.  Ribonuclease A and cytochrome C are 
hydrophilic proteins with relatively low molecular weights of 12, 200 and 13, 500, 
respectively, and therefore, they are expected to elute faster than other proteins. Other 
proteins having higher molecular weights such as BSA, -lactoglobulin A, ovalbumin are 




































Figure 10. Separation of standard proteins using linear ACN gradient on the M3 column. 
Solutes A, ribonuclease A; B, cytochrome C, lysozyme; D, transferrin; E, BSA; F, -
lactoglobulin A; D, ovalbumin. All the other conditions as in Fig. 2A. 
M3 monolithic stationary phase leading to more retention for these three proteins. Even 
though it has higher molecular weight than ovalbumin and -lactoglobulin A, BSA eluted 
faster than these two proteins. Similarly, despite the fact that ribonuclease A has a higher 
molecular weight than cytochrome C it eluted faster. This observation for RPC retention 
indicates that the protein hydrophobicity or its size are not the only factors determining 
the retention of the solutes, since proteins can undergo denaturation in a hydro-organic 
mobile phase. The acid and organic solvent in the mobile phase partially denature the 
proteins, thereby exposing the more hydrophobic interiors. Therefore, the proteins with 
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more hydrophilic exteriors, such as cytochrome C exhibited a larger degree of 
hydrophobicity and interacted were strongly with the monolithic column [18, 20, 33]. 
 
Reproducibility of the M3 column using a mixture of standard proteins 
 Standard proteins were injected in triplicates onto the M3 column and the 
reproducibility of the retention time and peak areas were evaluated in terms of % RSD of 
solute retention and peak area, see Tables 2 and 3. The M3 column showed % RSD in 
terms of retention time of less than 1 for all 4 standard proteins studied, see Table 3. 
Regarding peak area, the % RSD for ribonuclease A, cytochrome C, BSA, ovalbumin 
were 20.48, 18.92, 3.62 and 5.82, respectively, see Table 4.  The column showed good 
reproducibility in terms of retention time, but it showed deviation in peak area. This 
could be due to the minor fluctuations in sample preparation, such as sonication time 
amount weighted and storage. 
TABLE 3 




Protein Retention time tR (min) Mean value 
of tR 
% RSD 
Trial 1 Trial 2 Trial 3 
Ribonuclease 
A 
6.8 6.87 6.8 6.823 0.59 
Cytochrome C 7.76 7.73 7.81 7.767 0.52 
BSA 8.88 8.85 8.79 8.84 0.52 






REPRODUCIBILITY OF PEAK AREA ON M3 COLUMN EXPRESSED IN %RSD 
 
Incorporation of carbon nanotubes into the M3 monolithic column 
The M3 column, which showed the best performance for the separation of 
proteins was further optimized by incorporating MWCNTs. The M3 monolith is a 
hydrophobic monolith and proved useful for RPC separation [32]. Carbon nanotubes are 
carbon allotropes with cylindrical structure and they are hydrophobic in nature [34]. The 
goal of adding MWCNTs to the monolith was to increase the hydrophobic nature of the 
monolith, thereby increasing the retention time of the solutes of interest. In addition to 
hydrophobic interactions,  MWCNTs may establish  interactions with aromatic and 
π-bond rich solutes. On this basis, it was expected to enhance retention and in turn 
resolution of some solutes with the addition of MWCNTs to the M3 column.  
In this section, a series of columns prepared by adding different types and 
amounts of MWCNTs, see Table 1. The M7 monolith was the first monolith fabricated 
with added MWCNTs, where 150 mg of SN3202 MWCNTs was added. The 
polymerization mix was very thick in appearance and the resulting monolith showed very 
high pressure. It did not yield any separation for proteins or alkyl benzenes. This may 
 Area of the peak AP(mV) Mean value 
of AP 
 
 Trial1 Trial 2 Trial 3 % RSD 
Ribonuclease 
A 
2346 2201 2873 2807 20.48 
Cytochrome C 2058 3022 2699 2593 18.92 
BSA 5034 4941 5296 5090 3.62 




indicate that, since the monolith contained a large amount of nanoparticles it blocked the 
pores, thereby decreasing the permeability of the monolith leading to poor flow and 
finally resulting in high pressure. From the M8 to the M11 monolith, we decreased the 
amount of SN3202 type of MWCNTs. The column performance improved in terms of 
pressure and also showed improved separation of proteins. Since by decreasing the 
amount of SN2302 MWCNTs some improvements were observed, the amount of 
MWCNTs was further decreased from 150 mg to 8 mg. For this series of monoliths, an 
enhanced performance was obtained for the M11 monolith, which was prepared by 
adding 8 mg of MWCNTs (see Fig 11A). By considering the physical properties of 
SN3202 MWCNTs, it had an outer diameter (OD) of 10-20 nm, inner diameter (ID) 5-10 
nm with a length of 0.5-2 µm. Considering the characteristics of SN 6957838 MWCNTs, 
with the physical properties of an OD of 20-30 nm, an ID of  5-10 nm and a length of 1-2 
m, it was expected that the second MWCNTs having a larger OD expose  more surface 
area to interact with the solute, thereby leading to an increase in retention. Monoliths 
were prepared by adding different amounts of 25 mg, 12.5 mg and 8 mg of SN6957838 
MWCNTs, and the resulting monoliths were designated as M12, M13 and M14, 
respectively. It was observed that the optimum separation was achieved with the 
monolith containing 12.5 mg of MWCNTs, see Fig. 11B. The retention behavior of 
alkylbenzenes was evaluated on the series of monoliths, but a better separation than that 
obtained on the M4 column in terms of retention factor for alkylbenzenes could not be 
achieved. It is believed that M4 column has the ideal pore size for the separation of 





   
  Figure  11. Chromatograms of proteins obtained on (A) M11 and (B) M13 columns 
using a  linear ACN gradient. Solutes (A), ribonuclease A; (B),cytochrome C; (C), 
lysozyme; (D),transferrin; €, BSA; F, lactoglobulin A;  (G), ovalbumin. All other 

















































































































































Alkylbenzenes were less retained in the RPC column with the addition of 
MWCNTs. This may indicate that MWCNTs filled the pore structure to the point that the 
surface area available for alkyl benzenes interaction was reduced. Therefore, they eluted 
faster. On the other hand, the addition of MWCNTs to the monolith yielded enhanced 
performance for proteins mainly because MWCNTs have hydrophobic interactions and 
 interactions with the proteins. Nanoparticles help to increase the retention time and 
also results in efficient separation  with higher resolution, see Table 6. 
 
TABLE 5 









Alkyl benzenes Retention factor of monolithic columns 
M4 M8 M9 M10 M11 M12 M13 M14 
Toluene 2.08 1.05 1.81 1.88 1.92 1.7 1.92 1.75 
Ethyl benzene 2.56 1.26 1.95 1.91 2.0 1.81 2.0 1.92 
Propyl  
benzene 
3.35 1.69 2.45 2.57 3.05 2.4 3.05 2.4 
Butyl  benzene 4.34 2.11 2.91 3.18 3.97 2.8 3.97 3.1 
Amyl  benzene 5.79 2.83 3.25 4.425 5.22 3.12 5.22 3.97 
Hexyl  benzene 7.75 5.03 5.75 5.72 6.3 4.9 6.3 5.21 
Heptyl  
benzene 









The ODA/TRIM column was successfully scaled up/optimized for use in RPC 
separations by HPLC. A series of monolithic columns was developed and the 
performance of each column was evaluated with alkylbenzenes and standard proteins. 
The M3 column showed optimum performance towards proteins while M4 column 
yielded better separation for alkylbenzenes. The addition of MWCNTs to the M3 
monolith generally resulted in enhanced separation for proteins. The M13 column, which 
was prepared by adding 12.5 mg of SN 6957838 MWCNTs to the M3 monolith showed 
an optimum performance for the separation of a mixture of standard proteins. The 
enhanced separation of protein after addition of MWCNTs is believed to be due to the 
concurrence of both hydrophobic and interactions. Therefore, the M13 column was 
used in the RPC fractionation of complex proteomics samples in the subsequent chapters 
of this dissertation. 
Proteins  Retention time of monolithic columns 
M3 M9 M10 M11 M12 M13 M14 
Ribonuclease  A 5.85 5.92 5.97 6.06 6.14 5.63 6.05 
Cytochrome C 6.82 7.02 7.0 7.12 6.9 6.66 7.07 
Lysozyme 7.39 7.62 7.65 7.69 7.83 7.26 7.66 
Transferrin 7.9 8.09 8.1 8.14 8.22 7.73 8.1 
BSA 8.08 8.46 8.3 8.44 8.64 8.07 8.43 
Carbonic 
anhydrase 
8.51 8.93 8.7 9.06 9.06 8.6 9.02 
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ONLINE DEPLETION OF HIGH ABUNDANCE PROTEINS AND CAPTURING OF 
SIAOGLYCOPROTEINS FROM HUMAN SERA VIA TANDEM IMMUNO-, 
PROTEIN A/G´ AND LECTIN AFFINITY COLUMNS AND  
SUBSEQUENT FRACTIONATION OF THE CAPTURED  





Sialylation is an important post-translational modification (PTM) of proteins the 
level of which has been known for decades to be altered in diseases such as cancers. 
Therefore, the detection of aberrant sialylation of glycoproteins present in the serum 
should provide an insight into the pathological state of an individual. By measuring the 
level of this aberration over a time period one can have an idea of the progression of the 
disease [1]. Increased sialylation of tumor cell surfaces is well known and is due to either 
increased activity of the sialyltransferase or due to the increased branching of N-linked 
glycans leading to termini, which can be sialylated. Comparing the sialylation level 
before and after a given treatment one can predict the prognosis of cancer. The detection 




quantitative analytical methods of analysis [2]. Sialic acids are found attached at the non-
reducing terminus of the glycan moieties of glycoproteins via an -2,3 or -2,6 linkage 
to galactosyl residue and Hex-NAc (Hexose-N-acetyl glucosamine). Figure 1 shows the 
sialic acid moiety attached to the galactosyl residue with an -2,3 linkage [3].  
 
Figure 1. Sialic acid moiety attached to a galactosyl residue with an -(2, 3) linkage. 
 
In this chapter, the main goal is to specifically capture sialoglycoproteins from 
disease free and breast cancer sera with the aim of identifying their differential 
expressions in breast cancer serum with respect to disease free serum via liquid 
chromatography (LC) coupled to tandem mass spectrometry (MS/MS). The selective 
capturing of sialoglycoproteins has been achieved via lectin affinity chromatography 
(LAC), which involved the development of monolithic columns with surface 
immobilized lectins specific for sialic acids. Lectins are sugar-binding proteins, which are 
widely distributed in nature having the ability to recognize carbohydrates on the surface 
of proteins. In general, LAC has found increased use for capturing glycoproteins from 




nigra agglutinin (SNA) and Maackia amurensis (II) lectin (MAL-II), with 
complementary specificity to sialic acid bearing glycoproteins [8-10] were immobilized 
on a novel monolithic stationary phase that was originally introduced in our laboratory 
for immunoaffinity chromatography at reduced nonspecific interactions [11]. SNA lectin 
has been reported to show specificity towards sialic acids (Sia) in (2,6) linkages to 
galactose (Gal) or N-acetylgalactosamine (GalNAc), e.g., Sia-2,6-Gal/GalNAc [12]. 
Figure 2 shows the three N-glycans types and the possible binding of SNA lectin to the 
sialic acid linked by 2,6)- linkages to galactose. The preference of the SNA lectin to 
binding with the (2,6) linkage can be attributed to the free hydroxyl group at C-3, 
which may play an important role in the binding of galactosyl residues to SNA and there 
is a significant difference between the three-dimensional arrangement of the sialic acid 
and galactosyl residues in the oligosaccharides containing 2,3- or 2,6-linkages. It is 
possible that the 2,6-linked isomers can assume a conformation which facilitates better 
contact with the binding sites of SNA as reported in NMR spectroscopy studies [8]. 
MAL-II lectin binds with sialic acid (e.g., N-acetylneuraminic acid) linked by 
2,3 linkages to galactose with high affinity and shows weak affinity to the N-
acetylglucosamine (GlcNAc) and N-acetylgalactosamine (GalNAc) [9, 10]. Narrow 
specificity lectins such as SNA and MAL-II recognize and capture disease related 
glycoproteins and capture fewer plasma proteins than those with broader specificities. 
Therefore, narrow specificity lectins are attractive selectors for isolating disease specific 
glycosylated biomarkers [13]. The SNA and MAL-II columns should in principle be 





acids linked to galactosyl residues with (2,6) and (2,3) linkages in breast  cancer 
serum with respect to disease free serum. 
 
 
Figure 2. Typical N-glycans. The structures within the dashed box is the trimannosyl 
core which is common to all glycan structures. Sialic acid residues linked to galactose in 
2,6) linkages are shown to bind with SNA lectin. 
 
Several approaches have been used for the fractionation of complex 
glycoproteins. For instance, while single LAC is able to capturing a limited number of 
glycoproteins since most lectins show specificity towards a particular type of 
glycoproteins, serial LAC (serial-LAC) has been used to identify many types of 
glycoproteins in human serum [14-16]. However, in serial-LAC, serum fraction that pass 
through one lectin column as collected, dialyzed, dried and reconstituted and then 




allows collecting a large number of glycoproteins, it leads to sample loss due to excessive 
discontinues sample manipulation and experimental biases from column to column.  To 
remedy this situation, multi LAC (M-LAC) has been suggested. M-LAC uses a mixture 
of lectins having specificities for different glycoproteins immobilized in a given column 
(i.e., a mixed bed column) and each lectin is eluted using a given haptenic sugar [4, 17].  
However, this approach has a limitation due to the fact that the eluted glycoproteins from 
one lectin may bind again to another lectin in the mixed bed column, a fact that may 
require much harsher elution conditions such as lowering the pH of the eluting mobile 
phase. An elegant and effective column arrangement was demonstrated recently by 
Selvaraju and El Rassi that involved the use of tandem LAC columns with surface 
immobilized lectins of different selectivities to capture a wide range of glycoproteins 
form human serum [18, 19].  
In this Chapter, tandem LAC consisting of immobilized SNA and MAL-II 
columns were incorporating into a recently introduced multicolumn platform in our 
laboratory [6] for the capturing of sialoglycoproteins from disease free and breast cancer 
sera. The platform was also equipped with an RPC column developed in Chapter III for 
the on-line fractionation of the sialoglycoproteins captured by the two-lectin columns.  
Two sets of approaches were examined. In one approach, 3-fold diluted serum was 
injected into the multicolumn platform without depleting the high abundance proteins 
(e.g., albumin and immunoglobulins (Ig’s)) and in another approach the 3-fold diluted 
serum was depleted on-line from albumin and Ig’s prior to capturing the 
sialoglycoproteins by the two-lectin columns.  The depletion columns consisted of a 




antibody (anti-HSA), Protein A and Protein G´. While the anti-HSA column was for 
removing albumin, the Protein A and Protein G´ columns were for depleting the Ig’s. 
Captured glycoproteins by SNA and MAL-II columns were fractionated on the RPC 
column using a linear ACN gradient. Fractions were collected and submitted to LTQ 
Orbitrap MS for the identification of captured sialoglycoproteins. The multicolumn 
platform was operated via switching valves and high precision HPLC pumps to control 
and direct the mobile phase through the multi column system and to move the serum 
from column to column while staying in the liquid phase thus avoiding sample 




 A Model 105 IsoTemp  water bath from Fischer Scientific (Waltham, MA, USA) 
was used for the polymerization of monoliths.  The liquid chromatography platform 
consisted of a quaternary solvent delivery system model Q-grad pump from Lab Alliance 
(State Collage, PA, USA), a solvent delivery system Model CM4000, and a Model 3100 
UV-Vis variable wavelength detector from Milton Roy, LDC division (Riviera Beach, 
FL, USA) and a Rheodyne injector Model 7010 (Cotati, CA, USA) equipped with a 20 
L injection loop. Five Rheodyne switching valves and one 3-way valve was from SSI 
(State Collage, PA, USA) were used to control the direction of solvent flow. The fraction 
collector was from Spectra/Chrom CF-1 (Houston, TX, USA). Mass spectrometric 




Fisher Scientific (Waltham, MA, USA). Sample evaporation was done on a Savant 
SpeedVac Model AC 110 from Savant Instruments Inc. (Holbrook, NY, USA). 
 
Reagents and Materials  
The unconjugated lectins, namely SNA and MAL-II were obtained from Vector 
Laboratories (Burlingame, CA, USA). Pooled breast cancer serum from five donors and 
also pooled disease free human serum from five donors (same age group and race as the 
cancer serum) were purchased from Bioreclamation (Westbury, NY, USA). Stainless 
steel tubing of 4.6 mm id was obtained from Alltech Associates (Deerfield, IL, USA). 
TRIM, ODA, GMM, PETA, 1-dodecanol, sodium acetate, sodium periodate, sodium 
cyanoborohydride, lactose and AIBN were from Aldrich Chemical Co. (Milwaukee, WI, 
USA). Cyclohexanol was purchased from J.T. Baker (Phillipsburg, NJ, USA). Ethylene 
glycol was purchased from Fischer Scientific (Waltham, MA, USA). HPLC grade 
acetonitrile was purchased from Pharmco-Aaper (Farmers Branch, TX, USA). 
 
Monolithic Affinity Columns 
A 10 g polymerization mixture was made as follows: 7.6% w/w GMM and 7% 
PETA were mixed with a ternary porogenic solvent made of 59.1% w/w cyclohexanol, 
22.9% w/w dodecanol, and 3.4% w/w water. AIBN at 1% w/w with respect to monomers 
was added to the polymerization mixture as the radical free initiator [17]. The 
polymerization mixture was sonicated for 15 min, purged with nitrogen for 5 min and 




and heated in the water bath at 60 
o
C for 15 h. The mold was washed extensively with 
ACN followed by water. The monolith thus obtained was transferred from the 25 cm 
mold to two columns of 3 cm x 4.6 mm id each by connecting the mold column to the 
shorter column with a ¼” union and then pump water at a flow rate of 3 mL/min 
continuously until the unmodified monolithic support is completely transferred.  
Depletion columns were homemade and were prepared according to Selvaraju and 
El Rassi [6] with the dimensions of anti-HSA column 5 cm and protein G’ and protein A 
columns were 3 cm each with an internal diameter of  4.6 mm. 
 
Immobilization of lectin 
The SNA and MAL-II lectins were immobilized on the GMM/PETA monolithic 
column as follows. The 3 cm columns were allowed to react with a freshly prepared 0.1 
M NaIO4 for 2 h at room temperature to convert the diol groups into aldehyde groups 
followed by 10 min water wash. For MAL-II lectin, 0.5 mL volume was taken from the 
original vial and evaporated using a SpeedVac to remove all the solvent. The 
immobilization of lectin was done by passing through the column 1 mg of SNA lectin or 
concentrated MAL-II lectin described above in 0.5 mL of sodium acetate pH 6.4 
containing 0.1 M lactose and 50 mM sodium cyanoborohydride. After passing the 
immobilization solution overnight any unreacted aldehyde was scavenged by passing a 
solution of 0.4 M Tris-HCl, pH 7.2 containing 50 mM sodium cyanoborohydride for 3 h 
at room temperature. The lectin columns were stored with the 20 mM Tris-HCl, pH 7.4 





Testing the lectin columns 
Lectin columns were tested with standard proteins including 1-acid 
glycoprotein, fetuin, transferrin, healthy human serum and cancer serum at room 
temperature at a flow rate of 1 mL/min and the signal was monitored at =214 nm. The 
columns were first equilibrated with 10 column volumes of the binding mobile phase 
consisting of 20 mM Tris, 0.3 M NaCl, pH 7.4.  Each standard protein was injected while 
passing the binding mobile phase, and was eluted by passing the eluting mobile phase 
consisting of 0.1 M lactose in 20 mM Tris-HCl, pH 7.4. Once the peak has eluted, the 
column was re-equilibrated with the binding mobile phase for readying it for another 
injection. 
 
Chromatographic platform for the depletion of high abundance proteins (albumin and 
Igs) followed by capturing of sialoglycoproteins from serum 
The multicolumn platform used for the simultaneous depletion of high abundance 
proteins such as albumin and immunoglobulins (Igs) followed by enrichment/capturing of 
sialoglycoproteins and subsequent fractionation of the captured proteins by RPC is shown 
in Fig. 3.  The columns were connected in a predetermined order, and the flow direction 
for each column was controlled using independent switching valves. When the serum 
sample was injected into the platform, it entered the depletion columns first, namely anti 
human serum albumin column, protein G´ and protein A to deplete the high abundance 




lectin columns connected in the order SNA columnMAL-II column. Finally, each 
lectin column was eluted independently, and the captured proteins were moved by the 
eluting mobile phase to the RPC column. This was followed by RPC fractionation using a 
linear gradient at increasing acetonitrile concentration in the mobile phase. The 
dimensions of the columns and their connection order were as follows: Anti HSA column 
(5 cm x 4.6 mm id)  protein G’ column (3 cm x 4.6 mm id)  protein A column (3 cm 
x 4.6 mm id)  SNA column (3 cm x 4.6 mm id)  MAL-II column (3 cm x 4.6 mm id) 
 RPC column (10 cm x 4.6 mm id). The fabrication of the RPC column was described 
in Chapter III and it was designated as M3 column.   
The RPC column, which was initially stored in ACN was washed with 20 column 
volumes of water to remove the ACN. The binding mobile phase consisted of 20 mM 
Tris, pH 7.4, containing 0.3 M NaCl. The eluting mobile phase for depletion column was 
50 mM NaH2PO4, pH 2.2. The eluting mobile phase for lectin columns was 5 mM lactose 
in 20 mM Tris, pH 7.4. The aqueous rich mobile phase (mobile phase A) for the RPC 
column consisted of H2O/ACN (95:5 v/v) containing 0.1% TFA and the organic-rich 
mobile phase (mobile phase B) consisted of ACN/ H2O (95:5 v/v) containing 0.1% TFA. 
Three-fold diluted serum (20 L) was injected while passing the binding mobile phase 
through the three depletion columns and the two-lectin columns while bypassing the RPC 
column. After 20 min of washing with the binding mobile phase, the depletion columns 
were eluted at a flow rate of 0.8 mL/min, followed by equilibration of the depletion 
columns. Another 20 L of the same threefold diluted serum were injected onto the 





Figure 3. An integrated platform for the simultaneous depletion of albumin and Igs, the 
enrichment of sialoglycoproteins, and subsequent RPC fractionation of the captured 
proteins by SNA and MAL-II lectin columns. When the switching valves A, B, C, and D 
were in 2, 3, 5, and 7 positions, respectively, the threefold diluted serum was injected 
onto the depletion and the lectin columns, followed by washing with the binding mobile 
phase (BMP) using pump A. Then, the eluting mobile phase for the depletion columns 
was passed by changing the valve A position to 1, thus by-passing the lectin and the RPC 
columns. The depletion columns were re-equilibrated again with the BMP, after which 
the valve A was changed back to position 2. Then, the SNA column was eluted using 
pump B, while the 3-way valve was in position 9, valve B in position 3 and valve C in 
position 6, thus by-passing the MAL-II column and passing through the RPC column. 




mobile phase from pump B, while the 3-way valve is in position 10. Then, the MAL-II 
column was eluted by changing the 3-way valve position back to 9, valve B position to 4, 
valve C position to 5 and valve D position to 8. This was again followed by washing, 
eluting, and re-equilibrating the RPC column by keeping the 3-way-valve in the 10-
position. 
Serum proteins from a total of 40 L (20 L+20 L) of three fold-diluted serum were 
accumulated onto the lectin columns. Using the eluting mobile phase, the proteins 
captured by the SNA column were transferred to the RPC column. RPC column was 
washed with mobile phase A to remove the salts for 20 min. This was followed by a 
linear gradient elution of increasing acetonitrile from 0 to 75% v/v mobile phase B in 
mobile phase A for 12 min and then 2 min of isocratic elution at 75% of mobile phase B. 
The column was returned to initial conditions within 1 min. After running the gradient 
elution, the RPC column was washed with water for 15 min. The second lectin MAL-II 
was eluted to the RPC column while maintaining the linear gradient elution the same as 
described above. The eluted protein fractions were collected every 30 sec using fraction 
collector and evaporated to dryness using SpeedVac. These samples were subjected to 
LC-MS/MS Orbitrap analysis. 
Another set of data was obtained by injecting the 3-fold diluted non-depleted 
serum directly into the lectin columns and each lectin column was eluted to the RPC 






Results and discussion 
 
 As mentioned in the experimental section (see above), one set of data was 
collected by depleting the high abundance proteins from serum while another set of data 
was collected by omitting the depletion columns. Total number of captured proteins, 
including the number of glycoproteins, sialoglycoproteins and differentially expressed 
proteins was analyzed with the two data sets. Anti HSA, protein G´ and protein A 
columns were originally prepared and tested in our laboratory [18] . 
 
Testing the lectin columns 
 The two-lectin columns were evaluated with standard sialoglycoproteins and 
serum to ensure whether the two lectins were properly immobilized and they showed 
specificity toward sialoglycoproteins. Three standard glycoproteins including 1-acid 
glycoprotein, fetuin and transferrin, which are known for their sialic acid content [18-20] 
were analyzed on both the SNA and MALII columns.  In the case of the SNA column, 
and with the exception of myoglobin, the other sialoglycoproteins (1-acid glycoprotein, 
fetuin and transferrin) exhibited partial retention as was manifested by a large flow 
through fraction (unretained fraction) that eluted with the binding mobile phase that 
consisted of 20 mM Tris, 0.3 M NaCl, pH 7.4, and a small fraction retained on the 
column that eluted when applying the eluting mobile phase that was made of 20 mM Tris, 
pH 7.4, containing 0.1 M lactose as the haptenic sugar, see Fig. 4 A, B and C.  The large 




glycoprotein is primarily due to the many glycoform constituents for each 
sialoglycoproteins with no affinity to the immobilized lectin and probably to surpassing 
the binding capacity of the column. In the case of MAL II column, fetuin and to a lesser 
extent 1-acid glycoprotein showed some retention toward the immobilized lectin, see 
Fig. 4 A and B. This is due to the fact that MAL II lectin possesses more specific binding 
toward sialic acids with -2, 3 linkages while SNA possesses affinity toward sialic acids 
with -2,6 linkages. These sialoglycoproteins may contain higher number of -2,6 
linkages. For both lectins, myoglobin which is a non-glycoprotein was not captured and 
retained by the SNA or MAL columns, see Figs. 4D and 5C.  Concerning the retained 
fractions of diseased free and breast cancer sera captured by the SNA column one can see 
by quick visual comparison of the two corresponding chromatograms that the retained 
signal corresponding to the retained fraction in cancer serum Fig. 4F is higher than that of 
the disease free serum, Fig 4E. Similar statement can be made for the MAL-II columns 
based on the visual comparison of the corresponding chromatograms of the retained 
signal for cancer serum, see Fig. 5E. This gives the idea that the breast cancer serum 
contains more sialoglycoproteins than the disease free serum, see Fig 5D.  
Processing of serum via the multi column platform  
Three fold diluted human serum (20 L) were injected onto the depletion columns and 
the lectin columns while passing the binding mobile phase. In the anti-albumin column 
serum albumin was depleted and the serum passed to the protein A column and then to 
























Figure 4. Chromatograms of (A) -1-acid glycoprotein, (B) fetuin, (C) transferrin, (D) 
myoglobin, (E) disease free serum and (F) breast cancer serum injected onto the SNA 
lectin column (3 cm x 4.6 mm id). Binding mobile phase, 20 mM Tris, pH 7.4, 0.3 M 
NaCl; eluting mobile phase, 20 mM Tris, pH 7.4, 0.1 M lactose; flow rate, 1 mL/min; 
























Figure 5. Chromatograms of (A) -1-acid glycoprotein, (B) fetuin, (C) myoglobin, (D) 
disease free serum, and (E) breast cancer serum injected onto the MAL-II lectin column 
(3cm x 4.6 mm id ). All other conditions as in Fig. 4. 
 
Protein A and protein G´ are immunoglobulin binding proteins. These proteins are known 
to bind to the Fc region of antibodies from various species [18].  
Protein G´ has a strong affinity to all Iggy’s [19] while protein A binds with high 
affinity to IgG1, IgG2 and IgG4 and has moderate affinity to IgG3, IgA, IgD, IgE and IgM  
[20].  The columns were combined in the order of Protein G´ column and protein A 
column to remove high abundance immunoglobulins from the serum as much as possible. 
Sambucus nigra lectin binds preferentially to sialic acid attached to terminal galactose in 





by lactose or galactose. This lectin does not appear to bind sialic acid linked to N-
acetylgalactosamine. MAL-II lectin binds with the sialic acid in α-2,3 linkage. To capture 
maximum number of glycoproteins, serum was passed first to the SNA column and then 
to the MAL-II column. After passing the serum sample via lectin columns each lectin 
was eluted individually to the RPC column. RPC fractionation was carried out with a 
linear ACN gradient and 12 fractions were collected in 30 sec intervals from 8 min to 14 
min. The chromatographic platform is shown in Fig. 3. 
To assess the need for depletion, the same amount of serum sample was injected 
on the system with and without depletion columns. Fig. 8 shows the injection of disease 
free serum into the SNA and MAL columns in the absence of the depletion columns in 
the platform. Fig. 8A and B shows the injection of disease free and breast cancer sera into 
the multi column platform in the presence of depletion columns. When the serum is 
injected into the system without the depletion columns, high abundance proteins such as 
albumin, IgG’s (IgG1, IgG2, IgG3, IgG4), IgA, IgM and IgD prevent the binding of 
sialylated proteins to the lectin columns.  On the other hand, when the high abundance 
proteins are removed from the serum, sialoglycoproteins in the serum will have more 
access to the binding sites of the lectin columns. In fact, the lectin columns captured 
higher amount of proteins in the presence of albumin and Ig depletion columns. The 
number of proteins identified without depletion columns is relatively lower than in the 






Importance of depleting high abundance proteins 
A higher number of proteins were captured when the serum was depleted from 
high abundance proteins such as albumin and Ig’s than from serum injected without 
depletion columns. This is due to the fact that when the serum was injected without 
depletion columns, the high abundance proteins bind nonspecifically with the lectin 
columns and saturate the binding sites.  This is confirmed by the fact that the spectral 
count of albumin and Ig’s are significantly higher in the fractions captured by the SNA 
and MAL-II lectin columns from non-depleted disease free serum, see Tables 1 and 2. As 
can be seen in these Tables, the average spectral count of albumin in non depleted serum 
was 103 in the SNA fractions and 43 in MAL-II fractions, while in depleted serum 77 
spectral counts were detected for albumin in SNA fractions and 40 spectral counts in 
MAL-II fractions.  In all cases, in SNA fractions high abundance proteins are in much 
higher number spectral counts than in MAL-II fractions, since the SNA column is placed 
as the first column in the tandem column format. 
 To further evaluate the importance of depleting high abundance proteins on the 
capturing capacity of the tandem lectin affinity columns, attention was paid to the number 
of sialoglycoproteins and low abundance proteins captured by the lectin columns in the 
presence and absence of depletion columns while keeping everything else the same 
including the amount of serum injected that was kept at 40 L of three fold diluted 









Figure 6. Chromatograms of (A) RPC fractionation of the SNA captured proteins and (B) 
RPC fractionation of the MAL-II captured proteins without depletion. The RPC 
fractionation was carried out by a linear gradient elution at increasing ACN 
concentration in the mobile phase by going from 0 to 75% of mobile phase B in 12 min. 
Mobile phase A consisted of H2O/ACN (95:5 v/v) containing 0.1% TFA and mobile phase 
Time (min)





































































B consisted of ACN/H2O (95:5 v/v) containing 0.1% TFA. Flow rate, 1 mL/min; UV 
detection, 214 nm. 
 
SNA and MAL-II columns captured significantly higher number of unique 
proteins in the presence of depletion columns than in their absence. Among these unique 
proteins there were sialoglycoproteins as well as low abundance proteins. For the SNA 
column, 88 unique proteins were captured from the depleted disease free serum while 48 
unique proteins were captured from the non-depleted serum. In the presence of depletion 
columns, 21 low abundance proteins were identified while in the absence of depletion 
columns only 9 low abundance proteins were identified, see Table 3.  The 21 low 
abundance proteins identified in the presence of depletion columns were annexin A2, 
calmodulin-like protein 5, carboxypeptidase B2, cathelicidin antimicrobial peptide, 
cholinesterase, coagulation factor V, dermcidin, desmoplakin, extracellular matrix protein 
1,extracellular superoxide dismutase [Cu-Zn], galectin-7 gelsolin, intercellular adhesion 
molecule 2, lysozyme C, mannan-binding lectin serine protease 2, N-acetylglucosamine-
1-phosphotransferase subunit gamma, phosphatidylcholine-sterol acyltransferase, 
phosphatidylinositol-glycan-specific phospholipase D, protein Z-dependent protease 
inhibitor, trypsin, transforming growth factor-beta-induced protein, and secreted 
phosphoprotein.  The 9 low abundance proteins identified in the presence of depletion 
columns were catalase, cystatin-A, desmocollin-1, desmoglein-1, desmoplakin, 
extracellular matrix protein 1, filaggrin-2, glyceraldehyde-3-phosphate dehydrogenase, 




 The number of unique proteins captured by MAL-II column in the presence and 
absence of depletion columns were 80 and 35, respectively, as measured in the collected 
RPC fractions by LC-MS/MS analysis. In the presence of depletion columns 16 low 
abundance proteins were identified while in the absence of depletion columns only 8 low 
abundance proteins were identified. The 16 low abundance proteins identified with the 
online depletion were annexin A2, carboxypeptidase B2, cartilage oligomeric matrix 
protein, cathelicidin antimicrobial peptide,  cholinesterase, dermcidin, extracellular 
matrix protein 1, filaggrin, galectin-3-binding protein, histone H4, mannan-binding lectin 
serine protease, phosphatidylcholine-sterol acyltransferase, phosphatidylinositol-glycan-
specific phospholipase D, protein S100-A7, protein S100-A8, sulfhydryl oxidase 1, 
transferrin receptor protein 1, and trypsin. In the absence of depletion columns, 8 low 
abundance proteins were identified namely attractin, cadherin-5, catalase, coagulation 
factor XIII B chain, complement factor H-related protein 4, cystatin-A, mannan-binding 
lectin serine protease 1, and vitamin K-dependent protein C. 
 The number of low abundance proteins captured by the SNA column was 21 in 
the presence of depletion columns and 9 in the absence of depletion columns. For MAL-
II column, 18 and 8 low abundance proteins were identified in the presence and absence 
of depletion columns, respectively. Considering the amount of Igs captured, SNA lectin 
captured 12 Igs without depletion column while with the depletion columns it captured 
only 3 Igs. Considering MAL-II column, 6 Igs chains were captured without depletion 
columns and only 2 Ig’s were captured when the depletion columns were present. 
Considering the spectral count for serum albumin, the captured SNA fractions exhibited 




presence of depletion columns. In the case of MAL-II column, the captured fractions 
yielded 160 spectral counts for serum albumin in the absence of depletion columns versus 
only 28 spectral counts for the same protein in the presence of depletion columns. Online 
depletion always favored the capture of higher number of unique proteins and low 
abundance proteins while the depletion minimized the spectral counts for albumin and the 
number of captured chains of Ig’s. These data show that the online depletion is necessary 
for capturing a higher number of low abundance proteins. 
 The presence of serum albumin and Ig’s in the LC-MS/MS fractions obtained 
with online tandem format may be due to protein-protein interactions that are frequently 
observed in complex proteomic samples and protein based affinity assays [6, 20, 21].   
 
Reproducibility of the integrated multi column platform. 
 The day-to-day reproducibility of the multi column platform was evaluated in 
terms of the RPC fractionation chromatograms obtained by linear gradient elution of the 
SNA and MAL-II captured proteins from the depleted serum. The RPC chromatograms 
were readily reproducible. The day-to-day reproducibility was further assessed by 
calculating the percent RSD (%RSD) of the retention time and peak area. The average % 
RSD (n=2) for the retention times and the peak areas of the peaks for the SNA captured 
proteins were 0.11 and 12.2%, respectively, and for MAL-II the %RSD for the retention 
times and peak areas were 0.41 and 8.2%, respectively. In terms of reproducibility, it was 
observed that spectral counts of most proteins were similar in both day 1 and day 2. The 




identification probability, 95% peptide identification probability with minimum five 
unique peptides. As an example, galectin, which is a low abundance protein shows the 
spectral counts of 15 and 16 in day 1 and day 2, respectively. 
 Q-Q plots were determined for normal serum fractions 4 and 5, see Fig. 7. Q-Q 
plot or scatterplot is the representation of normalized spectral counts for each protein 
found in a given fraction on a certain day versus the normalized spectral count of the 
same protein found in that same fraction on another day. In the Q-Q plot for fraction 4 for 
day 1 and day 2, only 7 proteins were 2 standard deviations away of being the same in 
both categories while more than 40 proteins laid near the 45˚ line and are considered to 
have the same spectral counts. Proteins that were outside two standard deviation were 
afamin, antithrombin III, complement C3, 1-antitrypsin, apolipoprotein A-1, 
extracellular matrix protein and inter alpha trypsin heavy chain H4.  Also, in fraction 5, 
only 7 proteins were two standard deviations away from being the same. These 7 proteins 
were alpha-1-antitrypsin, apolipoprotein A-1, extracellular matrix protein, hemoglobin 
subunit beta, hemopexin, kininogen and plasminogen. 
 
LC-MS/MS identification of proteins captured by the lectin columns 
Identification of the proteins captured by the SNA columns. Sambucus nigra 
lectin (SNA) binds specifically to sialic acid linked with -2, 6-galactose containing 
structures [11]. The captured proteins by the SNA column were eluted stepwise with the 
haptenic sugar lactose to the RPC column. The subsequent fractionation of the RPC 
column was performed with a 12 min linear gradient at increasing ACN concentration in 




fractions were collected using a fraction collector that started the collection at 7.5 min of 
the gradient and ended at 12 min, which is the end of the gradient. Fractions of 0.5 mL 
were collected at 50 s intervals in Eppendorf tubes washed previously with ACN. 
Chromatograms of the RPC fractionation of SNA captured proteins are shown in Fig. 8a. 
These fractions were evaporated to dryness using RotorVap and submitted to the LC-
MS/MS analysis. In the LC-MS/MS scaffold report, the proteins reported were those 
possessing protein identification probability greater than 99% with peptide identification 
probability greater than 95% and containing at least two unique peptides. The proteins 
identified from disease free and cancer sera are listed in Table 3. 
The numbers of proteins identified from the disease free serum and breast cancer 
serum were 180 and 184, respectively. Fig. 9 shows the number of unique proteins to 
breast cancer and disease free serum samples. In the SNA fractions, the number of unique 
proteins identified from disease free and cancer serum were 20 and 24, respectively, 































Normalized spectral count for day 2 












Figure 7. Q-Q scatterplots for the day-to-day reproducibility of MS normalized spectral 
counts. The dots laid outside from the dotted lines were two-standard deviation away 
from being the same in both categories.  
 
The false discovery rate for peptide identification was 0.1% for both SNA and 
MAL-II captured proteins. The SNA column captured 184 proteins among them 83 have 
been reported to be sialoglycoproteins and 43 have been identified as low abundance 
proteins [3, 15, 16, 20, 22-32]. Concentration limits for low abundance of proteins in 
plasma range from ng level to ≤ 1 g level. Low abundance proteins were assigned 
according to the human plasma proteome reference set that contains 1929 non redundant 
proteins [31]. Concentrations of some representative low abundance proteins are fillagrin 
Normalized spectral count for day 1 
































(0.82 ng/mL), annexin-1 (6.2 ng/mL), desmolegein (2.7 ng/mL), and calmodulin like 




8. Comparison of chromatograms of the RPC fractionation of proteins captured by the 
SNA column (A) and the MAL-II column (B) from disease free serum (DFS) and breast 
cancer serum (CS). All other conditions as in Fig. 4. 
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Figure 9. Venn diagram for the LC-MS/MS identified proteins captured by the SNA 
column. 
 Proteins such as apolipoportein C-1, serum paraoxonase/aryleserase were 
identified as cancer biomarker candidates [33]. Galectin-3-binding protein which is a low 
abundance protein and clusterin were reported as tumor glycoprotein biomarkers. They 
are present in both disease free and breast cancer sera [34]. Histidine rich glycoprotein, 
complement C3, and kininogen 1 were identified as sialylated biomarkers for ovarian 
cancer and these were present in normal serum as well as breast cancer serum. These 
proteins are present in both disease free serum as well as cancer serum while histidine 
rich glycoprotein and kininogen 1 are elevated in breast cancer serum [35]. Plasminogen, 
coagulation factor XII, complement C3, kininogen-1, Ig mu chain c region, Ig alpha-2 
chain C, apolipoprotein A-I, apolipoprotein E (apo-E), apolipoprotein C-III, fibrinogen 
alpha chain, fibrinogen beta chain, complement C1q subcomponent subunit C, 
fibronectin, AMBP protein, vitronectin, histidine-rich glycoprotein, apolipoprotein D, 
complement factor H, clusterin, galectin-3-binding protein, interalpha-trypsin inhibitor 
heavy chain H4, complement factor h-related protein 5 were identified as sialylated  
glycoproteins bearing  sialylated lewis x antigen in breast cancer serum, while interalpha-
24 20 160 Disease free serum 
(180) 






trypsin inhibitor heavy chain H4, plasminogen, Ig gamma-2 chain c region, Ig mu chain 
C region, apolipoprotein A-I, apolipoprotein E, AMBP protein, vitronectin, clusterin, 
were identified as altered in their concentration by 3-fold or more in breast cancer serum 
compared to disease free serum [36].  
  Identification of proteins captured by MAL-II column. 153 and 157 non-
redundant proteins were identified in the fractions captured by the MAL-II column from 
disease free and cancer sera using the multi column platform shown in Fig. 3. See Table 3 
for the list of identified proteins and Fig. 10 for the Venn diagram. In the proteins 
captured by the MAL II column, 94 are known to be glycoproteins. Among the 94 
glycoproteins 62 proteins are reported to be sialoglycoproteins and among them 37 are 
reported as low abundance proteins [31]. In the MAL-II captured proteins, 20 and 24 
unique proteins were identified from disease free and cancer sera, respectively, while 133 
proteins were common to both sera. Pregnancy zone protein, Phosphatidylinositol-
glycan-specific phospholipase D, fetuin B, ficolin -3, galectin-3- binding protein, galectin 
7 were identified as low abundance sialoglycoproteins [30, 37]. MAL-II column was able 
to capture 37 low abundance proteins. Concentrations of low abundance proteins 
identified were filaggrin (4.6 ng/mL), annexin A3 (1.6 ng/mL), serpin B3 (6.1 ng/mL), 
galectin 7(6.9 ng/mL), Plexin domain-containing protein (1.6 ng/mL), plectin 1(2.8 
ng/mL)  and calmodulin like protein 5( 8.1 ng/mL)  [31]. 
  Leucine-rich alpha-2-glycoprotein was identified in the set of MAL-11 lectin 
captured proteins in both disease free and cancer serum as a novel serum biomarker for 












Figure 10. Venn diagram for the LC-MS/MS identified proteins captured by MAL-II 
column. 
 
particularly useful in patients with active disease but normal c-reactive protein levels, 
which increase in the time of inflammation [38]. Previously reported cancer biomarkers 
such as complement C3, histidine-rich glycoprotein, and kininogen-1 were also identified 
among the captured proteins [39]. Low abundance protein junction plakoglobin was also 
identified and it is reported as a hepatic fibrosis biomarker [40]. In our work, by injecting 
disease free and breast cancer sera, other disease biomarkers were detected. This may due 
to the fact that these volunteers may suffer from other diseases, which have not been 
diagnosed yet. Therefore, proteomic analysis of serum is an important tool to diagnose 
various pathological conditions.  
 Raw LC-MS/MS data were analyzed in scaffold 5 software using IPI human 
database. NetGly predictor and Uniprot software were utilized to predict N-glycosylation 
sites of the identified proteins for both SNA and MAL-II captured proteins from disease 
free and breast cancer sera. From the set of SNA captured proteins 73% are glycoproteins 
22 21 133 Disease free serum 
(154) 






and 27% are non-glycoproteins for the disease free serum while for the cancer serum 
79% are glycoproteins and 21% are non-glycoproteins. For MAL-II lectin for the normal 
serum 74% were glycoproteins and 26% were non-glycoproteins. For cancer serum 74% 
were glycoproteins while 22 % of proteins were non-glycoproteins. Capturing non 
glycoproteins by the lectin columns may be due to protein-protein interactions that are 
normally present in complex biological fluids such as serum and affinity based assays [6]. 
 
Differentially expressed proteins in SNA and MAL-II lectin fractions. 
 The RPC chromatograms of proteins captured by SNA and MAL-II columns from 
disease free and cancer sera are shown in Fig. 8 A and B. The two overlapping 
chromatograms exhibit differences such as peak intensity, retention time and peak 
shouldering. Differentially expressed proteins (DEP) from cancer serum were found 
relative to the disease free serum with 99.9% protein identification probability, 95% 
peptide identification probability and a minimum of five unique peptides. The DEP from 
breast cancer serum relative to disease free serum were identified using the quantitative 
Q-Q scatterplot, by plotting the normalized spectral count of proteins of breast cancer 
serum and disease free serum of the same fraction. The proteins that are more than two 
standard deviations away of being the same in both categories are considered as DEP. In 
addition, all these proteins had a p-value < 0.05 using the t-test. The DEP of cancer serum 
relative to disease free serum were conducted according to the approach by Selvaraju and 




 In the SNA captured proteins, 34 proteins were identified as DEP, and they are 
either up regulated or down regulated, see Table 7. Among them, 24 proteins were 
sialoglycoproteins [2, 41-43].  These DEP proteins showed differential expression in 
other types of malignancies than breast cancer. For instance, the level of clusterin was 
found to be significantly higher in patients with hepatocellular carcinoma (HCC) and it 
served as a candidate biomarker for the HCC [44]. Alpha-1-antitrypsin, apolipoprotein A-
IV, complement C3, fibronectin were down regulated in SNA cancer serum relative to 
the normal serum. Apolipoprotein A-I, complement factor H, hemoglobin subunit beta 
and inter alpha trypsin inhibitor heavy chain H4 were up regulated in more than 3 serum 
fraction. Again, afamin which was up-regulated in fraction 5, has been reported to 
increase in expression in pre-diagnostic breast cancer serum [45].  
  In the MAL-II captured proteins, 24 proteins were identified as DEP. These 
proteins are listed in Table 8. Five low abundance proteins were differentially expressed 
in the MAL-II column captured fractions. Desmoplakin, junction plakoglobin, 
glyceraldehyde-3-phosphate dehydrogenase, and hornerin were down regulated, while 
extracellular matrix protein was up regulated in breast cancer serum relative to the 
disease free serum. 14 sialoglycoproteins were identified in MAL-II lectin fractions. 
Alpha-1-antitrypsin, apolipoprotein A-IV, haptoglobin and plasminogen were down 
regulated in two serum fractions. Kininogen-1 was up regulated in 3 fractions. During 
breast cancer, epidermal growth factor suppresses the level of protein desmoplakin [46], 
and it is also observed in our investigation that desmoplakin is down regulated in breast 
cancer serum.  It has been reported that the level of serotransferrin is increased in breast 




fraction 2. The up-regulated serotransferrin was reported as a candidate cancer biomarker 




The integrated liquid phase multi column platform described here allowed the 
precise operation of various columns representing orthogonal modes of chromatography 
whereby each column accomplished its function in harmony with other columns. This 
was facilitated by incorporating in the platform high precision HPLC pumps and high 
pressure switching valves.   In its maximum configuration the multi column platform 
consisted of six different columns including 3 depletion columns to remove the high 
abundance albumin and Ig’s, 2 lectin columns to capture/enrich sialoglycoproteins, and 
one RPC column to fractionate the lectin captured proteins. The SNA column has 
captured 34 DEP while the MAL-II column captured 24 DEP with 11 DEP common to 
both lectins.  Previously, reported breast cancer candidate biomarkers such as histidine 
rich glycoprotein, kininogen 1, afamin and clusterin were identified in the LC-MS/MS 
fractions. The integrated platform eliminated experimental bias and sample loss due to its 
integrated nature and cascading operation in the sense that the sample is transferred from 







PROTEINS IDENTIFIED BY LC-MS/MS ANALYSIS OF SNA CAPTURED 
PROTEINS FROM NON DEPLETED DIESEASE FREE SERUM. DATA ON GS WERE 
FROM REFS. [2, 12, 15, 22-24, 35, 39, 45, 51, 52] 
  Fr # 1 Fr # 2 Fr # 3 Fr # 4 Fr # 5 Fr # 6 Fr # 7 
1 165 kDa protein 0 0 0 0 1 0 82 


















0 0 0 0 0 0 6 
6 Alpha-1-antitrypsin 
GS





0 0 1 5 10 1 0 
8 Alpha-2-antiplasmin
 GS






0 0 1 7 10 9 8 
10 Angiotensinogen
 GS
 0 0 0 0 0 0 5 
11 Antithrombin-III
 GS
 0 0 2 5 6 9 7 
12 Apolipoprotein A-I
 GS
 9 9 11 11 14 18 22 
13 Apolipoprotein A-II* 3 0 1 3 3 5 2 
14 Apolipoprotein A-IV* 6 1 8 7 8 14 15 
15 Apolipoprotein B-100
 GS
 1 0 2 2 0 1 28 
16 Apolipoprotein C-I* 1 0 0 3 4 2 3 
17 Apolipoprotein C-II* 1 1 2 2 6 6 3 
18 Apolipoprotein C-III
G
 0 1 2 4 5 4 0 
19 Apolipoprotein D
GS
 0 0 3 7 7 7 4 
20 Apolipoprotein E
G
 2 0 1 1 4 8 9 
21 Apolipoprotein M
GS
 0 0 0 0 0 6 3 
22 Attractin
1a
 0 0 0 0 0 9 2 
23 Beta-2-glycoprotein 1 
GS









0 0 0 0 5 2 0 
26 Cadherin-5 
1a



















 0 5 0 0 0 0 0 
30 CD5 antigen-like 0 0 0 0 0 3 4 
31 Ceruloplasmin 
GS
 0 0 0 3 11 30 18 
32 Coagulation factor IX
 1a
 0 0 0 0 0 4 2 
33 Coagulation factor X
1a
 0 0 0 6 0 0 0 
34 Coagulation factor XIII A chain 
1a
 0 0 0 0 0 0 6 
35 Coagulation factor XIII B chain 
1a
 0 0 0 28 17 8 0 






0 0 0 0 3 4 3 
38 Complement C1s subcomponent 0 0 0 0 0 16 6 
39 Complement C3 
GS
 5 3 3 5 6 6 48 
40 Complement C5 
GS
 0 0 0 0 0 0 18 
41 
Complement component C6 
precursor 
0 0 0 1 26 23 0 
42 Complement component C7 0 0 0 0 2 5 0 
43 Complement factor B 0 0 1 4 3 15 5 
44 Complement factor H 
GS
 0 0 20 38 26 15 4 
45 
Complement factor H-related 
protein 1 
0 0 3 4 0 0 0 
46 
complement factor H-related 
protein 4  
1a
 
0 0 7 7 1 1 0 
47 Complement factor I 0 0 3 1 20 14 10 
48 Corneodesmosin 
1a GS
 0 10 0 0 0 0 0 
49 Cystatin-A 
1a
 0 4 0 0 0 0 0 
50 Desmocollin-1 
1a
 0 6 0 0 0 0 0 
51 Desmoglein-1 
1a
 0 10 0 0 0 0 0 
52 Extracellular matrix protein 1 
1a
 0 0 0 7 0 0 0 
53 Fetuin-B 
1a GS
 0 0 0 0 7 9 3 
54 Fibrinogen beta chain 0 0 0 0 0 4 0 
55 Fibronectin 
GS
 0 9 15 16 7 10 28 
56 Fibulin-1 1 0 1 0 3 6 5 
57 Ficolin-3 
GS
 0 0 0 0 1 0 4 
58 Filaggrin-2 
1a
 1 7 0 0 0 0 0 
59 Galectin-3-binding protein 
1aGS
 0 0 0 4 1 0 8 
60 
Gamma-B of Fibrinogen gamma 
chain 
0 0 0 0 1 3 0 






0 5 0 0 0 0 0 
63 Haptoglobin 
GS
 0 0 2 22 23 24 21 
64 Haptoglobin-related protein 0 0 0 0 2 4 5 
65 Hemoglobin subunit alpha 0 0 0 0 0 5 0 
66 Hemoglobin subunit beta 0 0 0 0 0 7 2 
67 Hemopexin 
GS
 0 0 0 2 20 14 6 
68 Heparin cofactor 2 
GS





69 Histidine-rich glycoprotein 
GS
 0 0 0 8 12 10 8 
70 
Homo sapiens SNC73 protein 
(SNC73) mRNA 
0 0 0 0 6 18 18 
71 Hornerin 
1a
 1 1 0 1 2 0 3 
72 Hyaluronan-binding protein 2 0 0 0 0 6 4 0 
73 IGK@ protein 0 0 4 8 7 10 10 
74 IGL@ protein 0 0 0 0 0 1 3 
75 Immunoglobulin J chain 
GS
 2 3 4 2 1 2 6 
76 Immunolgoobulin heavy chain 0 0 0 0 0 1 3 
77 
Inter-alpha (Globulin) inhibitor 
H2 
1 0 5 4 3 4 17 
78 Ig kappa chain V-IV region Len 4 5 8 15 13 3 7 
80 Ig gamma chain-2 C region 12 15 22 13 31 2 4 
81 
Ig kappa chain V-III region WOL 
* 
5 4 7 3 8 5 8 
82 Ig lambda-2 chain C regions * 2 4 58 4 3 1 2 
83 Ig mu chain C region 2 2 7 8 3 1 3 
84 Ig alpha-2 chain C region G 4 5 3 2 3 5 6 
85 Ig gamma-1 chain C region G        
86 
Ig kappa chain V-III region WOL 
* 
5 6 3 9 7 5 2 
87 Ig heavy chain V-I region EU 15 16 23 25 25 26 2 
88 Ig heavy chain V-I region HG3 12 23 34 34 23 56 14 
84 Ig heavy chain V-III region GAL 11 32 21 12 14 26 14 
85 Ig gamma-3 chain C region 
G
 3 5 6 11 7 2 2 
86 
Inter-alpha-trypsin inhibitor 
heavy chain H1 
GS
 
0 0 0 0 0 1 12 
87 
Inter-alpha-trypsin inhibitor 
heavy chain H4 
GS
 
2 0 0 0 4 7 15 
88 Keratin, type I cytoskeletal 10 
1a
 17 25 15 15 14 13 22 
89 Keratin, type I cytoskeletal 13 0 5 0 0 0 0 0 
90 Keratin, type I cytoskeletal 16 
1a
 0 0 0 0 1 0 5 
91 Keratin, type I cytoskeletal 9 12 12 17 9 14 11 18 
92 Keratin, type II cytoskeletal 1 18 26 19 18 18 12 20 
03 Keratin, type II cytoskeletal 1b 0 11 0 0 0 0 0 
94 
Keratin, type II cytoskeletal 2 
epidermal 
13 25 10 15 9 8 16 
95 Keratin, type II cytoskeletal 6A 8 9 11 0 3 2 19 
96 Keratin, type II cytoskeletal 78 0 7 0 0 0 0 0 
97 Kininogen-1 
GS
 3 4 12 32 31 27 20 
98 




0 0 0 0 0 3 0 
99 Peroxiredoxin-2 0 5 0 0 0 0 0 
100 Plasma kallikrein 
GS
 0 0 0 0 0 1 12 
101 Plasma protease C1 inhibitor 
GS
 0 0 0 0 0 0 8 
102 Plasminogen 
GSGS





103 Pregnancy zone protein 
1a
 0 0 0 0 0 0 20 




0 5 0 0 0 0 0 
106 Prothrombin 1 1 7 8 11 11 6 
107 
Putative uncharacterized protein 
DKFZp686C11235 
0 0 0 0 0 3 3 
108 
Putative uncharacterized protein 
DKFZp686G11190 
0 0 0 0 0 7 3 
109 
Scavenger receptor cysteine-rich 
type 1 protein M130 
0 0 0 8 2 0 0 
110 Serum albumin 81 125 130 110 160 120 85 
112 
Serum paraoxonase/arylesterase 1 
GS
 
0 0 0 1 0 0 11 
113 suprabasin
 1a
 0 4 0 0 0 0 0 
114 Triosephosphate isomerase 
1a
 0 6 0 0 0 0 0 
115 Uncharacterized protein 1 1 2 3 2 2 0 
116 Uncharacterized protein 0 0 0 0 0 0 0 
117 Uncharacterized protein 3 4 9 16 13 19 32 
118 Uncharacterized protein 0 0 7 4 0 0 0 
119 Uncharacterized protein 0 3 0 3 0 0 4 
120 Uncharacterized protein 1 3 1 1 0 0 0 
121 Uncharacterized protein 0 0 0 0 0 0 3 
122 
vitamin D-binding protein 
isoform 1 precursor 
0 0 0 0 10 9 0 
123 Vitamin K-dependent protein C 
1a
 0 0 0 0 3 9 0 
124 Vitamin K-dependent protein S 0 0 0 0 0 0 13 
125 Vitronectin 
GS
 4 0 3 4 6 6 0 
126 Zinc-alpha-2-glycoprotein 
GS
 0 4 1 8 5 2 0 
G, glycoprotein; GS, sialylated glycoprotein; 1a, low abundance protein (few ng to sub g/mL 













PROTEINS IDENTIFIED BY LC-MS/MS ANALYSIS OF MAL-II CAPTURED 
PROTEINS FROM NON DEPLETED DIESEASE FREE SERUM. DATA ON GS WERE 
FROM REFS. [2, 16, 22-24, 32, 35, 39, 45, 51-53] 
 













1 165 kDa protein 0 0 0 24 46 3 42 
5 Antithrombin-III 
GS
 0 7 3 1 1 0 0 
6 Apolipoprotein A-I 
GS
 10 12 22 21 17 9 17 
7 Apolipoprotein A-II 2 2 5 4 3 2 3 
8 Apolipoprotein A-IV 3 3 11 11 11 4 7 
9 Apolipoprotein B-100 
GS
 2 3 4 14 25 6 22 
10 Apolipoprotein C-I 2 1 2 3 3 4 2 
11 Apolipoprotein D 
GS
 5 5 4 2 0 3 0 
12 Apolipoprotein E G 4 4 7 7 6 0 4 
13 Apolipoprotein M 
GS
 4 4 1 0 2 0 0 
14 
cDNA FLJ14473 fis, clone 
MAMMA1001080 
4 6 12 13 13 0 11 
15 Kininogen-1 
GS
 17 13 10 8 7 13 3 
16 Keratin, type II cytoskeletal 6A 3 1 3 29 6 17 8 
17 Alpha-2-HS-glycoprotein 
GS
 5 5 3 3 3 1 0 
18 Ceruloplasmin 
GS
 4 7 6 6 4 0 4 
19 Complement C1s subcomponent 2 8 2 2 0 0 0 
20 Complement C3 (Fragment) 
GS
 0 0 9 23 27 0 16 
21 Desmoglein-1  
GS
 0 0 0 0 0 3 0 
22 Haptoglobin 
GS
 11 13 13 10 11 7 8 
23 Hemopexin  
GS
 6 3 1 1 0 0 0 
24 Histidine-rich glycoprotein 
GS
 3 2 0 0 0 0 0 
25 Hornerin 
1a
 0 0 2 3 1 10 2 
26 IGK@ protein 2 5 7 10 9 3 9 
27 Inter-alpha inhibitor H2 3 0 5 12 4 2 0 
28 
Inter-alpha-trypsin inhibitor 
heavy chain H1 
0 0 4 5 1 0 0 
29 Alpha-1-antichymotrypsin 
GS
 0 0 4 5 2 0 2 
30 Alpha-1-antitrypsin 
GS
 5 8 21 18 18 3 9 
31 Complement factor H 
GS
 14 6 2 0 0 6 0 
32 
Inter-alpha-trypsin inhibitor 
heavy chain H4 
GS
 
3 0 5 4 5 0 4 
33 Keratin, type I cytoskeletal 13 0 0 0 0 0 4 0 
34 Pregnancy zone protein
1a GS
 0 0 0 0 5 0 5 





36 Apolipoprotein L1 G 3 2 1 1 1 0 0 
37 Ig mu chain C region 0 3 8 9 10 1 8 
38 Clusterin 
GS
 11 12 11 6 5 0 3 
39 Fibronectin 
GS
 3 2 7 17 19 3 17 
40 Desmoplakin
1a
 0 0 0 1 0 6 0 
41 Keratin, type I cytoskeletal 10 
1a
 16 12 18 18 18 21 16 
42 Keratin, type I cytoskeletal 14 
1a
 2 4 4 16 5 12 4 
43 Keratin, type I cytoskeletal 16 
1a
 0 0 1 13 1 7 3 
44 Keratin, type I cytoskeletal 17 0 0 0 7 0 3 0 
45 Keratin, type I cytoskeletal 9 8 12 15 17 15 16 16 
46 Keratin, type II cytoskeletal 1 13 14 17 23 20 25 18 
47 
Keratin, type II cytoskeletal 2 
epidermal 
8 6 10 16 15 22 13 
48 Ig kappa chain V-I region EU * 8 9 7 10 11 8 10 
49 
Ig kappa chain V-III region 
WOL* 
2 3 5 4 5 6 10 
50 Ig kappa chain V-IV region * 1 4 6 7 5 7 6 
51 Ig lambda chain V-I region WAH* 3 3 2 2 4 2 5 
52 Ig lambda chain V-III region LOI * 5 2 6 5 6 6 7 
53 Ig lambda chain V-III region SH * 3 2 6 7 4 6 3 
54 Keratin, type II cytoskeletal 5 
1a
 1 1 4 13 7 12 5 
55 Keratin, type II cytoskeletal6B 0 0 0 3 0 2 0 
56 Plasma protease C1 inhibitor
GS












6 9 12 13 14 5 12 
60 SAA2-SAA2 protein 4 5 3 2 0 0 0 
61 Serotransferrin 
GS
 18 11 6 1 3 6 0 




0 0 7 6 4 0 2 
64 Transthyretin 5 3 1 0 0 3 0 
65 Uncharacterized protein 2 0 0 0 0 3 0 
66 Uncharacterized protein 1 3 3 0 0 0 0 
67 Uncharacterized protein 0 0 4 4 4 0 1 
68 
vitamin D-binding protein 
isoform 1 precursor 
5 0 0 0 0 0 0 
69 Vitamin K-dependent protein S 0 0 4 0 0 0 0 
70 Vitronectin GS 4 3 3 3 1 0 0 






PROTEINS IDENTIFIED BY LC-MS/MS ANALYSIS OF THE SNA CAPTURED PROTEINS FROM DISEASE-FREE AND 
CANCER SERA AND FRACTIONATED ON THE RPC COLUMN. DATA ON GS WERE FROM REFS. [2, 12, 15, 16, 22-25, 
30, 32, 39, 43, 45, 51, 53-59] 
 Disease free serum Breast cancer serum 





































1 Actin, cytoplasmic 1* 0 0 0 0 0 0 0 0 0 7 0 0 0 1 0 0 0 0 
2 Afamin  
G S
 0 0 0 0 4 47 20 3 0 0 0 0 0 0 42 15 0 0 
3 Alpha-1-acid glycoprotein 1  
GS
 0 0 12 13 4 0 0 0 0 0 0 16 14 5 0 0 14 0 
4 Alpha-1-acid glycoprotein 2  
GS
 0 0 12 11 8 8 0 4 0 0 0 17 10 6 1 2 10 0 
5 Alpha-1-antichymotrypsin 
 GS
 0 0 0 0 0 23 36 30 26 0 0 0 0 0 8 27 0 20 
6 Alpha-1-antitrypsin 
GS
 2 9 15 18 42 101 180 124 65 3 7 7 3 5 52 120 3 49 
7 Alpha-1B-glycoprotein  
GS
 0 0 12 31 6 6 0 0 0 0 0 17 34 6 4 0 34 0 
8 Alpha-2-antiplasmin 
GS
 0 0 4 2 24 0 14 26 21 0 0 2 0 1 0 13 0 23 
9 Alpha-2-HS-glycoprotein  
GS
 0 0 22 30 0 20 15 15 18 0 0 23 34 8 20 16 34 12 
10 Alpha-2-macroglobulin 
GS
 0 0 2 0 0 0 15 132 169 0 2 0 0 1 0 23 0 185 
11 Angiotensinogen 
GS
 0 0 0 0 0 0 14 19 16 0 0 0 0 0 0 10 0 11 
12 Annexin A3 
1a
 0 0 0 0 0 0 0 0 0 2 0 0 0 1 0 0 0 0 
13 Antileukoproteinase 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
14 Antithrombin-III 
 GS
 0 0 12 13 33 48 20 22 16 0 0 4 11 1 33 6 11 12 
15 Apolipoprotein A-I  
GS
 1 4 18 15 15 88 121 90 67 0 3 15 23 6 157 138 23 92 
16 Apolipoprotein A-II * 0 2 1 6 8 8 13 13 14 0 3 1 5 1 15 16 5 10 
17 Apolipoprotein A-IV * 0 10 32 25 13 30 37 34 31 0 2 22 18 8 47 78 18 34 
18 Apolipoprotein B-100 
GS
 0 2 11 2 0 0 0 19 156 0 2 6 2 3 0 1 2 112 





20 Apolipoprotein C-II * 0 0 0 4 7 7 1 0 4 0 2 2 3 1 13 4 3 0 
21 Apolipoprotein C-III 
G
 0 0 4 13 13 6 4 1 6 0 0 8 13 3 10 6 13 6 
22 Apolipoprotein D 
GS
 0 3 8 1 10 22 15 9 9 0 5 15 11 7 29 21 11 14 
23 Apolipoprotein E 
G
 0 5 4 5 4 1 10 34 40 0 0 2 4 1 8 25 4 54 
24 Apolipoprotein L1 
G
 0 0 0 2 10 0 0 4 13 0 0 0 9 0 0 0 9 23 
25 Apolipoprotein M 
GS
 0 0 0 0 12 5 2 4 0 0 0 0 1 0 7 2 1 5 
26 Attractin 
1a
 0 0 0 1 28 6 0 0 0 0 0 0 13 0 2 0 13 0 
27 Beta-2-glycoprotein 1  
GS
 0 22 31 11 7 0 0 1 4 0 25 27 10 17 4 2 10 3 
28 Beta-2-microglobulin 
GS
 0 4 0 0 0 0 0 0 0 0 5 0 0 2 0 0 0 0 
29 Beta-Ala-His dipeptidase  
1a
 0 0 0 0 0 0 0 8 20 0 0 0 0 0 0 0 0 14 
30 Biotinidase 
GS
 0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 
31 C4b-binding protein alpha chain  
G
 0 0 0 0 0 0 0 0 0 0 0 5 2 2 0 0 2 0 
32 Cadherin-5 
GS
 0 0 1 0 0 0 0 0 0 0 0 3 0 1 0 0 0 0 
33 Calmodulin-like protein 5 
1a
 0 0 0 0 0 0 0 0 0 1 0 2 0 0 0 0 0 0 




 0 0 0 0 27 6 0 0 0 0 0 0 0 0 9 0 0 0 
35 
Carboxypeptidase N catalytic chain 
GS1a
 
0 0 0 0 0 24 2 1 1 0 0 0 0 0 20 0 0 0 
36 Carboxypeptidase N subunit 2 
GS
 0 0 0 0 1 0 0 0 7 0 0 0 0 0 0 0 0 10 
37 Cartilage acidic protein 1 
G
 0 0 0 0 0 0 0 0 0 0 0 0 1 0 2 0 1 0 
38 Cathelicidinant-imicrobial peptide 
1a
 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 
39 CD5 antigen-like * 0 0 0 0 0 6 4 3 1 0 0 0 0 0 15 9 0 8 
40 Ceruloplasmin 
GS
 0 0 4 15 97 70 51 54 47 0 0 5 12 2 65 56 12 44 
41 Cholinesterase 
1a
 0 0 0 0 0 1 0 1 4 0 0 0 0 0 2 1 0 3 
42 Clusterin 
GS
 0 0 0 7 42 38 8 11 11 0 0 0 17 0 34 11 17 9 
43 Coagulation factor IX
GS 1a
 0 0 3 6 6 0 0 2 4 0 0 0 7 0 4 0 7 6 
44 Coagulation factor V  
GS1a
 0 0 5 0 0 0 0 0 0 0 0 4 0 1 0 0 0 0 
45 Coagulation factor VII  
GS
 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 
46 Coagulation factor X 
GS
 0 0 0 0 0 0 0 0 0 0 0 8 0 3 0 0 0 0 
47 Coagulation factor XII 
GS









 0 0 88 12 2 0 0 0 0 0 0 87 10 29 0 0 10 0 
49 Complement C1r subcomponent 3 0 0 27 10 0 0 0 0 0 0 0 57 0 0 6 57 0 
50 




0 0 0 11 1 2 0 0 0 0 0 0 11 0 0 0 11 0 
51 Complement C1s subcomponent  
GS
 0 0 0 0 49 11 2 6 3 0 0 0 0 0 6 6 0 0 
52 Complement C2 
G
 0 0 0 0 0 0 0 0 16 0 0 0 0 0 0 0 0 0 
53 Complement C3 
GS
 5 3 1 19 17 143 81 303 220 2 0 0 1 1 62 84 1 229 
54 Complement C4-A 
GS
 0 0 0 0 0 0 0 64 0 0 0 0 0 0 0 63 0 0 
55 Complement C4-B  
GS
 0 0 0 0 6 54 56 67 51 0 0 0 0 0 52 96 0 78 
56 Complement C5 
G
 0 0 0 0 0 0 9 54 51 0 0 0 0 0 0 6 0 50 
57 Complement component C6 
G
 0 0 0 43 26 0 0 0 0 0 0 0 57 0 1 0 57 0 
58 Complement component C7 
G
 0 0 0 1 4 0 0 0 0 0 0 0 11 0 0 0 11 0 
59 




0 0 0 0 10 0 0 0 0 0 0 0 0 0 0 0 0 0 
60 




0 0 0 0 9 0 0 0 0 0 0 0 0 0 0 0 0 0 
61 




0 0 0 0 9 0 0 0 0 0 0 0 0 0 0 0 0 0 
62 Complement component C9 
G
 0 0 0 0 0 16 1 1 0 0 0 0 0 0 12 0 0 0 
63 Complement factor B 
G
 0 0 8 4 56 34 9 21 14 0 0 10 4 3 24 5 4 13 
64 Complement factor H 
GS
 0 2 66 5 0 0 0 10 1 0 46 101 25 49 2 7 25 1 
65 




0 2 3 0 0 0 0 0 0 0 8 11 0 7 0 0 0 0 
66 




0 4 11 0 0 0 0 0 0 0 6 13 0 6 0 0 0 0 
67 




0 0 5 0 0 0 0 0 0 0 5 0 0 2 0 0 0 0 
68 















0 0 6 0 0 0 0 0 0 0 0 4 0 1 0 0 0 0 
70 Complement factor I 
G
 0 0 0 55 32 22 13 18 15 0 0 0 65 0 14 17 65 11 
71 Corticosteroid-binding globulin 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 2 
72 Cystatin-C 
GS
 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 
73 Cysteine-rich secretory protein 3  
GS
 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
74 Dermcidin 
1a
 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
75 Desmoplakin *
1a
 0 0 0 0 0 0 0 0 0 3 0 0 0 1 0 0 0 0 
76 Extracellular matrix protein 1 
G1a
 0 0 8 0 0 0 0 0 0 0 0 17 0 6 0 0 0 0 
77 




0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
78 Fetuin-B 
GS1a
 0 0 0 17 13 2 0 2 0 0 0 0 19 0 4 1 19 0 
79 Fibrinogen alpha chain 
GS
 9 6 0 0 0 0 0 1 0 10 5 0 0 5 0 0 0 0 
80 Fibrinogen beta chain 
GS
 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 
81 Fibronectin 
GS
 2 3 10 0 0 36 27 36 33 0 5 3 0 3 35 27 0 26 
82 Fibulin-1 
GS
 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 
83 Ficolin-2 
GS
 0 0 0 2 0 0 0 0 0 0 0 0 0 0 1 0 0 0 
84 Ficolin-3 
GS1a
 0 0 0 1 5 10 8 13 13 0 0 0 4 0 11 10 4 11 
85 Galectin-3-binding protein 
1a GS
 0 0 2 0 0 0 0 0 5 0 0 0 0 0 0 0 0 14 
86 Galectin-7 
1a
 0 4 8 0 5 0 0 0 0 3 0 0 0 1 7 10 0 0 
87 




0 0 0 0 1 2 0 0 0 0 0 0 0 0 0 0 0 0 
88 Gelsolin 
1a
 0 0 0 0 0 5 0 0 0 0 0 0 0 0 2 0 0 0 
89 Haptoglobin 
GS
 6 8 78 100 92 88 79 83 81 4 8 90 106 34 79 65 106 68 
90 Haptoglobin-related protein* 0 0 0 52 52 49 44 45 43 0 0 0 54 0 47 42 54 37 
91 Hemoglobin subunit alpha 
G
 0 0 0 0 20 5 0 0 0 0 4 0 7 1 25 9 7 9 
92 Hemoglobin subunit beta 
G
 0 0 0 0 21 11 0 4 2 0 0 0 10 0 22 12 10 15 
93 Hemoglobin subunit delta 
G
 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 1 0 0 
94 Hemopexin  
GS
 2 0 4 67 42 22 16 13 14 0 0 4 73 1 16 15 73 9 
95 Heparin cofactor 2 
GS










0 0 8 0 0 0 0 0 0 0 0 3 0 1 0 0 0 0 
97 Histidine-rich glycoprotein 
GS
 0 0 23 28 10 5 1 4 3 0 0 39 32 13 5 5 32 5 
98 Hornerin  *1a 0 0 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
99 Hyaluronan-binding protein 2 * 0 0 0 15 6 0 0 0 0 0 0 0 19 0 1 0 19 0 
100 
Hydrocephalus-inducing protein 
homolog  * 
0 0 0 0 3 0 0 0 0 0 0 0 1 0 0 0 2 0 
101 Ig alpha-1 chain C region 
G
 0 0 0 3 39 39 41 35 31 0 0 0 12 0 46 40 12 36 
102 Ig alpha-2 chain C region 
G
 0 0 0 0 31 34 32 28 0 0 0 0 0 0 33 30 0 19 
103 Ig gamma-1 chain C region 
G
 0 2 3 8 11 13 9 10 10 1 1 0 8 1 9 7 8 11 
105 Ig kappa chain C region * 0 2 17 12 24 24 20 24 22 0 6 19 14 8 22 22 14 24 
106 Ig kappa chain V-III region WOL * 0 3 4 0 1 3 5 4 3 0 4 0 1 1 5 5 1 5 
107 Ig lambda-2 chain C regions * 0 0 12 0 11 15 15 14 16 0 0 12 0 4 17 5 0 10 
108 Ig mu chain C region  
GS
 0 0 0 4 17 21 17 22 25 0 0 0 9 0 34 31 9 32 
109 Immunoglobulin J chain 
 GS
 1 0 0 0 7 3 5 3 6 3 0 0 0 1 6 6 0 6 
110 
Immunoglobulin lambda-like 
polypeptide 5 * 
0 1 8 8 14 15 11 11 11 0 2 7 9 3 15 14 9 13 
111 
Insulin-like growth factor-binding 
protein 3  
GS
 
0 0 0 0 0 0 0 0 0 5 0 0 0 2 0 0 0 0 
112 
Insulin-like growth factor-binding 
protein complex acid labile subunit  
GS
 
0 2 4 0 0 0 0 8 0 0 0 0 0 0 0 0 0 1 
113 




0 0 0 4 2 50 80 64 28 0 0 0 0 0 36 92 0 32 
114 




0 7 7 7 9 30 86 69 42 0 3 9 4 4 11 112 4 52 
115 




0 0 0 0 0 19 6 0 0 0 0 0 0 0 15 5 0 0 
116 




0 0 0 8 14 23 66 43 39 0 0 0 18 0 47 88 18 64 
117 Intercellular adhesion molecule 2 
1a





118 Junction plakoglobin  *
1a
 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
119 Kallistatin 
GS
 0 0 0 0 0 0 12 18 8 0 0 0 0 0 0 22 0 11 
120 Keratin, type I cytoskeletal 10 
1a
 17 28 42 14 32 13 14 28 28 35 33 30 8 33 19 23 8 58 
121 Keratin, type I cytoskeletal 14 
1a*
 12 13 36 0 0 0 0 0 11 37 14 16 0 23 0 0 0 21 
122 Keratin, type I cytoskeletal 16 
1a
 0 0 30 0 0 0 0 0 0 30 12 0 0 14 0 0 0 0 
123 Keratin, type I cytoskeletal 17 
1a
 0 0 14 0 0 0 0 0 0 45 0 0 0 15 0 0 0 0 
124 Keratin, type I cytoskeletal 9* 25 33 44 7 18 11 15 22 48 27 25 25 16 26 16 10 16 38 
125 Keratin, type II cytoskeletal 1* 30 39 58 18 34 25 20 26 46 39 33 45 22 39 20 15 22 59 
126 
Keratin, type II cytoskeletal 2 
epidermal* 
16 33 51 12 31 14 5 24 29 20 33 25 9 26 14 9 9 62 
127 Keratin, type II cytoskeletal 5* 
1a
 8 24 33 0 0 0 0 6 11 40 16 5 0 20 0 0 0 23 
128 Keratin, type II cytoskeletal 6A * 10 12 30 0 0 1 0 0 5 44 16 13 0 24 0 0 0 18 
129 Keratin, type II cytoskeletal 6B * 0 0 0 0 0 0 0 0 0 43 0 0 0 14 0 0 0 0 
130 Keratin, type II cytoskeletal 6C* 0 0 0 0 0 0 0 0 0 44 0 0 0 15 0 0 0 0 
131 Keratinocyte proline-rich protein 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 
132 Leucine-rich alpha-2-glycoprotein 
GS
 0 0 0 0 0 12 0 0 0 0 0 0 0 0 8 0 0 0 
134 
Leukocyte immunoglobulin-like 
receptor subfamily A member 3 
G
 
0 0 3 0 0 0 0 0 0 0 0 2 0 1 0 0 0 0 
135 LMW of Kininogen-1 
GS
 2 6 75 75 48 43 34 33 30 0 7 93 89 33 48 43 89 36 
136 




0 0 0 0 0 0 0 0 0 0 0 5 0 2 0 0 0 0 
137 Lumican  
GS
 0 0 0 2 0 0 1 0 0 0 0 0 0 1 0 3 0 0 
138 Lysozyme C 
1a
 2 0 4 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 
139 




0 0 0 0 6 4 0 0 4 0 0 0 1 0 5 0 1 3 
140 
Mannan-binding lectin serine 
protease 2 * 
0 0 0 0 0 0 0 0 0 0 0 6 0 2 0 0 0 0 
141 Mannose-binding protein C * 0 1 0 0 3 0 0 0 0 0 0 3 0 0 0 0 1 0 
142 























0 0 0 0 0 11 0 2 1 0 0 0 0 0 11 0 0 0 
145 Ovalbumin 
GS
 0 7 15 12 19 26 37 35 27 0 7 12 4 6 25 29 4 24 












0 0 0 0 0 0 0 19 10 0 0 0 0 0 0 1 0 13 
149 Plasma kallikrein heavy chain  
GS
 0 0 0 5 15 0 0 14 24 0 0 0 8 0 0 0 8 18 
150 Plasma protease C1 inhibitor 
GS
 0 0 2 0 0 0 5 2 6 0 0 0 0 0 1 7 0 8 
151 Plasma serine protease inhibitor 
GS
 0 0 0 0 0 0 0 0 10 0 0 0 0 0 0 0 0 13 
152 Plasminogen 
GS
 0 0 67 55 0 0 0 0 0 0 2 77 40 26 0 0 40 0 
153 Pregnancy zone protein 
GS1a






0 0 0 0 0 0 0 0 0 0 0 19 12 6 4 0 12 0 
155 Prenylcysteine oxidase 1 
G
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 
156 Protein AMBP 
GS
 0 0 0 13 15 15 20 17 9 0 0 4 16 1 17 23 16 13 
157 Protein S100-A8 
1a
 0 0 0 0 0 0 0 0 0 2 0 0 0 1 0 0 0 0 
158 Protein S100-A9 0 0 0 0 0 0 0 0 0 5 0 0 0 2 0 0 0 1 
159 




0 0 0 0 0 5 0 2 0 0 0 0 0 0 0 0 0 5 
160 Prothrombin 0 6 6 37 20 12 3 10 15 1 8 7 21 5 14 4 21 11 
161 Retinol-binding protein 4 * 0 0 6 9 8 7 7 1 0 0 0 12 9 4 8 4 9 4 




 0 0 0 0 0 0 0 0 0 0 0 4 0 1 0 0 0 0 
164 Selenoprotein P 
G1a
 0 0 10 4 0 0 0 0 0 0 0 12 5 4 0 2 5 0 
165 Serotransferrin 
GS
 0 0 103 105 47 23 14 18 14 0 0 132 113 44 37 18 113 16 






167 Serum albumin 
G
 6 8 32 110 98 101 90 78 66 3 10 26 216 13 114 94 216 78 
168 Serum amyloid A-1 protein 
GS
 0 0 0 0 0 0 0 0 0 0 0 0 5 0 0 0 5 0 
169 Serum amyloid A-4 protein 
GS
 0 0 0 1 6 3 5 2 3 0 0 0 9 0 6 4 9 2 
170 Serum amyloid P-component  
GS












0 0 0 0 0 1 4 4 0 0 0 0 0 0 3 5 0 1 
173 Sex hormone-binding globulin 0 0 0 0 10 0 0 0 0 0 0 0 0 0 0 0 0 0 
174 Tetranectin 
G
 0 0 10 9 3 0 0 0 0 0 0 10 5 3 0 0 5 0 
175 Transthyretin * 0 0 0 0 0 0 1 3 4 0 0 0 0 0 0 3 0 2 
176 Trypsin-1 
1a
 0 7 0 0 5 0 0 0 0 0 0 0 0 0 0 0 0 0 
177 Ubiquitin* 0 0 8 20 18 10 10 10 2 0 0 3 19 1 5 5 19 0 
178 Vitamin D-binding protein 
GS
 7 9 9 8 9 9 5 7 9 7 8 7 10 7 7 4 10 7 
179 Vitamin K-dependent protein C 
1a
 2 0 0 0 0 0 0 0 0 3 0 0 0 1 0 0 0 0 
180 Vitamin K-dependent protein S 0 0 0 17 10 0 0 0 0 0 0 0 30 0 0 0 30 0 
181 Vitamin K-dependent protein Z 
GS1a
 0 0 0 12 9 0 0 0 0 0 0 0 13 0 0 0 13 0 
182 Vitronectin 
GS
 0 0 0 0 0 24 9 6 6 0 0 0 0 0 23 14 0 7 
183 von Willebrand factor 
1a GS
 0 0 9 0 0 0 0 0 0 0 0 21 4 7 0 0 4 0 
184 Zinc-alpha-2-glycoprotein 
GS
 1 0 0 25 23 16 12 13 14 0 0 3 34 1 13 10 34 12 







PROTEINS IDENTIFIED BY LC-MS/MS ANALYSIS OF THE MAL-II CAPTURED PROTEINS FROM DISEASE –FREE 
AND CANCER SERA AND FRACTIONATED ON THE RPC COLUMN.. DATA ON GS WERE FROM REFS. [2, 12, 16, 23, 
24, 27, 43, 45, 51, 56, 57, 59-61] 
 
Average Spectral count for disease-free  
serum 
Average Spectral count for cancer  serum 

































1 Actin, cytoplasmic 1  * 2 5 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
2 Afamin 
GS
 0 0 0 0 15 11 0 0 0 0 0 0 17 10 0 0 
3 Alpha-1-acid glycoprotein 1 
GS
 0 5 4 0 0 2 0 0 0 4 3  3 0 0 0 
4 Alpha-1-acid glycoprotein 2 
GS
 0 4 5 4 3 3 3 0 0 5 5 4 4 4 2 2 
5 Alpha-1-antichymotrypsin 
GS
 0 0 0 0 8 14 12 9 0 0 0 0 5 14 11 9 
6 Alpha-1-antitrypsin  
GS
 3 2 3 6 17 24 24 14 2 2 0 2 8 25 21 17 
7 Alpha-1B-glycoprotein  
GS
 0 0 10 0 2 0 2 0 0 2 9 3 3 3 2 2 
8 Alpha-2-antiplasmin 
GS
 0 0 0 0 0 3 8 3 0 0 0 0 0 4 11 10 
9 Alpha-2-HS-glycoprotein 
GS
 0 3 6 5 6 6 7 5 0 5 6 5 7 7 6 6 
10 Alpha-2-macroglobulin 
GS
 0 0 0 0 0 3 51 50 0 0 0  0 7 50 55 
11 Alpha-enolase 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
12 Alpha-S1-casein 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 
13 Angiotensinogen  
GS
 0 0 0 0 0 2 6 0 0  0 0 0 4 8 4 
14 Annexin A2  
1a
 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
15 Antithrombin-III  
GS
 0 0 0 7 14 3 4 4 0 0 0 8 8 3 2 2 
16 Apolipoprotein A-I 
GS






17 Apolipoprotein A-II * 0 0 3 4 4 3 3 4 2 2 3 4 3 3 4 4 
18 Apolipoprotein A-IV * 6 11 8 6 11 18 14 3 5 5 5 0 10 19 18 16 
19 Apolipoprotein B-100  
GS
 0 0 0 0 3 2 9 100 0 0 0  0 3 6 39 
20 Apolipoprotein C-I* 0 2 3 2 0 2 2 0 0 2 4 4 3 2 4 3 
21 Apolipoprotein C-II* 0 0 0 0 3 2 0 0 2 2 0 2 2 2 0 0 
22 Apolipoprotein C-III  
G
 0 0 2 2 2 2 2 2 0 2 0 2 2 3 0 2 
23 Apolipoprotein D 
GS
 0 0 0 2 7 7 6 2 0 0 0 3 7 7 6 6 
24 Apolipoprotein E  
G
 0 0 0 0 0 5 12 11 2 0 0 0 0 7 14 15 
25 Apolipoprotein L1 
G
 0 0 2 4 4 2 3 3 0 0 2 4 2 2 6 8 
26 Apolipoprotein M  
GS
 0 0 0 4 4 2 4 0 0 0 0 5 3 3 4 3 
27 Arginase-1 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
28 Beta-2-glycoprotein 1 
GS
 9 10 5 4 3 2 2 0 11 9 3 4 3 2 0 2 
29 Beta-2-microglobulin 
GS
 2 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 
30 Beta-Ala-His dipeptidase 
1a
 0 0 0 0 0 0 4 0 0 0 0 0 0 0 8 9 
31 Bone marrow proteoglycan 
GS





 0 0 0 0 2 2 0 0 0 0 0 0 3 0 0 0 
33 Carboxypeptidase N catalytic chain 
G1a
 0 0 0 3 4 0 0 0 0 0 0 6 2 0 0 0 
34 Carboxypeptidase N subunit 2 
G
 0 0 0 0 0 0 2 3 0 0 0 0 0 0 0 5 
35 Cartilage oligomeric matrix protein 
G1a
 0 0 0 0 3 0 0 0 0 0 0 0 2 0 0 0 
36 Cathelicidin antimicrobial peptide 
1a
 0 0 0 0 0 0 0 0 0 0 0 3 0 0 0 0 
37 CD5 antigen-like* 0 0 0 0 2 0 0 0 0 0 0 0 3 4 2 3 
38 Ceruloplasmin 
GS
 0 0 5 25 21 19 21 12 0 0 3 24 23 21 16 19 
39 Cholinesterase
1a
 0 0 0 0 2 0 2 2 0 0 0 0 2 0 2 2 
40 Clusterin  
GS
 0 0 0 9 9 3 3 0 0  0 9 7 4 2 2 
41 Coagulation factor IX
GS1a
 0 0 0 0 0 0 0 0 0 0 0 7 0 0 3 0 
42 Coagulation factor X 
GS
 0 3 0 0 0 0 0 0 0 2 0 0 0 0 0 0 
43 Coagulation factor XII 
GS
 0 0 5 2 0 0 2 0 0 0 8 3 0 0 0 0 
44 Complement C1r subcomponent 
GS
 0 0 3 0 0 0 0 0 0 0 3 0 0 2 0 0 
45 Complement C1s subcomponent G 
GS
 0 0 0 14 8 5 2 0 0 0 0 19 7 5 2 3 
46 Complement C2 G 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 2 
47 Complement C3 G 0 0 6 6 45 45 97 59 0 0 0 0 57 59 106 93 
48 Complement C4-A 
GS




49 Complement C4-B G 0 0 0 0 32 38 43 21 0 0 0  37 60 48 41 
50 Complement C5 G 0 0 0 0 0 0 20 10 0 0 0 0 0 3 24 27 
51 Complement component C6 G 0 0 10 4 0 0 0 0 0 0 9 8 0 0 0 0 
52 Complement component C7 G 0 0 7 12 0 0 0 0 0 0 10 13 0 0 0 0 
53 Complement component C8 alpha chain G 0 0 0 7 4 3 0 0 0  0 8 3 3 0 2 
54 Complement component C8 beta chain G 0 0 0 8 0 0 0 0 0 0 0 8 0 0 0 0 
55 Complement component C8 gamma chain G 0 0 0 5 0 0 0 0 0 0 0 6 0 2 0 0 
56 Complement component C9 
G
 0 0 0 0 16 10 7 3 0 0 0 2 16 11 7 7 
57 Complement factor B 
G
 0 0 0 23 19 10 10 2 0 0 0 22 19 7 9 8 
58 Complement factor H 
GS
 0 8 2 0 0 0 2 0 2 22 2 0 0 0 0 0 
59 Complement factor H-related protein 1  
GS
 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 
60 Complement factor H-related protein 2 
G
 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
61 Complement factor I 
G
 0 0 16 13 10 6 9 2 0 0 19 13 8 6 6 5 
62 Corneodesmosin  
GS
 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
63 Cornifin-A 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
64 Corticosteroid-binding globulin G 0 0 0 0 0 0 3 2 0 0 0 0 0 0 4 2 
65 Dermcidin 
1a





 0 0 0 0 0 0 0 0 0 0 0 0 4 0 2 0 
67 Desmoglein-1
G1a
 0 0 0 0 0 0 0 0 0 7 0 8 0 0 0 0 
68 Desmoplakin *
1a
 36 26 0 0 0 0 0 4 0 3 0 0 0 0 2 6 
69 Extracellular matrix protein 1 
G1a
 0 3 0 0 0 0 0 0 0 8 0 0 0 0 0 0 
70 Fatty acid-binding protein, epidermal  
G





 0 0 2 2 2 0 0 0 0 0 2 2 0 0 0 0 
72 Fibrinogen alpha chain 
G
 3 0 0 0 0 0 0 0 3 0 0 0 0 0 0 0 
73 Fibronectin  
GS
 0 0 0 0 3 2 7 11 0 0 0 0 2 4 5 8 
74 Ficolin-3 
GS1a
 0 0 0 0 3 3 5 3 0 0 0 0 3 4 4 4 
75 Filaggrin 
1a
 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
76 Filaggrin-2 
1a
 3 2 0 0 0 0 0 0 0 0 0 0 0 0 0 2 
77 Galectin-3-binding protein
1a   GS
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 
78 Galectin-7 
1a
 0 0 0 0 0 0 0 0 0 0 0 0 4 0 1 0 
79 Gelsolin * 0 0 0 2 4 0 0 0 0 0 0 2 3 0 0 0 
80 Glyceraldehyde-3-phosphate dehydrogenase 
1a






 2 20 25 25 24 24 23 20 2 21 24 24 23 23 19 20 
82 Haptoglobin-related protein * 0 0 4 4 3 4 4 2 0 0 4 3 4 4 4 2 
83 Hemoglobin subunit alpha 
G
 0 0 0 0 2 0 0 0 0 0 0 6 5 2 0 3 
84 Hemoglobin subunit beta 
G
 0 0 0 2 0 0 0 0 0 0 0 8 6 6 4 4 
85 Hemopexin  
GS
 0 0 14 10 6 7 6 2 0 0 15 9 8 6 3 5 
86 Heparin cofactor 2 
GS
 0 0 0 0 2 8 7 3 0 0 0 0 4 7 6 6 
87 Histidine-rich glycoprotein  
GS
 0 3 4 4 2 3 3 0 0 3 4 4 2 3 3 2 
88 Histone H4 
1a
 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
89 Hornerin *
1a
 10 4 0 2 0 2 0 2 0 3 0 0 0 0 0 2 
90 Hyaluronan-binding protein 2 0 0 5 2 0 0 0 0 0 0 5 2 0 0 0 0 
91 Ig alpha-1 chain C region 0 0 0 9 8 8 9 7 0 0 4 9 8 10 10 9 
92 Ig gamma-1 chain C region 0 0 3 5 6 6 7 6 0 0 3 6 6 6 7 7 
93 Ig kappa chain C region * 0 3 0 5 5 5 6 5 0 3 4 6 5 7 6 5 
94 Ig mu chain C region 
GS
 0 0 0 6 9 5 10 6 0 0 2 12 10 7 12 11 
95 Immunoglobulin J chain 
GS
 0 0 0 2 3 0 2 0 0 0 0 3 3 4 3 3 
96 Immunoglobulin lambda-like polypeptide 5 0 3 2 5 5 4 5 4 0 2 2 6 5 5 5 4 
97 
Insulin-like growth factor-binding protein 
complex acid labile subunit 
0 0 0 0 0 0 3 0 0 0 0 0 0 0 5 0 
98 Inter-alpha-trypsin inhibitor heavy chain H1 0 0 2 2 12 15 17 8 0 0 0 0 14 20 14 10 
99 Inter-alpha-trypsin inhibitor heavy chain H2  
GS
 3 3 3 3 5 19 22 9 0 3 0 0 3 27 22 13 
100 Inter-alpha-trypsin inhibitor heavy chain H3 
GS
 0 0 0 0 5 3 0 0 0 0 0 0 6 3 0 0 
101 Inter-alpha-trypsin inhibitor heavy chain H4 
GS
 0 0 3 10 6 17 15 16 0 0 3 10 8 27 17 21 
102 Junction plakoglobin *
1a
 0 0 0 0 0 0 0 0 0 0 0 7 0 0 8 0 
103 Kallistatin 
GS
 0 0 0 0 0 5 12 4 0 0 0 0 0 11 10 3 
104 Keratin, type I cytoskeletal 10 *
1a
 19 20 10 17 14 21 18 18 16 18 13 17 15 21 20 20 
105 Keratin, type I cytoskeletal 13 
1a
 0 0 0 2 0 2 0 0 0 0 4 0 0 0 0 0 
106 Keratin, type I cytoskeletal 14* 
1a
 23 22 2 12 8 12 8 15 13 18 4 7 5 11 14 18 
107 Keratin, type I cytoskeletal 16 *
1a
 10 13 0 0 0 0 2 7 5 11 2 0 0 5 3 5 
108 Keratin, type I cytoskeletal 17 *
1a
 2 3 0 2 0 0 0 3 0 3 0 0 0 0 2 2 
109 Keratin, type I cytoskeletal 9* 30 28 9 20 14 19 13 19 17 20 12 11 12 22 23 19 
110 Keratin, type I microfibrillar 0 0 0 0 0 0 0 0 0 0 0 0 0 7 0 0 




112 Keratin, type II cytoskeletal 1 36 34 18 31 22 30 24 32 23 32 23 23 20 26 30 33 
114 Keratin, type II cytoskeletal 2 epidermal* 22 15 10 18 12 22 16 24 15 22 13 16 13 20 19 24 
115 Keratin, type II cytoskeletal 4 2 0 0 0 0 0 0 0 0 2 0  0 0 0 0 
116 Keratin, type II cytoskeletal 5 *
1a
 33 32 4 14 7 13 9 22 15 24 6 8 5 12 14 25 
117 Keratin, type II cytoskeletal 6A * 2 2 0 0 0 0 0 0 2 2 0 0 0 0 0 0 
118 Keratin, type II cytoskeletal 6C * 19 17 0 5 0 0 4 7 11 15 2 0 0 5 3 5 
120 Keratin, type II cytoskeletal 78* 6 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
121 Keratin, type II cytoskeletal 80 4 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
122 Keratin, type II microfibrillar 0 0 0 0 0 0 0 0 0 0 0 0 0 6 0 0 
123 Keratin, type II microfibrillar 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 
124 Keratinocyte proline-rich protein 0 3 0 0 0 0 0 0 0 0 0 0 0 2 0 0 
125 Leucine-rich alpha-2-glycoprotein  
GS
 0 0 0 0 2 0 0 0 0 0 0 0 10 0 0 0 
126 LMW of Kininogen-1 
GS
 3 19 25 24 19 22 20 10 4 24 26 26 23 22 21 22 
127 Lumican G
 GS
 0 0 0 8 0 0 0 0 0 0 0 7 0 0 0 0 
128 Mannan-binding lectin serine protease*
1a
 0 0 0 0 2 0 0 0 0 0 0 0 2 0 0 0 
129 N-acetylmuramoyl-L-alanine amidase G 
GS
 0 0 0 0 5 3 0 0 0 0 0  6 0 0 0 
130 Ovalbumin 
GS
 4 5 6 7 8 11 12 11 3 4 2 6 10 11 11 9 
131 Peroxiredoxin-1 * 2 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
132 Peroxiredoxin-2* 3 0 0 0 0 0 0 0 0 0 0 0 4 4 2 0 
133 Phosphatidylcholine-sterol acyltransferase 
1a






0 0 0 0 0 0 6 0 0 0 0 0 0 0 7 6 
135 Pigment epithelium-derived factor 0 0 0 0 0 0 4 0 0 0 0 0 0 0 6 3 
136 Plasma kallikrein heavy chain 
GS
 0 0 0 0 0 0 3 0 0 0 0 0 0 0 0 3 
137 Plasma protease C1 inhibitor  
GS
 0 0 0 0 2 2 3 2 0 0 0 0 5 5 7 6 
138 Plasma serine protease inhibitor 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 3 
139 Plasminogen 
GS
 0 18 33 14 12 5 3 0 0 25 30 9 4 4 4 3 
140 Platelet-activating factor acetylhydrolase 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 
141 Plectin * 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
142 Plexin domain-containing protein 2 
G
 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 0 




 0 0 0 0 0 0 0 11 0 0 0 0 0 0 0 12 
144 Pregnancy-specific beta-1-glycoprotein 1 
G S




145 Pregnancy-specific beta-1-glycoprotein 9  
GS
 0 0 0 0 0 0 0 0 0 0 0 3 0 0 0 0 
146 Prenylcysteine oxidase 1
G
 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 
147 Protein AMBP 
GS
 0 0 4 6 8 5 7 2 0 0 5 6 6 9 7 5 
148 Protein POF1B 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
149 Protein S100-A7 
1a
 0 3 0 0 0 0 0 0 0 0 0 2 0 0 0 0 
150 Protein S100-A8 
1a
 0 0 0 0 0 0 0 0 0 0 0 4 0 0 2 0 
151 Protein S100-A9 0 0 0 0 0 0 0 0 0 0 0 3 0 0 0 0 
152 Protein-glutamine gamma-glutamyltransferase E 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
153 Prothrombin 0 0 7 2 2 0 3 3 5 0 3 2 3 2 3 4 
154 Trypsin 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 3 
155 Retinol-binding protein 4 * 0 4 7 7 7 9 8 3 0 5 9 8 8 9 7 7 
156 Serotransferrin  
GS
 0 23 41 22 22 13 14 3 0 34 42 22 18 16 17 14 
157 Serpin B12 * 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
158 Serpin B3 * 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
159 Serum albumin 20 0 3 0 5 0 0 0 0 0 9 0 18 0 0 7 
160 Serum amyloid A-4 protein 
GS
 0 0 0 5 3 4 3 2 0 0 0 5 3 2 4 4 
161 Serum amyloid P-component  
GS
 0 0 0 6 6 5 6 5 0 0 2 7 6 6 5 5 
162 Serum paraoxonase/arylesterase 1  
GS
 0 0 0 0 5 5 5 4 0 0 0 0 6 6 5 4 
163 Serum paraoxonase/lactonase 3 
G
 0 0 0 0 0 0 0 0 0 0 0 0 0 3 2 0 
164 Sex hormone-binding globulin 
G
 0 0 0 3 0 0 0 0 0 0 0 4 0 0 0 0 
165 Small proline-rich protein 2A 
G
 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
166 Sulfhydryl oxidase 1 
1a
 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 
167 Tetranectin 
GS
 0 3 4 2 0 0 0 0 0 4 4 0 0 0 0 0 
168 Thioredoxin 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
169 Transferrin receptor protein 1 
1a
 0 0 0 0 0 0 3 0 0 0 0 0 0 0 3 0 
170 Transthyretin * 0 4 5 4 3 3 4 0 0 0 7 7 7 7 2 2 
171 Ubiquitin* 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
172 Vitamin D-binding protein  
GS
 0 0 10 10 2 0 0 0 0 0 15 12 3 0 0 0 
173 Vitamin K-dependent protein  
GS
 0 0 0 0 5 3 2 0 0 0 0  6 7 4 2 
174 Vitronectin  
GS
 0 0 7 7 4 3 4 0 0 0 6 7 4 3 4 4 
175 Zinc-alpha-2-glycoprotein 
GS
 0 5 3 0 0 0 0 0 0 4 3 0 0 0 0 0 





UNIQUE PROTEINS IDENTIFIED IN THE RPC FRACTIONS OF THE SNA 
CAPTURED PROTEINS FROM DISEASE-FREE SERUM WITH AND WITHOUT 
DEPLETION COLUMNS. DATA ON GS WERE FROM REFS. [10, 12, 25, 30, 32, 43, 
51, 56, 57, 59, 60, 62] 
Without depletion With depletion 
Catalase 
1a
 Actin, cytoplasmic 1 * 















 Antileukoproteinase  
Desmoglein-1 
1a





 Apolipoprotein F 
G
 















 Carboxypeptidase B2 
GS1a
 
Homo sapiens SNC73 protein (SNC73) mRNA  Cartilage acidic protein 1 
1aG
 
Ig kappa chanin V-IV region Len Cathelicidin antimicrobial peptide 
1a
 
Ig gamma chain-2 C region Cholinesterase 
1a
  
Ig kappa chain V-III region WOL * Coagulation factor V 
GS1a
 
Ig lambda-2 chain C regions * Coagulation factor VII 
GS
 
Ig mu chain C region   Coagulation factor X 
GS
 
Ig alpha-2 chain C region G Coagulation factor XII 
GS
 
Ig gamma-1 chain C region G Complement C2 
G
 
Ig kappa chain V-III region WOL * Complement C4-A 
GS
 
Ig heavy chain V-I region EU Complement C4-B 
GS
 
Ig gamma-3 chain C region 
G
 Complement C5 
G
 
Ig heavy chain V-III region GAL Complement component C8 alpha chain 
G
 
Ig heavy chain V-I region HG3 Complement component C8 beta chain 
G
 
IGK@ protein Complement component C8 gamma chain 
G
 
Inter-alpha (Globulin) inhibitor H2, isoform 
CRA_a 
Complement component C9 
G
 
Keratin, type I cytoskeletal 13 Complement factor H-related protein 2 
GS
 
Keratin, type II cytoskeletal 1b Complement factor H-related protein 3 
GS
 
Keratin, type II cytoskeletal 78 Complement factor H-related protein 5 
GS
 































Prothrombin (Fragment) Fibrinogen alpha chain 
GS
 
Putative uncharacterized protein Ficolin-2 
GS
 





Putative uncharacterized protein 
DKFZp686I15212 
Gamma-A of Fibrinogen gamma chain 
GS
 





Putative uncharacterized protein 
DKFZp686P15220 
Hemoglobin subunit delta 
G
 
SAA2-SAA2 protein Hepatocyte growth factor-like protein 
G
 
Scavenger receptor cysteine-rich type 1 protein 
M130 
Hydrocephalus-inducing protein homolog   
suprabasin
 1a
 Ig alpha-1 chain C region G 
Triosephosphate isomerase 
1a
 Ig gamma-1 chain C region G 
Uncharacterized protein Ig kappa chain C region * 
Uncharacterized protein Immunoglobulin lambda-like polypeptide 5  




Insulin-like growth factor-binding protein 
complex acid labile subunit 
GS
 
  Inter-alpha-trypsin inhibitor heavy chain H2 
GS
 
  Inter-alpha-trypsin inhibitor heavy chain H3 
GS
 
  Intercellular adhesion molecule 2 
1a
 
  Keratin, type II cytoskeletal 6B  
  Keratin, type II cytoskeletal 6C 




Leukocyte immunoglobulin-like receptor 
subfamily A member 3 
G
 




Low affinity immunoglobulin gamma Fc 
region receptor III-A 
G
 
  Lumican 
GS
 
 Lysozyme C 1a 
 Mannan-binding lectin serine protease 2 1a 
 Mannose-binding protein C  















 Peroxiredoxin-2  








 Plasma serine protease inhibitor 
GS
 
 Pregnancy-specific beta-1-glycoprotein 1 
GS
 
 Prenylcysteine oxidase 1 
G
 
 Protein S100-A8 
GS
 
 Protein S100-A9  
 Protein Z-dependent protease inhibitor 
G1a
 
 Prothrombin  
 Retinol-binding protein 4 
 
Scavenger receptor cysteine-rich type 1 protein 
M130 
 Secreted phosphoprotein 24  
G1a
 
 Serpin B3  
 Serum amyloid A-1 protein 
GS
 
 Serum amyloid A-4 protein 
GS
 
 Serum paraoxonase/lactonase 3  
 Thyroxine-binding globulin 
 








G, glycoprotein; GS, sialylated glycoprotein; 1a, low abundance protein (few ng to sub g/mL 










UNIQUE PROTEINS IDENTIFIED IN THE RPC FRACTIONS OF THE SNA 
CAPTURED PROTEINS FROM DISEASE-FREE SERUM WITH AND WITHOUT 
DEPLETION COLUMNS. DATA ON GS WERE FROM REFS. [10, 12, 25, 30, 32, 43, 






 Actin, cytoplasmic 1  
C4b-binding protein alpha chain Afamin 
Cadherin-5 
1a
 Alpha-2-macroglobulin  
Catalase 
1a




Coagulation factor XIII B chain
 1a





 Arginase-1  
Complement factor H-related protein 4 
1a
 Beta-2-microglobulin  
Cystatin-A 
1a
 Bone marrow proteoglycan  





 Cartilage oligomeric matrix protein
1a
 
Fibulin-1 Cathelicidin antimicrobial peptide 
1a
 
Gamma-B of Fibrinogen gamma chain Cholinesterase
1a
 





IGK@ protein Coagulation factor X  
Kininogen-1 
GS
 Coagulation factor XII  




Complement C2  
Mannan-binding lectin serine protease 1 
1a
 Complement C4-A 
Phospholipid transfer protein  Complement C4-B  
Protein-glutamine gamma-
glutamyltransferase K 
Complement C5  
Putative uncharacterized protein Complement component C8 alpha chain  
Putative uncharacterized protein 
DKFZp686I04196 (Fragment) 
Complement component C8 beta chain  
Putative uncharacterized protein 
DKFZp686I15212 






Putative uncharacterized protein 
DKFZp686L19235 
Complement component C9  
Putative uncharacterized protein 
DKFZp686P15220 
Complement factor H-related protein 2  
SAA2-SAA2 protein Corneodesmosin  
Scavenger receptor cysteine-rich type 1 
protein M130 
Cornifin-A  
selenoprotein P isoform 2 Corticosteroid-binding globulin  
suprabasin isoform 1 precursor Dermcidin 
1a
 
Triosephosphate isomerase Extracellular matrix protein 1 
1a
 
Uncharacterized protein Fatty acid-binding protein, epidermal  
Uncharacterized protein Fibrinogen alpha chain 
Uncharacterized protein Fibronectin  





Vitamin K-dependent protein Z Galectin-3-binding protein
1a
 
Ig kappa chain V-I region EU * Gelsolin  
Ig kappa chain V-III region WOL*  Histone H4 
1a
 
Ig kappa chain V-IV region * Ig gamma-1 chain C region 
Ig lambda chain V-I region WAH* Ig kappa chain C region  
Ig lambda chain V-III region LOI * Immunoglobulin lambda-like polypeptide 5  
Ig lambda chain V-III region SH *2 
Insulin-like growth factor-binding protein 
complex acid labile subunit  
 Inter-alpha-trypsin inhibitor heavy chain H2 
 Inter-alpha-trypsin inhibitor heavy chain H3  
 Keratin, type I microfibrillar  
 Keratin, type II cuticular Hb3 
 Keratin, type II cytoskeletal 4  
 Keratin, type II cytoskeletal 6C  
 Keratin, type II microfibrillar 
 Keratin, type II microfibrillar 
 Kininogen-1  
 Leucine-rich alpha-2-glycoprotein  
 Lumican 
 Mannan-binding lectin serine protease
1a
 
 N-acetylmuramoyl-L-alanine amidase  
 Ovalbumin 
 Peroxiredoxin-1  












 Pigment epithelium-derived factor  
 Plasma serine protease inhibitor  
 Platelet-activating factor acetylhydrolase  
 Plectin 
 Plexin domain-containing protein 2  
 Pregnancy-specific beta-1-glycoprotein 1  
 Pregnancy-specific beta-1-glycoprotein 9  
 Prenylcysteine oxidase 1  
 Protein POF1B  
 Protein S100-A7 
1a
 
 Protein S100-A8 
1a
 
 Protein S100-A9 
 Retinol-binding protein 4  
 Serpin B12  
 Serpin B3  
 Serum amyloid A-4 protein  
 Serum paraoxonase/lactonase 3  
 Skin-specific protein 32  
 Small proline-rich protein 2A  
 Sulfhydryl oxidase 1 
1a
 
 Tetranectin  
 Thioredoxin  







 Vitamin D-binding protein  
 Vitamin K-dependent protein S 
G, glycoprotein; GS, sialylated glycoprotein; 1a, low abundance protein (few ng to sub 













DIFFERENTIALLY EXPRESSED PROTEINS CAPTURED BY THE SNA COLUMN. 





































ACTB_HUMAN 42 kDa Up 0 7 
F5-Up Afamin 
GS



































APOA1_HUMAN 31 kDa Up 170 255 




























C9JF17_HUMAN 24 kDa Up 10 7 
F2, F7-Down 
Apolipoprotein E  
G
 












FA9_HUMAN 52 kDa Up 6 0 
F3-Up 
Coagulation 
factor X  
1aGS
 













F9-Down Complement C2 
G























FHR1_HUMAN 38 kDa Up 2 8 
F2-Up 
Complement factor 
H-related protein 3 
GS
 






ECM1_HUMAN 64 kDa Up 8 17 
F1,F3-Down Fibronectin 
GS
 FINC_HUMAN 240 kDa Down 12 3 
F5-Up Hemopexin  
GS
 HEMO_HUMAN 52 kDa Up 13 73 
F2-Up 
Ig kappa chain C 
region 
IGKC_HUMAN 12 kDa Up 2 6 
F5-Up Ig mu chain C 
GS



















KNG1_HUMAN 48 kDa Up 75 89 
F4-Down Plasminogen
 GS
 PLMN_HUMAN 91 kDa Down 55 40 
F4-Down Prothrombin THRB_HUMAN 70 kDa  37 21 
F5-Up 













55 kDa Up 17 30 
F3-Up 
Vitamin K-
dependent protein Z 
GS
 
PROZ_HUMAN 47 kDa Up 9 21 
G, glycoprotein; GS, sialylated glycoprotein; 1a, low abundance protein (few ng to sub g/mL 






DIFFERENTIALLY EXPRESSED PROTEINS CAPTURED BY MAL-II COLUMN. 














































Down 10 9 
F4-Up Antithrombin-III ANT3_HUMAN 
53 
kDa 










































Up 9 11 
F4-Up 
Carboxypeptidase 





























Down 36 0 
F2-Up 
Extracellular 






















F3,F6-Down Haptoglobin  
GS




HBB_HUMAN 16 kDa Up 2 8 
F1-Down Hornerin 
1a
 HORN_HUMAN 282 kDa Down 10 0 
F4-Up 

















PLAK_HUMAN 82 kDa Down 8 0 
F1,F2,F5-Up Kininogen-1 
GS
 KNG1_HUMAN 48 kDa Up 42 51 
F3,F5,F6-Down Plasminogen 
GS
 PLMN_HUMAN 91 kDa Down 50 38 
F1-Up Prothrombin THRB_HUMAN 70 kDa Up 0 5 
F2-Up Serotransferrin  
GS
 TRFE_HUMAN 77 kDa Up 23 34 
G, glycoprotein; GS, sialylated glycoprotein; 1a, low abundance protein (few ng to sub g/mL 



















DEP UNIQUE TO SNA LECTIN AND MAL-II LECTIN AND COMMON TO BOTH 
LECTINS. DATA ON GS WERE FROM REFS. [10, 25, 27, 28, 43, 51, 59, 61, 65] 
DEP only in SNA 
lectin 
DEP common to both 
lectins 
DEP only in MAL lectin 
Actin cytoplasmic Alpha-1-antitrypsin  GS Alpha-1-antitrypsin  GS 
Afamin GS Antithrombin-III GS Alpha-1B-glycoprotein GS 
Alpha-1-
antichymotrypsin GS Apolipoprotein A-I  GS Antithrombin-III 
Alpha-1-antitrypsin GS  Apolipoprotein A-IV  Apolipoprotein A-I GS 
Antithrombin-III GS Apolipoprotein B-100 GS Apolipoprotein A-IV 
Apolipoprotein A-I  GS Complement C3 GS Apolipoprotein B-100 GS 
Apolipoprotein A-IV  Complement factor H GS Apolipoprotein M GS 
Apolipoprotein B-100 
GS 
Extracellular matrix protein 
G1a Beta-2-glycoprotein 1 GS 
Apolipoprotein C-I  Kininogen-1  GS 
Carboxypeptidase N catalytic 
chain GS 
Apolipoprotein D GS Plasminogen GS Complement C3 GS 
Apolipoprotein E  G Prothrombin Complement factor H GS 
Clusterin GS Alpha-1-antitrypsin  GS Desmoplakin 1a 





Coagulation factor X  




subcomponent  GS Apolipoprotein A-IV  Haptoglobin  GS 
Complement C2 G Apolipoprotein B-100 GS Hemoglobin subunit beta 
Complement C3 G Complement C3 GS Hornerin 1a 
Complement C4-B GS Complement factor H GS Ig mu chain C region GS 
Complement factor H 
GS 
Extracellular matrix protein 
G1a 
Inter-alpha-trypsin inhibitor 
heavy chain H4 GS 
Complement factor H-
related protein 1GS Kininogen-1  GS Junction plakoglobin G1a 
Complement factor H-
related protein 3 GS Plasminogen GS Kininogen-1 GS 
Extracellular matrix 
protein G1a Prothrombin Plasminogen GS 
Fibronectin GS Alpha-1-antitrypsin  GS Prothrombin 
Hemopexin  GS Antithrombin-III GS Serotransferrin  GS 
Ig kappa chain C region Apolipoprotein A-I  GS Alpha-1-antitrypsin  GS 
Ig mu chain C GS Apolipoprotein A-IV  Alpha-1B-glycoprotein GS 
Inter-alpha-trypsin 





Kininogen-1  GS Complement C3 GS Apolipoprotein A-I GS 
Plasminogen GS Complement factor H GS Apolipoprotein A-IV 
Pregnancy-specific 
beta-1-glycoprotein  GS 
Extracellular matrix protein 
G1a Apolipoprotein B-100 GS 
Prothrombin Kininogen-1  GS Apolipoprotein M GS 
Serum amyloid A-4 
protein GS Plasminogen GS Beta-2-glycoprotein 1 GS 
Vitamin D-binding 
protein GS Prothrombin 
Carboxypeptidase N catalytic 
chain GS 
Vitamin K-dependent 
protein Z GS Alpha-1-antitrypsin  GS Complement C3 GS 
Actin cytoplasmic Antithrombin-III GS Complement factor H GS 
Afamin GS Apolipoprotein A-I  GS Desmoplakin 1a 
Alpha-1-
antichymotrypsin GS Apolipoprotein A-IV  
Extracellular matrix protein 1 
G1a 
Alpha-1-antitrypsin GS  Apolipoprotein B-100 GS 
Glyceraldehyde-3-phosphate 
dehydrogenase 1a 
Antithrombin-III GS  Haptoglobin  GS 
G, glycoprotein; GS, sialylated glycoprotein; 1a, low abundance protein (few ng to sub 
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MULTI COLUMN LIQUID PHASE BASED PLATFORM FOR THE ONLINE 
ENRICHMENT AND FRACTIONATION OF SIALOGLYCOPROTEINS 
 FROM DISEASE FREE AND BREAST CANCER SERUM – EFFECT  





 This chapter is a continuation to Chapter IV aiming at investigating the effect of 
the order of the lectin columns in the multi column platform (described in Chapter IV) on 
the number and identity of the captured proteins. Also, this chapter examines the effect of 
the performance of the RPC column used in the fractionation of the captured proteins by 
the two-lectin columns. In this regards, an ODA-TRIM monolithic column with 
incorporated multi wall carbon nanotubes that proved superior in the RPC of proteins 
than its counterpart ODA-TRIM column without incorporated nanotubes (introduced in 
Chapter III) has been evaluated in terms of its usefulness in revealing additional 








The experimental design was the same as in Chapter IV. The following 
summarizes the major experimental parts and their equivalent in previous chapters: 
 The instruments and reagents were same as in chapter IV 
 The monolithic RPC column preparation was described in chapter III 
 RPC fractionation of captured proteins was the same as in chapter IV 
 The preparation and immobilization of lectins were described in chapter IV 
 The LC-MS/MS conditions were same as in chapter IV 
 LC-MS/MS data analysis was the same as in chapter IV 
 
Arrangement of the lectin affinity columns in the multi column platform 
 The SNA and MAL-II columns were used for capturing the human serum 
sialoglycoproteins. The proteins were first captured in the order SNA column  MAL-II 
column, and then the order was changed to MAL-II column  SNA column. 
Additionally, the RPC fractionation of the captured proteins was performed using an 
optimized ODA/TRIM column that incorporated 12.5 mg of MWCNTs (with a serial 
number SN 6957838) and the monolith thus prepared is designated M13, see chapter III. 
 
Results and Discussion 
LC-MS/MS identification of proteins captured by the lectin columns arranged in the 





Identification of proteins captured by the SNA columns.  The captured proteins by 
the SNA column were eluted stepwise with the haptenic sugar lactose to the RPC 
column. The fractionation of RPC column was subsequently conducted with a linear 
ACN gradient at increasing ACN concentration in the mobile phase by going from 0-75% 
mobile phase B in mobile phase A for 12 min. The fractions were collected using a 
fraction collector starting at 7.5 min of the gradient and ended at 12 min (end of the 
gradient). Fractions of 0.5 mL each were collected at each 50 sec in Eppendorf tubes 
previously washed with ACN. Chromatograms of the RPC fractionation of the SNA 
captured proteins from disease free and cancer sera are shown in Fig. 1. The various 
fractions were evaporated to dryness using SpeedVac and then submitted for the LC-
MS/MS analysis. In the LC-MS/MS scaffold report, the proteins reported were those with 
protein identification probability of at least 99%, and peptide identification probability of 
not less than 95% and containing at least two unique peptides. The false discovery rate 
for the peptide identification was 0.1% for both SNA and MAL-lectins. The identified 
proteins from disease free and cancer sera are listed in Table 1. The Venn diagram in Fig. 
2 shows the number of proteins captured by the SNA column from disease free and 
cancer sera totaling 182 and 210 non-redundant proteins, respectively, with 30 and 58 
unique proteins, respectively, and 152 common proteins for both type of sera.  
Among the captured proteins, 155 proteins were reported to be glycosylated 
including 85 sialoglycoproteins and 83 low abundance proteins [1-26]. In the SNA 
captured proteins some novel biomarkers for breast cancer have been reported such as, 
















Figure 1. Chromatograms of the RPC fractionation of proteins captured by SNA column 
(A) and MAL-II column (B) from disease free (DFS) and breast cancer sera (CS). The 
RPC fractionation was carried out by a linear gradient elution at increasing ACN 
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concentration in the mobile phase by going from 0-75% of mobile phase B in 12 min. 
Mobile phase A consisted of H2O/ACN (95:5 v/v) containing 0.1% TFA and mobile phase 
B consisted of ACN/H2O (95:5 v/v) containing 0.1% TFA. Flow rate, 1 mL/min; UV 





Figure 2. Venn diagram for the LC-MS/MS identified proteins captured by the SNA 
lectin. 
 
Furthermore, apolipoprotein B-100, ceruloplasmin and fibronectin were reported 
as lung cancer biomarkers [32]. Plectin which is a low abundance protein was qualified 
as a pancreatic cancer biomarker [33]. Clusterin, leucine-rich-alpha-2-glycoprotein and 
complement H were identified as ovarian cancer biomarkers [34]. Calmodulin like 
protein, caspase 14, corneodesmosin were identified as biomarkers for the neuro-
degerative diseases such as schizophrenia and Parkinson’s disease [35]. Filaggrin-2 is a 
low abundance protein was associated with skin cancer [36]. Finally, semenogelin-1 was 
reported as a biomarker for prostate cancer [37].  
  Proteins, which have a reported concentration in the range of a few ng to less than 
1 g were considered as low abundance proteins. To cite a few of these low abundance 
proteins one can mention filaggrin-2 (4.6 ng/mL), desmolegein-2 and desmocolin-2 (2.7 
ng/mL), plectin-1 (2.8 ng/mL). The concentration for these typical low abundance 
58 30 152 Disease free serum 
(182) 







proteins can be found in the human plasma proteome reference set that has non redundant 
set of 1929 protein sequences [38].  
Identification of proteins captured by the MAL-II column. Using the same 
methodology as that reported above, proteins were eluted from the MAL-II column and 
then fractionated on the RPC column using a linear gradient elution at increasing ACN 
concentration from 0-75% mobile phase B in mobile phase A for 12 min, see Fig. 1-B for 
the resulting chromatograms. In this set of experiments, 138 and 163 proteins were 
identified in disease free and cancer sera, respectively, in the collected fractions by LC-
MS/MS analysis using protein identification probability of 99% with peptide 
identification probability of 95% containing at least two unique peptides. These identified 
proteins are listed in Table 2. In the collected fractions, the number of proteins unique to 
disease free and cancer sera were 15 and 40 proteins, respectively, while 123 proteins 
were common to both sera, see the Venn diagram in Fig. 3. Among these identified 
proteins, 50 proteins were reported to be of the low abundance types and 57 were 
sialoglycoproteins [13, 39-42]. Among the captured low abundance proteins, one can 
mention the following sialoglycoproteins: cartilage acidic protein 1, cartilage oligomeric 
protein, coagulation factor IX, coagulation factor X, coagulation factor XII B chain, 
complement C1r subcomponent like proteincyctatin A, fetuin B, phosphatidylinositol-
glycan-specific phospholipase D, pregnancy zone protein, and prolactin inducible protein 
[41, 43-45]. The sialylated low abundance protein such as pregnancy zone protein, 
prolactin inducible protein, cartilage oligomeric matrix protein and cystatin A were 
previously reported as breast cancer biomarkers [46-49]. Beta ala his dipepetidase and 





protein, tetranectin, and cartilage acidic protein were identified as cancer biomarkers 
[52].  According to the protein atlas by Farrah et al. [38], the concentrations of some 
typical low abundance proteins are mentioned here including caspase 14 (1.9 ng/mL), 
filaggrin (0.82 ng/mL) plexin domain containing protein 2 (1.6 ng/mL), serpin B3 (6.1 






Figure 3. Venn diagram for LC-MS/MS identified proteins captured by the MAL lectin. 
In the preceding chapter (i.e., Chapter IV), the RPC fractionation of captured 
proteins was performed using ODA/TRIM column without addition of nanoparticles. The 
preparation of the RPC column was described in chapter III and the column was 
designated as M3. In this chapter, a novel version of the M3 RPC column was used. It 
involved the addition of multi walled carbon nanotubes and the column was designated as 
M13. In both cases depleted disease free and breast cancer sera were analyzed. When 
compared to the RPC fractionation using the M3 column, the RPC on the M13 column 
facilitated the identification by LC-MS/MS of higher number of total proteins as well as 
sialoglycoproteins and low abundance proteins for both disease free and cancer sera. For 
instance, the SNA captured proteins when fractionated using the M3 column yielded for 
40 15 123 Disease free serum 
(138) 







disease free and breast cancer sera 180 and 182 identified proteins, respectively. Among 
these identified proteins, 125 of them were found to be glycoproteins including 83 
sialoglycoproteins as well as 43 low abundance proteins. Fractionation via M13 column 
of the SNA captured proteins from disease free and breast cancer sera permitted the 
identification of 183 and 210 proteins by LC-MS/MS analysis, respectively. In these 
identified proteins, 155 proteins were glycoproteins including 85 sialoglycoproteins as 
well as 83 low abundance proteins. From these data obtained from the SNA captured 
proteins that were subsequently fractionated on the M13 one can assess the higher 
number of total proteins and sialoglycoproteins than in the case of fractionation on the 
M3 column. Also, the number of low abundance proteins that was identified by LC-
MS/MS subsequent to RPC fractionation on the M13 column was almost the double of 
that identified by LC-MS/MS subsequent to the RPC fractionation on the M3 column.  
 The total number of proteins identified in the RPC fractions obtained on the M3 
column after capturing these proteins by MAL-II column from disease free and breast 
cancer sera were 153 and 157, respectively, while the total number of proteins identified 
in the RPC fractions obtained on the M13 column after capturing these proteins by the 
same lectin column (i.e., MAL-II column) from the same sera were 138 and 163 proteins, 
respectively. In the case of RPC fractionation via M3 column, a total of 94 glycoproteins 
were identified including 63 sialoglycoproteins as well as 37 low abundance proteins. 
These numbers changed to 82 glycoproteins with 57 sialoglycoproteins and 50 low 
abundance proteins when performing the fractionation on the M13 while keeping other 





In the case of RPC fractionation on M3 column, and using Uniprot software and 
NetNGly-predictor, which was used to predict the N-glycosylation sites of the protein 
one can find in the SNA captured proteins from disease free serum 75% of these proteins 
as glycoproteins and 25% as non-glycoproteins. For the SNA captured proteins from 
breast cancer serum, 81% of the identified proteins were found to be glycoproteins while 
19% were non-glycoproteins. For the MAL-II captured proteins from disease free serum 
74% of the identified proteins were found to be glycoproteins while 26 % were non-
glycoproteins.  
 On the other hand, in the case of RPC fractionation on the M13 column, and 
relying on the same software mentioned above, the percentage of glycoproteins found 
among the captured proteins by MAL-II column from the normal serum were lower than 
that found in the fractions obtained with the M3 column.  Oppositely, the percentage of 
glycoproteins in the factions obtained on the M13 column was higher for the cancer 
serum than that in the fractions of the M3 column. However, sialoglycoproteins were 
higher with the M3 column than the M13 column but a higher number of low abundance 
proteins were identified in the fractions of the M13 column.  
 
Differentially expressed proteins for the column order SNA  MAL-II  
The RPC chromatograms of the captured proteins by SNA and MAL-II columns 
from disease free and cancer sera are shown in Fig. 1 A and B, respectively. By simple 
visual inspection of the chromatograms one can readily identify differences in the peak 
intensity and shouldering in the chromatograms. The DEPs in the SNA and MAL-II 





into consideration only proteins with 99.9% protein identification probability, 95% 
peptide identification probability and minimum of five unique peptides.  The DEPs 
captured by the SNA column are shown in Table 3. These DEPs were identified using the 
quantitative Q-Q scatterplots which plot the normalized spectral count for each protein 
found in the breast cancer serum versus the normalized spectral count of that same 
protein found in disease free serum. The proteins that are two standard deviation away in 
cancer serum relative to the disease free serum are considered as DEPs. The scatterplot 
method for identifying DEPs was initially proposed by Selvaraju and El Rassi [17], and 
proved successful in identifying candidate biomarkers. 
Using the Q-Q scatterplots, 37 proteins were identified in the SNA captured 
fractions as DEPs in breast cancer serum relative to the disease free serum, see Table 3. 
Among the identified proteins, 26 were down regulated while 11 proteins were up 
regulated. Among the DEPs, alpha-1-antichymotrypsin, alpha-1-antitrypsin, ant 
thrombin-III, Apolipoprotein B-100, cadherin-5, carboxypeptidase N catalytic chain, 
carboxypeptidase N subunit 2, coagulation factor IX, coagulation factor XIII B chain, 
complement C3, desmoglein-1, plasma kallikrein heavy chain, plasminogen and 
serotransferrin have been previously reported as sialoglycoproteins. The DEP galectin-3-
binding protein is a low abundance protein.  It has been previously reported of having 
enhanced levels in breast cancer patients [53]. Cadherin 5 is up regulated in breast cancer 
serum relative to disease free serum. The overexpression of cadherin family proteins was 
found indicative of invasive breast carcinomas [54]. In a recent study using multi lectin 
affinity chromatography with agarose bound wheat germ agglutinin and jacalin lectin for 





breast cancer patients, pregnancy zone protein, apolipoprotein C-III, and alpha-1- 
antichymotrypsin were present in higher concentration in breast cancer serum relative to 
the disease free serum [47]. Another recent study reported alpha-1-antitrypsin as a novel 
biomarker for the breast cancer and down regulated in stage 1 and in later stages (stage II 
and III) of breast cancer it was shown to be up regulated [55]. In our work, it is observed 
that alpha-1-antitrypsin is up regulated in the SNA captured protein fractions.  
Similarly, using Q-Q scatterplots, 18 DEPs were identified in MAL-II captured 
fractions either up regulated or down regulated in the cancer serum relative to the disease 
free serum, see Table 4 for the DEPs.  Afamin, alpha-1-antitrypsin, antithrombin-III, 
apolipoprotein B-100, ceruloplasmin, clusterin, complement C5, serotransferrin, and 
inter-alpha-trypsin inhibitor heavy chain H2 have been previously reported as 
sialoglycoproteins. The DEPs Desmoplakin, carboxypeptidase N catalytic chain, and 
C4b-binding protein alpha chain are low abundance proteins. 
Recently identified breast cancer biomarker alpha-1-antitrypsin was down 
regulated in cancer serum relative to disease free serum. Afamin is a vitamin D binding 
protein and was found at elevated levels in breast cancer patients [56]  which agrees with 
our present findin
GS
 whereby afamin was also found significantly up-regulated in breast 
cancer serum. Clusterin, which is up-regulated in the current study, was reported up 
regulated in breast, lung and colon cancer patients [57, 58]. The up-regulated 
sialoglycoprotein serotransferrin has been reported as differentially expressed in cancer 
patients [59, 60]. The DEP desmoplakin was identified as a lung cancer biomarker [61]. 
The SNA column has captured 25 unique DEPs, MAL has captured 6 unique 





identified with both lectins and can be viewed as candidate biomarkers for breast cancer, 
see Table 5. Among the 43 DEPs, 11 were previously reported in the literature as breast 
cancer biomarkers. Therefore, this investigation has revealed 32 new potential 
biomarkers for breast cancer. 
Differentially expressed proteins captured from SNA column using the M3 and 
M13 column were 32 and 37, respectively.  Among the 32 DEPs captured by the SNA 
column and fractionated on the M3 column only three of them were low abundance 
proteins.  Among the 37 DEPs in the fractions of the M13 column, 9 low abundance 
proteins were found, see Table 3 for DEPs captured by SNA lectin and fractionated on 
the M13 column.  The DEPs captured by the MAL-II column and fractionated on the M 3 
and M 13 columns were 24 and 18, respectively, with 5 and 3 low abundance proteins for 
M3 and M13 column, respectively, see Table 3 for DEPs captured by MAL lectin and 
fractionated on the M13 column. It has been observed that the RPC fractionation of SNA 
captured proteins using M13 column yielded higher number of DEPs with higher number 
of low abundance proteins than those found in the fractions of the M3 column. By 
comparing the identified DEPs in the fractions of M3 column and M13 column it is 
observed that the M13 column exhibited a better performance.  
 
LC-MS/MS identification of proteins captured by the lectin columns arranged in the 
order of  MAL-II  SNA  
Identification of proteins captured by the MAL-II columns. The captured proteins 
by the MAL-II column were eluted stepwise with the haptenic sugar lactose and 





chromatograms obtained for MAL-II and SNA lectins are shown in Fig. 5. The identified 
proteins are those with protein identification probability of at least 99% with peptide 
identification probability of not less than 95% and containing at least two unique 
peptides. The identified proteins are listed in Table 6. The number of identified proteins 
from disease free and breast cancer sera are 180 and 191, respectively.  In the MAL-II 
captured fractions, the identified proteins that were unique to disease free and cancer sera 
were 29 and 40, respectively, see Fig. 6. Among the captured proteins, 119 proteins were 
identified as glycoproteins including 78 sialoglycoproteins and 97 low abundance 
proteins. 40 proteins were identified as non-glycoproteins. It is observed that previously 
identified low abundance proteins as well as new low abundance proteins were identified.  
In the tandem lectin affinity format SNA lectin was connected followed by MAL-II 
lectin. By changing the order of lectin columns it is expected to see changes in the 
number of captured proteins, glycoproteins, sialoglycoproteins, low abundance proteins 
and DEPs. The proteins captured by the lectin columns were subjected to LC/MS/MS 
analysis after fractionation on the RPC column. The identified proteins are listed in Table 
7. Using the same approach as in the above sections, 176 and 188 non-redundant proteins 
were found in the proteins captured by the SNA column from the disease free and breast 
cancer sera, respectively.  
In the SNA fractions, the identified proteins that were unique to the disease free 
serum and the breast cancer serum were 17 and 29 for the disease free and cancer sera, 
respectively. Among the captured proteins, 110 were glycoproteins including 84 
sialoglycoproteins and 66 were identified as low abundance proteins. Upon inverting the 





abundance proteins as compared to 83 low abundance proteins when the lectin columns 
order was SNA  MAL-II.  On the other hand, MAL-II lectin has captured 97 proteins 
when the order was MAL-II  SNA as compared to 50 captured proteins in the reverse 









































































































Figure 4. Chromatograms of the RPC fractionation of proteins captured by MAL-II column (A) 
and SNA column (B) from disease free (DFS) and breast cancer sera (CS). All other conditions as 










Figure 5. Venn diagram for LC-MS/MS identified proteins captured by MAL-II lectin 
arranged in the reversed order (i.e., MAL-II  SNA).  
Using the Uniprot database and NetNgly predictor, which predicts the N-
glycosylation sites in proteins, the majority of identified proteins were found to be 
glycoproteins and certain number were non-glycoproteins. For the disease free serum, 
and when MAL-II column was arranged as the first column, 66% of the identified 
proteins were glycoproteins while 34% were non-glycoproteins. For the breast cancer 
serum, 73% were identified as glycoproteins and 27% were identified as non-
glycoproteins. For the SNA lectin placed in the reversed order (MAL-II SNA), 58% of 
the captured proteins were identified as glycoproteins while 42% of the proteins were 
non-glycoproteins for the disease free serum.  With breast cancer serum, 64% of the 
40 29 151 Disease free serum 
(180) 







captured proteins by the SNA column were identified as glycoproteins while 36 % were 
non-glycoproteins. When considering the percentage of captured glycoproteins, it was 
noticed that the order SNA column  MAL-II column is better for capturing a higher 
amount of glycoproteins. Overall, comparing the total number of captured glycoproteins, 
sialoglycoproteins and low abundance proteins, it is observed that the lectin columns 
connected in the order SNA column  MAL-II column have captured higher number of 






Figure  6. Venn diagram for LC-MS/MS identified proteins captured by the SNA lectin 
with the reversed order (i.e., MAL-IISNA) 
 
Differentially expressed proteins for the column order MAL-II  SNA The RPC 
chromatograms of the captured proteins by MAL-II  SNA columns from disease free 
and cancer sera are shown in Fig. 5 A and B. The two overlapping chromatograms 
exhibit differences in peak intensity, retention times and peak shouldering. DEPs from 
cancer serum were found relative to the disease free serum with 99.9% protein 
identification probability, 95% peptide identification probability with a minimum of five 
unique peptides. The DEPs were identified using the Q-Q scatterplot by plotting the 
29 17 
 
159 Disease free serum 
(176) 







normalized spectral count of proteins in breast cancer serum relative to the disease free 
serum for the same fractions and same proteins. The DEPs were for proteins identified 
with p < 0.05 and that are more than two standard deviations away from being the same 
in both categories in the Q-Q scatterplots [17]. 
The MAL-II column, which was connected as the first lectin column has captured 
27 DEPs, see Table 8. The DEPs were either up or down regulated. Among these 
captured DEPs, 20 proteins were sialoglycoproteins and four low abundance proteins. 
The low abundance DEPs were coagulation factor IX, coagulation factor XIIB chain, 
fibronectin, and vitronectin. For the SNA column 26 DEPs were identified with 15 
sialoglycoproteins and seven low abundance DEPs, see Table 9. The captured low 
abundance proteins were annexin 1, fibronectin, hemoglobin subunit beta, junction 
plakoglobin, phosphatidylinisito-1-glycan-specific phospholiphase D, protein S100-A7, 
and vitamin D-binding protein.  
Table 10 summarizes the DEPs unique to MALII (17 DEPs), those unique to SNA 
(21 DEPs) and those common to both columns (12 DEPs).  Therefore, a panel of 50 
DEPs was identified as candidate biomarkers for breast cancer. 11 DEPs were previously 
identified as candidate breast cancer biomarkers. As a result, 39 novel potential candidate 
biomarkers were revealed in this investigation.  
To summarize, 22 common DEPs were identified for both lectin column orders, 
with 21 unique DEPs for the order SNA column  MAL column and 28 unique DEPs 
for the order MAL column  SNA column. Therefore, the order of columns seems to 
lead to a significant difference not only in the total numbers of captured DEPs but also in 





by considering both column orders. That is; a panel of 71 DEPs for both orders of 





 This chapter has shown the importance of the RPC fractionation step of the 
proteins captured by the two lectin columns prior to LC-MS/MS analysis.  The M13 RPC 
column with incorporated MWCNTs provided better fractionation than the M3 RPC 
column without incorporated nanotubes, since it has captured higher number of 
glycoproteins, sialoglycoproteins and low abundance proteins from the disease free and 
breast cancer sera. Regarding the order of the lectin columns, the investigation 
demonstrated that is beneficial to identify the DEPs for both column orders; that is SNA 







IDENTIFIED BY THE LC-MS/MS ANALYSIS OF THE SNA CAPTURED PROTEINS FRACTIONATED ON THE RPC 
COLUMN FROM DISEASE- FREE AND CANCER SERA USING M13.DATA ON GS WERE FROM REFS. [15, 19, 24-26, 
32, 34, 39, 40, 42, 46, 47, 51, 62-69] 
 
  Average spectral count for disease-free serum Average spectral for cancer serum 










Fr# 6 Fr #1 Fr #2 Fr 
#3 
Fr #4 Fr#5 Fr#6 
1 14-3-3 protein beta/alpha 
1 a
 0 0 0 0 0 0 0 0 2 0 0 0 
2 14-3-3 protein zeta/delta 
1a
 0 0 0 0 0 0 0 0 3 0 0 0 
3 Actin, cytoplasmic 1 * 0 0 0 0 5 0 0 0 12 0 2 5 
4 Afamin
GS
 0 0 4 16 0 0 0 0 0 4 3 0 




0 5 4 2 0 0 0 4 3 2 0 0 
6 Alpha-1-acid glycoprotein 2 
GS
 
0 5 5 6 0 2 0 5 6 5 3 0 
7 Alpha-1-antichymotrypsin
GS
 0 0 0 2 8 7 0 0 0 8 13 9 
8 Alpha-1-antitrypsin 
GS
 5 5 11 14 23 19 5 8 14 25 25 22 
9 Alpha-1B-glycoprotein 
GS
 0 11 8 5 2 2 2 11 10 6 2 2 
10 Alpha-2-HS-glycoprotein 
GS
 0 6 6 5 5 5 0 6 5 4 6 5 
11 Alpha-2-antiplasmin 
GS
 0 2 0 0 11 10 0 0 2 0 11 11 
12 Alpha-2-macroglobulin 
GS





0 0 0 0 0 0 0 0 3 0 0 0 
14 Angiotensinogen
GS
 0 0 0 0 9 5 0 0 0 2 11 8 
15 Apolipoprotein A-I 
GS
 5 11 17 23 29 31 2 11 11 24 28 28 





17 Apolipoprotein A-IV 6 14 20 19 30 26 11 15 17 21 25 27 
18 Apolipoprotein B-100 
GS
 0 7 0 2 8 56 0 11 3 3 45 42 
19 Apolipoprotein C-I  0 5 6 4 4 4 0 4 3 4 3 4 
20 Apolipoprotein C-II  0 3 5 5 3 4 0 3 5 5 2 3 
21 Apolipoprotein C-III G 2 5 5 5 3 4 2 3 6 4 2 3 
22 Apolipoprotein C-IV  0 1 0 0 0 0 0 0 0 0 0 0 
23 Apolipoprotein D 
GS
 0 6 7 7 7 5 0 6 5 7 6 5 
24 Apolipoprotein E G 3 5 9 8 19 22 2 3 5 11 15 20 
25 Apolipoprotein F  G 0 2 2 2 0 0 0 2 0 0 0 0 
26 Apolipoprotein M  
GS
 0 0 5 6 3 4 0 0 5 5 3 4 
27 Apolipoprotein(a) 
1a
 2 2 2 0 0 0 2 3 2 0 0 0 
28 Beta-2-glycoprotein 1 
GS
 8 9 6 9 3 5 9 9 7 5 3 3 
29 Beta-Ala-His dipeptidase  
1a
 0 0 0 0 0 10 0 0 0 0 2 8 
30 Bleomycin hydrolase  
1a
 0 0 0 0 0 0 3 0 0 0 0 0 
31 C4b-binding protein alpha 
chain G 
0 10 12 11 5 5 0 5 10 5 3 4 
32 CD5 antigen-like  0 0 0 4 6 4 0 0 0 2 3 4 
33 Cadherin-5  
GS1a
 0 8 4 4 0 0 0 6 2 0 0 0 
34 Calmodulin-like protein 3  0 0 0 0 0 0 0 0 2 0 0 0 
35 Calmodulin-like protein 5 
1a
 0 0 0 0 0 0 0 0 2 0 0 0 
36 Calpain-1 catalytic subunit  
1a
 
0 0 0 0 0 0 2 0 0 0 0 0 
37 Carboxypeptidase N 
catalytic chain  
GS1a
 
0 0 10 12 4 3 0 0 5 11 7 4 




0 0 0 0 0 13 0 0 0 0 10 8 
39 Caspase-14  0 0 0 0 0 0 6 0 0 0 0 0 











 0 6 28 34 24 26 0 10 28 33 22 20 
42 Cholinesterase  
1a
 0 0 0 0 2 0 0 0 0 0 0 0 
43 Coagulation factor IX 
GS1a
 0 3 12 11 2 0 0 6 8 6 0 0 
44 Coagulation factor V  G
1a
 0 5 2 2 0 0 0 5 0 0 0 0 
45 Coagulation factor X 
1a
 0 3 0 0 0 0 0 3 0 0 0 0 
46 Coagulation factor XII 
GS
 0 3 6 4 2 2 0 3 4 2 6 2 




20 32 12 14 4 2 21 31 14 7 2 4 




0 9 24 21 7 3 0 9 18 16 13 4 





0 2 2 2 0 0 0 0 0 0 0 0 




0 0 14 15 6 2 0 0 17 19 6 3 
51 Complement C2 G 0 0 0 0 0 2 0 0 0 0 0 0 
52 Complement C3 G 2 7 2 12 58 98 3 15 15 50 82 88 
53 Complement C4 beta chain 
G 
0 0 0 8 46 36 0 0 0 15 37 38 
54 Complement C4-B G 0 0 0 0 2 3 0 0 0 0 2 2 
55 Complement component C6 
G 
0 3 12 8 0 0 0 3 11 3 0 0 
56 Complement component C7 
G 
0 0 4 4 0 0 0 0 4 0 0 0 
57 Complement component C8 
alpha chain G 
0 0 0 2 0 0 0 0 0 0 0 0 
58 Complement component C8 
gamma chain G 
0 0 0 2 0 0 0 0 0 0 0 0 
59 Complement component C9 
G 





60 Complement factor B G 0 2 11 13 6 3 0 0 11 13 2 4 
61 Complement factor H  45 52 36 31 20 24 53 52 30 16 16 19 
62 Complement factor H-
related protein 1 
GS
 
4 3 0 0 0 0 2 4 0 0 0 0 
63 Complement factor H-
related protein 2 
GS
 
2 2 0 0 0 0 0 2 0 0 0 0 
64 Complement factor H-
related protein 3  
1aG
 
2 5 0 0 0 0 3 5 2 0 0 0 
65 Complement factor H-
related protein 4 
1aG
 
0 1 0 0 0 0 0 0 0 0 0 0 
66 Complement factor I G 0 5 22 17 9 4 0 10 17 14 5 6 
67 Corneodesmosin 
1a GS
 0 0 0 0 0 0 2 0 0 0 0 0 
68 Cornifin-A  0 0 0 0 0 0 0 0 2 0 0 0 
69 Cystatin-A 
1aGS
 0 0 0 0 0 0 2 0 0 0 0 0 
70 Desmoglein-1 
 1aGS
 0 0 0 0 0 0 11 0 0 0 0 0 
71 Desmoplakin  
1a
 5 0 0 0 0 0 23 0 8 0 3 3 
72 Elongation factor 1-alpha 1 
1a
 
0 0 0 0 0 0 0 0 2 0 0 0 
73 Extracellular 
serine/threonine protein 
kinase FAM20C  
0 0 2 0 0 0 0 0 0 0 0 0 
74 Fetuin-B  
GS1a
 0 4 8 7 0 0 0 4 7 7 0 0 
75 Ficolin-2 
1aGS
 0 2 4 4 0 0 0 0 0 0 0 0 
76 Filaggrin-2 
1a 
 0 2 0 2 0 0 9 0 0 0 0 2 
77 Galectin-3-binding protein  
GS1a
 
0 3 0 0 0 6 0 2 0 0 7 14 
78 Galectin-7  
1aGS
 0 0 0 0 0 0 0 0 3 0 0 0 
79 Gamma-
glutamylcyclotransferase  





80 Gasdermin-A  0 0 0 0 0 0 3 0 0 0 0 0 
81 Glutathione peroxidase 3 
1a





0 0 0 0 0 0 4 0 5 0 0 0 
83 Haptoglobin 
GS
 3 25 28 28 23 21 8 24 28 28 23 22 




0 0 0 0 0 0 0 0 2 0 0 0 
85 Heat shock protein beta-1 
 1a
 0 0 0 0 0 0 0 0 2 0 0 0 
86 Hemopexin 
GS
 0 13 18 12 5 4 0 12 14 11 5 4 
87 Heparin cofactor 2 
GS
 0 0 0 0 2 2 0 0 0 0 4 3 
88 Histidine-rich glycoprotein 
GS
 
0 19 12 13 7 8 0 20 15 10 5 6 
89 Histone H2A type 1-B/E  
1a
 0 0 0 0 0 0 0 0 2 0 0 0 
90 Histone H4 
1a
 0 0 0 0 0 0 0 0 4 0 0 0 
91 Hornerin 
1a
 3 0 0 2 0 0 0 0 2 0 0 2 
92 Ig alpha-1 chain C region G 0 1 10 11 10 9 0 0 8 11 12 9 
93 Ig alpha-2 chain C region G  0 0 2 2 0 0 0 0 0 2 0 1 
94 Ig gamma-1 chain C region  0 2 2 2 2 4 4 3 6 0 2 3 
95 Ig gamma-2 chain C region  0 0 0 0 0 0 0 0 3 0 0 0 
96 Ig heavy chain V-III region  0 0 0 0 2 2 0 0 0 2 2 2 
97 Ig heavy chain V-III region 
VH26  
0 0 0 2 0 2 0 0 0 2 2 0 
98 Ig kappa chain C region * 3 5 6 7 7 6 3 5 6 7 7 7 
99 Ig kappa chain V-I region 
EU * 
0 0 0 2 0 0 0 0 0 0 0 0 
100 Ig kappa chain V-II region 
TEW * 
0 0 0 2 0 0 0 0 0 0 0 0 
101 Ig kappa chain V-III region 
B6* 





102 Ig kappa chain V-III region 
WOL * 
2 2 2 3 3 2 2 2 0 2 2 3 
103 Ig kappa chain V-IV region 
Len * 
0 0 0 2 0 2 0 0 0 0 0 1 
104 Ig lambda chain V-I region 
HA * 
0 2 0 0 2 0 0 2 0 2 2 2 
105 Ig lambda chain V-III region 
LOI * 
0 0 0 2 0 0 0 0 0 2 0 1 
106 Ig lambda chain V-III region 
SH * 
0 0 0 2 0 0 0 0 0 2 2 0 
107 Ig lambda-2 chain C regions 
* 
0 2 2 2 2 2 0 2 0 2 2 2 
108 Ig mu chain C region 
GS
 0 0 7 13 13 13 0 0 4 13 13 14 
109 Immunoglobulin J chain 
GS
 0 0 3 3 3 3 0 0 0 3 3 3 
110 Immunoglobulin lambda-
like polypeptide 5 * 
2 3 4 4 4 5 2 2 3 5 5 4 
111 Insulin-like growth factor-
binding protein 3  
2 0 0 0 0 0 0 0 0 0 0 0 
112 Inter-alpha-trypsin inhibitor 
heavy chain H1 
GS
 
0 2 0 5 26 12 0 2 2 20 24 18 
113 Inter-alpha-trypsin inhibitor 
heavy chain H2 
GS
 
2 3 0 2 29 17 3 3 3 12 27 18 
114 Inter-alpha-trypsin inhibitor 
heavy chain H4 
1aGS
 
0 4 10 10 24 23 0 4 7 8 18 22 
115 Fibronectin 
GS
 3 4 2 10 47 40 4 4 3 7 36 43 
116  Desmocollin-1 
 1aGS
 0 0 0 0 0 0 4 0 0 0 0 1 
117 Disintegrin and 
metalloproteinase with 
thrombospondin motifs 13  










119 Annexin A2 
1a
 0 0 0 0 0 0 4 0 0 0 0 0 
120 Apolipoprotein L1 G 0 0 5 6 5 10 0 0 4 5 6 9 
121 Arginase-1 0 0 0 0 0 0 2 0 0 0 0 0 




0 2 0 0 0 0 0 0 0 0 0 0 
123 Attractin 
1a
 0 0 4 3 0 0 0 0 3 0 0 0 




0 2 0 0 0 0 0 2 0 0 0 0 
125  Cartilage acidic protein 1
1aG
 0 0 4 2 0 0 0 0 2 0 0 0 
126 Clusterin 
GS
 0 4 17 18 8 10 0 5 13 19 10 8 
127 Dermcidin 
1a
 2 2 0 0 0 0 2 2 0 0 0 0 
128 EGF-containing fibulin-like 
extracellular matrix protein 
1 G 
0 0 0 0 0 2 0 0 0 0 0 0 
129  Fibrinogen alpha chain 
GS
 5 3 4 2 0 2 5 3 3 0 0 0 
130  Ficolin-3 
GS
 0 0 2 3 4 4 0 0 0 3 3 4 
131 Haptoglobin-related protein 
1a*
 
0 0 5 5 4 4 0 0 5 5 3 4 
132 Histidine ammonia-lyase  0 0 0 0 0 0 2 0 0 0 0 0 
133 Histone H2B type 2-F  0 0 0 0 0 0 0 0 2 0 0 0 
134 Hyaluronan-binding protein 
2 * 
0 9 6 4 2 0 0 8 6 2 0 2 
135  Ig delta chain C region 
1a
G 0 0 0 0 0 0 0 0 2 0 0 0 
136 Insulin-like growth factor-
binding protein complex 
acid labile subunit 
GS
 
0 0 0 0 6 0 2 0 0 0 3 6 
137 Inter-alpha-trypsin inhibitor 
heavy chain H3 
GS
 
0 0 0 0 0 0 0 0 0 2 0 0 












0 0 0 2 0 0 0 0 0 3 0 0 
140 Semenogelin-1  
1a
 0 2 0 0 0 0 0 2 0 0 0 0 




0 8 9 8 4 3 0 2 0 0 0 0 
142 Calumenin 
GS
 0 3 0 0 0 0 0 0 0 0 0 0 









0 6 5 5 0 0 0 0 0 0 0 0 
145 Collectin-11 
1a
 0 0 0 2 0 0 0 0 0 0 0 0 
146 Coagulation factor VII  
1a
 0 0 0 3 0 0 0 0 0 3 0 0 
147 Fibulin-1 
GS
 0 0 4 4 0 0 0 0 3 3 0 0 




0 0 2 2 0 0 0 0 2 0 0 0 
149  Kininogen-1 
GS
 5 26 22 22 15 11 7 22 20 17 13 15 
150 Alpha-enolase 
1a
 0 0 0 0 0 0 0 0 3 0 0 0 
151 Junction plakoglobin 
1a
 0 0 0 0 0 0 4 0 0 2 0 0 
153 Kallistatin 
GS
 0 0 0 0 6 3 0 0 0 0 2 4 




17 12 3 10 9 10 24 11 25 15 6 14 




0 0 0 0 0 0 0 0 3 0 0 0 




8 7 0 0 2 0 15 5 11 10 0 7 




2 2 0 0 0 0 7 0 14 2 0 3 
158 Keratin, type II cytoskeletal 
1b * 









14 7 3 5 4 4 21 6 21 8 6 10 
160 Keratin, type II cytoskeletal 
6A* 
6 3 0 0 0 0 5 2 5 2 0 2 
161 Keratin, type II cytoskeletal 
6B * 
20 8 2 3 5 2 25 3 29 15 3 15 
162 Keratin, type II cytoskeletal 
78 * 
0 0 0 0 0 0 7 0 0 0 0 0 
163 Keratin, type II cytoskeletal 
80* 
0 0 0 0 0 0 9 0 0 0 0 0 
164 Keratinocyte proline-rich 
protein  










0 0 0 0 0 3 0 0 0 0 0 0 
167 Lumican 
GS
 0 0 7 3 0 0 0 0 4 3 0 0 
168 Mannan-binding lectin 
serine protease 2  
0 1 0 0 0 0 0 0 0 0 0 0 




0 0 0 0 0 0 0 0 0 3 0 0 
170 Myosin-9 
1a





0 0 2 2 0 0 0 0 0 0 0 0 
172 Neutrophil defensin 1  0 0 0 0 0 0 0 0 0 0 0 1 





0 0 0 4 3 3 0 0 0 4 2 3 
175 Phosphatidylinositol-
glycan-specific 





phospholipase D  
GS1a
 
176 Phosphoglycerate mutase 2  
1a
 
0 0 0 0 0 0 0 0 3 0 0 0 




0 0 0 0 0 3 0 0 0 0 3 2 
178 Plasma kallikrein heavy 
chain  
0 0 7 7 5 4 0 0 3 0 4 5 
179 Plasma protease C1 
inhibitor  
0 0 0 0 11 9 0 0 0 0 9 8 




0 0 0 0 0 6 0 0 0 0 0 3 
182 Plasminogen  0 35 8 8 2 2 0 30 21 2 2 2 
183 Plectin 
1a
  0 0 0 0 0 0 2 0 0 0 0 0 




0 0 0 2 0 0 0 0 0 0 0 0 
185 Pregnancy zone protein 
GS1a





0 0 2 3 0 0 0 0 0 0 0 0 
187 Prenylcysteine oxidase 1 G
1a
 0 0 0 0 0 4 0 0 0 0 0 2 
188 Protein AMBP 
GS
 0 5 7 9 11 5 0 5 7 12 9 8 
189 Protein S100-A11 
1a
 0 0 0 0 0 0 0 0 2 0 0 0 
190 Protein S100-A7 
1a
 0 0 0 0 0 0 0 0 3 0 3 0 
191 Protein S100-A8  0 0 0 0 0 0 0 0 2 0 0 0 
192 Protein S100-A9  0 0 2 3 0 0 0 0 5 2 2 2 




0 0 0 0 2 3 0 0 0 3 3 2 
194 Protein-glutamine gamma-
glutamyltransferase E  
1a
 
0 0 0 0 0 0 7 0 0 0 0 0 
195 Protein-glutamine gamma-
glutamyltransferase K  





196 Prothrombin  2 6 20 21 6 6 2 6 11 19 4 5 
197 Alpha-S1-casein 0 2 0 4 0 0 2 0 2 0 0 0 
198 Alpha-S2-casein 0 0 0 2 0 0 0 0 0 0 0 0 
199 Alpha-lactalbumin 0 4 0 0 0 0 0 4 0 0 0 0 
200 Antithrombin-III 
GS
 0 4 16 18 7 5 2 7 9 22 12 6 
201 Beta-2-microglobulin 
GS
 2 2 0 0 0 0 0 2 0 0 0 0 
202 Beta-casein 0 0 0 2 0 0 0 0 0 0 0 0 
203 Catalase 
1a
 0 0 0 0 0 0 3 0 0 0 0 0 
204 Cathepsin D 
GS
 0 0 0 0 0 0 2 0 0 0 0 0 
205 Cationic trypsin 3 0 0 0 0 0 2 0 0 0 0 0 
206 Complement C5  0 0 0 0 2 14 0 0 0 0 27 16 
207 Gelsolin 
1a
 0 0 0 3 0 0 0 0 0 0 0 0 
208 Glutathione S-transferase P  
1a
 
0 0 0 0 0 0 0 0 2 0 0 0 
209 Hemoglobin subunit alpha 
G 
0 0 7 8 4 4 0 0 3 2 0 3 
210 Hemoglobin subunit beta G 0 2 9 10 7 6 0 0 3 3 0 6 




19 22 20 24 23 19 25 20 20 24 26 24 
212 Keratin, type I cytoskeletal 
9* 
17 14 13 19 14 16 23 15 15 18 14 20 
213 Keratin, type II cytoskeletal 
1* 
27 26 22 29 23 26 36 25 24 29 27 28 
214 Keratin, type II cytoskeletal 
2 epidermal * 
26 25 19 26 19 23 44 26 24 26 26 34 




0 0 0 0 0 0 0 0 2 0 0 0 
216 Retinol-binding protein 4 0 4 5 3 4 2 0 4 4 4 3 4 
217 Serotransferrin 
GS





218 Serum albumin 10 33 55 52 42 40 17 45 57 50 41 39 
219 Thioredoxin 
1a
 0 0 0 0 0 0 3 0 0 0 0 0 
220 Trypsin 
1a
 4 4 4 4 2 3 4 4 4 3 3 3 
221 Ubiquitin * 0 0 0 0 0 0 2 0 0 0 0 0 
222 Secreted phosphoprotein 24 
1a
 
0 3 0 0 0 0 0 2 0 0 0 0 
223 Selenoprotein P G 5 7 5 5 0 4 3 7 2 0 0 0 
224 Serpin B12 0 0 0 0 0 0 3 0 0 0 0 0 
225 Serum amyloid A-1 protein 
GS
 
0 0 3 2 0 0 0 0 0 0 0 0 
226 Serum amyloid A-4 protein 
GS
 
0 2 5 5 3 3 0 0 4 6 4 4 









0 0 3 5 9 8 0 0 0 5 9 8 
229 Serum 
paraoxonase/lactonase 3  
1aGS
 
0 0 0 2 3 3 0 0 0 0 2 3 




0 0 2 2 0 0 0 0 2 0 0 0 
231 Small proline-rich protein 
2E G 
0 0 0 0 0 0 0 0 0 0 2 0 
232 Suprabasin  
1a
 0 0 0 0 0 0 2 0 0 0 0 0 
233 Tetranectin  0 7 4 2 0 0 0 7 5 2 0 0 
234 Transthyretin   0 8 9 8 4 3 5 8 9 8 6 6 
235 Tubulin alpha-1B chain  0 0 0 0 0 0 0 0 5 0 0 0 
236 Tubulin beta-4A chain  
1a





G, glycoprotein; GS, sialylated glycoprotein; 1a, low abundance protein (few ng to sub g/mL level); *, non-glycoprotein. 
237 Vitamin D-binding protein 
GS
 
0 0 0 0 0 0 0 0 15 7 0 0 
238 Vitamin K-dependent 
protein C  
1a
 
0 7 4 2 0 0 0 0 7 6 0 0 
239 Vitamin K-dependent 
protein S  
0 0 0 0 0 0 0 0 0 10 6 4 
240 Vitronectin 
GS










TABLE 2  
PROTEINS IDENTIFIED BY THE LC-MS/MS ANALYSIS OF THE SNA CAPTURED PROTEINS FRACTIONATED ON 
THE RPC COLUMN FROM DISEASE- FREE AND CANCER SERA USING M13 COLUMN. DATA ON GS WERE FROM 
REFS.[15, 24, 34, 39, 40, 42, 56, 62, 63, 67, 69-72] 
 
 Average spectral count for disease-free 
serum 
Average spectral count for cancer serum 
# 
























1 Actin, aortic smooth muscle * 0 0 0 0 0 0 0 0 0 2 0 0 
2 Afamin 
GS
 0 3 12 4 0 0 0 6 19 18 0 0 
3 Alpha-1-acid glycoprotein 1 
GS
 0 3 0 0 0 0 4 0 0 0 0 0 
4 Alpha-1-acid glycoprotein 2 
GS
 0 3 2 3 3 2 5 6 3 2 2 0 
5 Alpha-1-antichymotrypsin
GS
 5 2 13 12 10 10 0 2 12 11 8 5 
6 Alpha-1-antitrypsin 
GS
 17 14 28 29 28 22 6 19 28 27 20 15 
7 Alpha-1B-glycoprotein 
GS
 0 8 0 2 0 0 6 5 0 0 0 0 
8 Alpha-2-antiplasmin 
GS
 0 0 2 6 5 2 2 0 2 7 7 2 
9 Alpha-2-HS-glycoprotein 
GS
 3 7 6 6 7 7 5 7 6 6 5 4 
10 Alpha-2-macroglobulin 
GS
 28 0 0 21 48 59 0 0 3 39 51 58 
11 Alpha-S1-casein 0 0 0 0 0 2 0 0 0 0 0 2 
12 Angiotensinogen  0 0 2 6 8 6 0 0 2 6 4 2 
13 Antithrombin-III 
GS
 6 4 10 7 7 5 0 12 7 5 0 0 
14 Apolipoprotein A-I 
GS
 19 29 33 35 35 33 14 31 33 36 33 31 





16 Apolipoprotein A-IV * 12 17 24 29 28 24 12 22 25 26 24 17 
17 Apolipoprotein B-100 
GS
 26 0 2 4 38 60 0 0 0 10 26 34 
18 Apolipoprotein C-I * 2 4 2 3 2 3 4 5 4 4 5 4 
19 Apolipoprotein C-II * 2 2 2 0 0 2 2 5 2 2 2 3 
20 Apolipoprotein C-III 
G
 0 5 2 0 2 3 3 4 3 3 3 3 
21 Apolipoprotein D 
GS
 4 8 8 8 6 8 3 8 9 7 7 5 
22 Apolipoprotein E 
G
 6 8 11 15 14 15 4 13 18 20 17 11 
23 Apolipoprotein F 
G
 2 0 0 0 0 0 0 0 0 0 0 0 
24 Apolipoprotein L1 
G
 4 3 4 5 7 7 4 4 4 7 10 4 
25  Apolipoprotein M 
GS
 2 5 3 3 3 3 2 6 4 3 3 0 
26 Apolipoprotein(a) 
1a
 2 0 0 0 0 0 0 0 0 0 0 0 
27  Arginase-1 0 0 0 0 0 0 0 0 0 0 2 0 
28 Beta-2-glycoprotein 1 
GS
 6 5 3 2 2 2 6 7 7 3 3 2 
29 Beta-Ala-His dipeptidase  
1a
 0 0 0 0 6 8 0 0 0 3 12 0 
30 




0 15 6 4 5 5 6 12 6 5 3 3 
31 




0 2 0 2 0 0 0 0 0 0 0 0 
32 




2 0 5 6 3 0 0 8 5 2 0 0 
33 
Carboxypeptidase N subunit 2 
GS
 
5 0 0 0 4 12 0 0 0 0 5 8 
34 Cartilage acidic protein 1 
1aG
 0 0 0 0 0 0 0 2 0 0 0 0 
35 




0 0 0 2 2 2 0 0 2 0 0 0 
36 Caspase-14  
1a*
 0 0 0 0 0 0 0 3 0 0 4 3 
37 Cationic trypsin 3 2 2 3 0 0 0 0 0 0 0 4 







 4 12 17 21 17 12 4 29 24 22 11 7 
40 Clusterin 
GS
 6 9 13 9 8 7 5 16 9 6 4 3 
41 Coagulation factor IX 
1a GS
 0 0 0 0 0 0 0 3 0 0 0 0 
42 Coagulation factor X 
1a GS
 0 0 0 0 0 0 2 0 0 0 0 0 
43 Coagulation factor XII 
GS
 0 2 0 3 3 0 0 8 2 3 0 0 
44 




3 4 0 0 0 0 2 0 0 0 0 0 
45 
Complement C1r subcomponent 
GS
 
0 5 2 3 3 0 0 17 6 3 0 0 
46 
Complement C1r 
subcomponent-like protein  
1a GS
 
0 0 0 0 0 0 0 0 2 0 0 0 
47 Complement C1s subcomponent  2 6 4 6 5 2 0 11 6 5 0 2 
48 Complement C3 
GS
  26 24 41 81 93 96 3 16 51 96 120 88 
49 Complement C4 beta chain 
G
 3 2 31 40 42 38 0 6 42 45 34 24 
50 Complement C4-B 
GS
 0 0 0 0 0 0 0 0 2 2 2 0 
51 Complement C5 4 0 0 4 11 21 0 0 0 5 16 10 
52 Complement component C6 
G
 0 4 0 0 0 0 0 8 0 0 0 0 
53 Complement component C7 
G
 0 4 0 0 0 0 0 7 0 0 0 0 
54 




0 0 0 0 2 0 0 3 0 0 0 0 
55 




0 0 0 0 0 0 0 3 0 0 0 0 
56 Complement component C9 
G
 0 0 3 2 2 0 0 2 4 0 0 0 
57 Complement factor B 
G
 2 2 7 5 0 0 0 9 6 5 0 0 
58 Complement factor H 
GS
 60 54 18 23 21 25 47 44 32 25 21 8 
59 




3 2 0 0 0 0 2 0 0 0 0 0 
60 Complement factor I 
 G
 4 19 10 9 10 8 6 22 13 11 7 2 
61 Cystatin-A 
1a GS







 0 2 0 0 0 2 0 2 0 0 0 3 
63  Desmocollin-1 
1a
 0 0 0 0 0 0 2 0 0 0 4 2 
64 Desmoglein-1 
1a G
 2 0 0 0 0 0 0 0 0 0 5 3 
65 Desmoplakin 
1a *
 5 2 2 0 0 2 4 2 0 2 3 20 
66 Extracellular matrix protein 1  0 0 0 0 0 0 2 0 0 0 0 0 
67 Fetuin-B 
1a GS
 2 8 3 3 2 2 3 8 3 4 2 0 
68  Fibrinogen alpha chain 3 0 0 0 0 0 2 0 0 0 0 0 
69 Fibronectin  4 0 8 16 21 25 0 0 14 24 25 12 
70 Fibulin-1 
GS
 0 0 0 4 0 0 0 2 3 0 0 2 
71 Ficolin-3  2 0 0 2 3 3 0 2 3 3 2 3 
72 Filaggrin-2 
1a
 3 2 0 2 0 2 3 2 0 2 9 5 
73 Galectin-3-binding protein 
1a GS
 0 0 0 0 0 5 0 0 0 0 2 3 






0 0 0 0 0 0 0 0 0 0 4 2 
76 Haptoglobin  
GS
 20 24 20 19 21 20 22 25 19 21 18 16 
77  Haptoglobin-related protein  
1a
 0 3 4 4 4 5 0 5 4 5 4 2 
78 Hemoglobin subunit alpha 0 0 0 0 0 0 0 4 2 2 0 0 
79 Hemoglobin subunit beta 0 0 0 0 0 0 0 4 7 5 3 3 
80 Hemopexin  
GS
 4 9 3 5 4 3 3 10 6 4 3 0 
81 Heparin cofactor 2  
GS
 0 0 3 3 2 0 0 0 3 4 0 0 
82 Histidine-rich glycoprotein  
GS
 2 9 3 5 4 5 5 9 8 5 3 2 
83 Hornerin *
1a
 2 3 2 0 0 2 2 6 0 0 2 6 
84 Hyaluronan-binding protein 2  0 5 0 0 0 0 4 6 2 0 0 0 
85 Ig alpha-1 chain C region 
G
 8 7 9 10 12 11 2 11 13 14 10 9 
86 Ig gamma-1 chain C region 
G
 2 4 7 6 7 7 0 4 6 6 7 7 
87 Ig gamma-2 chain C region 
G
 0 0 0 0 0 0 0 0 0 2 0 0 
88 Ig gamma-3 chain C region
 G






Ig heavy chain V-II region 
ARH-77 * 
0 0 0 0 0 2 0 0 0 2 0 0 
90 
Ig heavy chain V-III region 
BRO * 
0 0 0 2 2 2 0 0 0 2 2 0 
91 
Ig heavy chain V-III region 
GAL * 
0 0 0 0 0 0 0 0 0 2 0 0 
92 
Ig heavy chain V-III region TIL 
* 
0 0 0 0 0 0 0 0 2 2 0 0 
93 Ig kappa chain C region * 4 5 6 8 7 7 3 8 8 8 7 7 
94 Ig kappa chain V-I region EU * 0 0 0 0 0 0 0 0 0 2 0 0 
95 
Ig kappa chain V-II region 
RPMI 6410 * 
0 0 0 0 0 0 0 0 0 2 0 0 
96 




2 0 2 2 2 2 0 2 2 3 2 2 
97 
Ig kappa chain V-IV region Len 
* 
0 0 0 0 0 2 0 0 0 0 0 0 
98 Ig lambda chain V region 4A 
1a*
 0 0 0 0 0 0 0 0 0 2 2 0 
99 Ig lambda-2 chain C regions * 4 3 6 5 6 5 2 5 5 5 5 5 
100 Ig mu chain C region 6 4 9 11 11 13 0 8 12 11 12 11 
101 Immunoglobulin J chain  0 0 3 4 4 4 0 2 4 4 3 2 
102 
Immunoglobulin lambda-like 
polypeptide 5 * 
0 0 2 0 0 2 0 0 0 0 0 0 
103 
Insulin-like growth factor-
binding protein complex acid 
labile subunit  
2 0 0 0 0 0 0 0 0 0 0 0 
104 
Inter-alpha-trypsin inhibitor 
heavy chain H1 
GS
 
4 4 10 18 19 9 0 2 13 20 11 5 
105 
Inter-alpha-trypsin inhibitor 
heavy chain H2 
GS
 
5 2 15 24 26 17 0 3 19 32 14 9 





heavy chain H3  
107 
Inter-alpha-trypsin inhibitor 
heavy chain H4 
GS
 
8 5 14 15 14 16 4 10 18 18 14 14 
108 Junction plakoglobin 0 0 0 0 0 0 0 0 0 0 0 2 
109 Junction plakoglobin 
1a
 0 0 0 0 0 0 0 0 0 0 0 5 
110 Kallistatin 
GS
 0 0 5 5 5 0 0 0 3 10 3 0 
111 
Keratin, type I cytoskeletal 10 
1a*
 
22 25 22 21 23 22 23 20 19 25 27 27 
112 
Keratin, type I cytoskeletal 13 
1a*
 
0 0 0 0 2 8 0 0 0 0 0 0 
113 
Keratin, type I cytoskeletal 14 
1a*
 
6 10 8 4 3 6 6 5 7 7 7 9 
114 
Keratin, type I cytoskeletal 16  
1a*
 
16 26 16 5 7 17 18 13 11 12 11 22 
115 
Keratin, type I cytoskeletal 17  
1a*
 
4 6 2 0 0 2 3 3 0 3 0 4 
116 Keratin, type I cytoskeletal 9* 19 25 25 21 18 22 19 23 22 22 17 28 
117 Keratin, type II cytoskeletal 1 31 33 35 29 27 28 32 27 24 30 31 36 
118 Keratin, type II cytoskeletal 1b* 3 0 0 0 0 0 2 0 0 3 3 0 
119 
Keratin, type II cytoskeletal 2 
epidermal 
27 29 28 27 35 25 33 22 21 32 42 41 
120 Keratin, type II cytoskeletal 4  0 2 0 0 0 3 0 0 0 0 0 0 
121 
Keratin, type II cytoskeletal 5 
1a*
 
15 13 14 7 9 16 13 5 6 9 16 19 
122 
Keratin, type II cytoskeletal 
6A* 
2 2 0 0 0 0 0 0 0 0 0 2 
123 
Keratin, type II cytoskeletal 6B 
* 
0 2 0 0 0 0 0 0 0 0 0 0 






Keratin, type II cytoskeletal 78 
* 
0 0 0 0 0 0 0 0 0 0 0 2 
126 
Keratin, type II cytoskeletal 80 
* 




2 0 0 2 2 0 0 0 0 3 6 5 
128  LMW of Kininogen-1
 GS
 8 23 16 15 15 13 22 26 19 20 11 10 
129 Lumican 
GS
 0 2 0 0 0 0 0 7 0 0 0 0 
130 Lysozyme C 
1a 
0 0 0 0 0 0 0 0 0 0 0 2 
131 




0 0 0 0 0 0 0 0 3 0 0 0 
132 Ovalbumin 0 0 0 2 2 0 0 0 2 0 0 0 
133 Pepsin A 0 0 0 0 2 0 0 0 0 0 0 0 
134 Peroxiredoxin-2  
1a*






0 0 0 0 0 0 0 0 3 0 0 0 
136 
Phosphatidylinositol-glycan-
specific phospholipase D 
1a GS
 
0 0 0 0 3 7 0 0 0 5 8 4 
137 
Plasma kallikrein heavy chain  
GS
 
0 0 0 3 0 0 0 0 3 3 0 0 
138 Plasma protease C1 inhibitor  
GS
 0 0 8 9 11 11 0 2 10 9 5 5 
139 
Plasma serine protease inhibitor 
1a
 
0 0 0 0 4 2 0 0 0 0 5 0 
140 Plasminogen 
GS






0 0 0 0 0 0 0 4 2 0 0 0 
142 Pregnancy zone protein  
1a GS











144 Prenylcysteine oxidase 1  
1a G
 0 0 0 0 0 3 0 0 0 0 0 0 
145 Prolactin-inducible protein 
1a GS
 0 0 0 0 0 6 0 0 0 0 0 0 
146 Protein AMBP 
GS
 2 5 5 8 9 3 2 7 9 7 4 2 
147 Protein S100-A7 
1a
 0 0 0 0 0 2 0 0 0 0 0 2 
148 Protein S100-A8  
1a
 0 0 0 0 0 0 0 0 0 0 0 2 






0 0 0 0 0 0 0 0 0 0 3 0 
151 Prothrombin 0 3 2 3 2 0 2 4 3 2 0 0 






0 0 0 0 0 0 0 2 0 0 0 0 
154 Selenoprotein P 
1a
 2 3 0 0 0 0 3 3 0 0 0 0 
155 Serotransferrin 
GS
 5 30 14 12 8 7 27 27 49 13 7 24 
156 Serpin B3
 1a
 2 0 0 0 0 0 0 0 0 0 0 0 
158 Serum albumin 36 64 52 49 43 43 47 62 51 42 41 32 
159 Serum amyloid A-1 protein  
GS
 0 2 0 0 0 0 2 2 0 0 0 0 
160 Serum amyloid A-4 protein  
GS
 3 6 4 2 4 4 3 5 4 4 3 4 
161 Serum amyloid P-component  
GS






3 2 4 6 6 7 0 3 7 6 6 6 
163 
Serum paraoxonase/lactonase 3  
1a
 
0 0 0 3 2 2 0 0 3 3 0 0 
164 
 Short of Complement factor H-
related protein 2 
2 0 0 0 0 0 0 2 0 0 0 0 
165 Skin-specific protein 32  0 0 0 0 0 0 0 0 0 0 4 0 
166  Sulfhydryl oxidase 1 
1a
 0 0 0 3 0 0 0 0 7 0 0 0 
167 Suprabasin  
1a





G, glycoprotein; GS, sialylated glycoprotein; 1a, low abundance protein (few ng to sub g/mL level); *, non-glycoprotein.
168 Tetranectin  
GS
 0 7 2 2 2 3 4 2 2 2 0 0 
169 Transthyretin  * 0 6 3 4 3 4 3 9 7 5 2 0 
170 Trypsin 
1a
 5 4 3 3 3 3 4 3 3 3 4 4 
171 




0 0 0 0 0 0 0 0 0 2 0 0 
172  Vitamin D-binding protein 
GS
14 0 5 0 0 0 0 2 12 0 0 0 0 
173 
Vitamin K-dependent protein C  
1a
 
0 3 0 0 0 0 0 7 0 0 0 0 
174 Vitamin K-dependent protein S  0 2 3 8 2 0 0 3 11 3 2 0 
175 Vitronectin  
GS
 2 8 3 4 5 5 6 7 6 7 5 5 
176 Zinc-alpha-2-glycoprotein 
GS






DIFFERENTIALLY EXPRESSED PROTEINS IN THE SNA FRACTIONS FROM 
DISEASE FREE SERUM (DFS) AND CANCER SERUM (CS). DATA ON GS WERE 






































cytoplasmic 1  ACTB_HUMAN 42 kDa 




 AACT_HUMAN  48 kDa 






T_HUMAN 47 kDa 
Up 14 25 
F5-up Alpha-2-
macroglobulin  A2MG_HUMAN 163 kDa 
Down 28 55 
F2-Down Alpha-
lactalbumin LALBA_BOVIN 16 kDa 






N  40 kDa 
Down 5 0 
F2-Down Antithrombin-III 
GS
 ANT3_HUMAN  53 kDa 




 APOB_HUMAN 516 kDa 
Down 56 42 





N 13 kDa 
Up 5 10 






N 67 kDa 






N 88 kDa 
Up 4 9 






N catalytic chain 
GS
 CBPN_HUMAN 52 kDa 
 5 10 
F1-Down Carboxypeptidase 
N subunit 2 
GS
 CPN2_HUMAN 61 kDa 




 FA9_HUMAN 52 kDa 
Down 6 3 
F4-Up Coagulation 
factor XIII B 
chain 
GS1a
 F13B_HUMAN 76 kDa 





  CO3_HUMAN 187 kDa 
Down 30 9 
F5, F6-
Down Complement C5 
G
 CO5 _HUMAN  188 kDa 
Down 43 2 
F2,F4-Down Complement 
component C6  CO6_HUMAN 105 kDa 
Down 14 11 
F2-Down Complement 
factor I  CFAI_HUMAN  66 kDa 
Down 10 5 
F1- Down Desmoglein-1 
GS1a
 DSG1_HUMAN 114 kDa 




 DESP_HUMAN 332 kDa 
 Down 31 5 
F1- Down Filaggrin-2 
1a




 LG3BP_HUMAN 65 kDa 
Up 6 14 
F3-Up Hemoglobin 
subunit alpha  HBA_HUMAN  15 kDa 
Up 3 7 
F3-Up Hemoglobin 
subunit beta HBB_HUMAN  16 kDa 
Up 3 9 
F1- Down Ig gamma-1 chain 
C region  IGHG1_HUMAN 36 kDa 
 4 0 
F4-Down Inter-alpha-
trypsin inhibitor 
heavy chain H1  ITIH1_HUMAN 101 kDa 
Down 20 5 
F1,- Down Inter-alpha-
trypsin inhibitor 
heavy chain H2  ITIH2_HUMAN  106 kDa 
Down 17 3 
F1- Down Junction 
plakoglobin 
1a
 PLAK_HUMAN 82 kDa 
Down 6 0 





AN 77 kDa 




 PLMN_HUMAN 91 kDa 
Up 37 10 





G, glycoprotein; GS, sialylated glycoprotein; 1a, low abundance protein (few ng to sub 








 PSG1_HUMAN 48 kDa 
Up 0 6 
F3-Up Serotransferrin 
GS
 TRFE_HUMAN  77 kDa Up 31 46 
F2-Down Serum albumin ALBU_HUMAN  69 kDa Down 45 33 







DIFFERENTIALLY EXPRESSED PROTEINS IN THE MAL FRACTIONS FROM 
DISEASE-FREE SERUM (DFS) AND CANCER SERUM (CS) M13 COLUMN. DATA 








n or up) 


































T_HUMAN 47 kDa 
Down 46 57 
F3-Up Alpha-2-
macroglobulin  A2MG_HUMAN 163 kDa 
Up 0 3 
F1-Down Antithrombin-III 
GS
 ANT3_HUMAN  53 kDa 




 APOB_HUMAN 516 kDa 




N 9 kDa 
Up 2 5 






N 67 kDa 
Up 6 2 
F1-Up Carboxypeptidase 
N catalytic chain 
1a 
 CBPN_HUMAN 52 kDa 
Up 2 8 
F1-Up Ceruloplasmin 
GS 
 CERU_HUMAN 122 kDa Up 4 12 
F2-Up Clusterin 
GS
 CLUS_HUMAN  58 kDa Up 9 16 
F2-Up Complement C1r 
subcomponent  C1R_HUMAN 80 kDa 





 CO5 _HUMAN  188 kDa 





G, glycoprotein; GS, sialylated glycoprotein; 1a, low abundance protein (few ng to sub 
g/mL level); *, non-glycoprotein.
F5-Down Complement 
factor I  CFAI_HUMAN  66 kDa 
Down 8 2 
F6-Up Desmoplakin 
1a
 DESP_HUMAN 332 kDa Up 2 20 
F3-Up Hemoglobin 
subunit beta  HBB_HUMAN  16 kDa 
Up 0 7 
F5-Down Inter-alpha-trypsin 
inhibitor heavy 
chain H1  ITIH1_HUMAN 101 kDa 







 ITIH2_HUMAN  106 kDa 
Down 43 25 
F2-Up Serotransferrin 
GS







 DEPS UNIQUE TO SNA LECTIN AND MAL LECTIN AND COMMON TO BOTH 
LECTINS.  
DATA ON GS WERE FROM REFS. [15, 32, 39, 56, 62, 63, 70, 73, 74] 
DEPs unique to SNA 
lectin 
DEPs common to both 
lectins 
DEPs unique to MAL 
lectin 

























C4b-binding protein alpha 
chain  G  Clusterin 
GS
 







 Complement factor I   












heavy chain H1   




heavy chain H2 
GS
  








    
Complement C5 G   
Complement component 
C6    
Desmoglein-1 
GS1a





G, glycoprotein; GS, sialylated glycoprotein; 1a, low abundance protein (few ng to sub 
g/mL level); *, non-glycoprotein.
Filaggrin-2 
1a
   
Galectin-3-binding protein 
1a
   
Hemoglobin subunit alpha    
Ig gamma-1 chain C 
region    
Junction plakoglobin 
1a
   
Plasma kallikrein heavy 
chain 
GS
   
Plasminogen 
GS
   
Pregnancy zone  protein 
GS1a
   
Pregnancy-specific beta-1-
glycoprotein 1 G   
Serotransferrin 
GS
   
Serum albumin   






PROTEINS IDENTIFIED BY THE LC/MS ANALYSIS OF THE MAL-II CAPTURED PROTEINS FRACTIONATED ON THE 
RPC COLUMN FROM DISEASE- FREE AND CANCER SERA USING M13 COLUMN. DATA ON GS WERE FROM REFS. 
[14, 15, 24, 26, 32, 39, 40, 42, 56, 62-64, 69, 70, 73] 
  Average Spectral count for disease-free 
serum 
Average Spectral count for cancer serum 












1 14-3-3 protein beta/alpha  
1a
 0 0 2 0 0 0 0 0 0 0 0 0 
2 14-3-3 protein zeta/delta 
1a
 0 0 3 0 0 0 0 0 0 0 0 0 
3 A disintegrin and metalloproteinase 




0 0 0 0 0 0 0 0 2 3 0 0 
4 Actin, cytoplasmic 1 * 0 0 12 0 2 0 0 0 0 0 5 0 
5 Afamin  
GS
 0 0 0 18 3 0 0 0 4 16 0 0 
6 Alpha-1-acid glycoprotein 1 
GS
 0 4 3 2 0 0 0 5 4 2 0 0 
7 Alpha-1-acid glycoprotein 2 
GS
 0 5 6 5 3 0 0 6 5 6 0 2 
8 Alpha-1-antichymotrypsin 
GS
 0 0 0 8 13 9 0 0 0 2 8 7 
9 Alpha-1-antitrypsin 
GS
 5 8 14 25 25 22 5 5 11 14 23 19 
10 Alpha-1B-glycoprotein 
GS
 2 11 10 6 2 2 0 11 8 5 2 2 
11 Alpha-2-antiplasmin 
GS
 0 0 2 0 11 11 0 3 0 0 11 10 
12 Alpha-2-HS-glycoprotein 
GS
 0 6 5 4 6 5 0 6 6 5 5 5 
13 Alpha-2-macroglobulin 
GS









0 0 3 0 0 0 0 0 0 0 0 0 
15 Alpha-actinin-1 
1a
 0 0 3 0 0 0 0 0 0 0 0 0 
16 Alpha-lactalbumin
 GS
 0 4 0 0 0 0 0 0 0 0 0 0 
17 Alpha-S1-casein 2 0 2 0 0 0 0 2 0 4 0 0 
18 Alpha-S2-casein 0 0 0 0 0 0 0 0 0 2 0 0 
19 Angiotensinogen 
GS
 0 0 0 2 11 7 0 0 0 0 9 5 
20  Annexin A2 
1a
 4 0 0 0 0 0 0 0 0 0 0 0 
21 Antithrombin-III    
GS
 2 7 9 22 12 5 0 2 16 18 7 5 
22 Apolipoprotein A-I 
 GS
 2 11 11 24 28 28 5 11 17 23 29 31 
23 Apolipoprotein A-II * 0 3 4 6 7 7 3 2 6 5 7 7 
24 Apolipoprotein A-IV* 11 15 17 21 25 26 6 14 20 19 30 26 
25 Apolipoprotein B-100 
 GS
 0 11 3 3 45 54 0 6 0 2 8 56 
26 Apolipoprotein C-I * 0 4 3 4 3 3 0 6 6 4 4 4 
27 Apolipoprotein C-II * 0 3 5 5 2 3 0 4 5 5 3 4 
28 Apolipoprotein C-III 
G
 2 3 6 4 2 3 2 5 5 5 3 4 
29 Apolipoprotein C-IV * 0 0 0 0 0 0 0 2 0 0 0 0 
30 Apolipoprotein D
 GS
 0 6 5 7 6 5 0 5 7 7 7 5 
31 Apolipoprotein E 
 G
 2 3 5 11 15 20 3 5 9 8 19 22 
32 Apolipoprotein F 
G
 0 2 0 0 0 0 0 2 2 2 0 0 
33 Apolipoprotein L1
 G
 0 0 4 5 6 10 0 0 5 6 5 10 
34 Apolipoprotein M  
GS
 0 0 5 5 3 4 0 0 5 6 3 4 
35 Apolipoprotein(a)  
1a
 2 3 2 0 0 0 2 2 2 0 0 0 
36  Arginase-1 
1a
 2 0 0 0 0 0 0 0 0 0 0 0 
37 Asialoglycoprotein receptor 2 
1a G
 0 0 0 0 0 0 0 2 0 0 0 0 
38 Attractin 
1a
 0 0 3 0 0 0 0 0 4 3 0 0 
39 Beta-2-glycoprotein 1  
GS
 9 9 7 5 3 3 8 9 6 9 3 5 
40 Beta-2-microglobulin  
GS





41 Beta-Ala-His dipeptidase 
1a
 0 0 0 0 2 11 0 0 0 0 0 10 
42 Beta-casein 0 0 0 0 0 0 0 0 0 2 0 0 
43 Bleomycin hydrolase  
1a
 3 0 0 0 0 0 0 0 0 0 0 0 
44 C4b-binding protein alpha chain  
G
 0 5 10 5 3 3 0 11 12 11 5 5 
45 C4b-binding protein beta chain 
G
 0 2 0 0 0 0 0 2 0 0 0 0 
46 Cadherin-5  
1a GS
 0 6 2 0 0 0 0 9 4 4 0 0 
47 Calmodulin-like protein 3  0 0 2 0 0 0 0 0 0 0 0 0 
48 Calmodulin-like protein 5 
1a
 0 0 2 0 0 0 0 0 0 0 0 0 
49 Calpain-1 catalytic subunit  
1a
 2 0 0 0 0 0 0 0 0 0 0 0 
50 Calumenin 
GS
 0 0 0 0 0 0 0 3 0 0 0 0 
51 Carboxypeptidase N catalytic chain 
1a GS
 
0 0 5 11 7 4 0 0 10 12 4 3 
52 Carboxypeptidase N subunit 2  
GS
 0 0 0 0 10 10 0 0 0 0 0 13 
53 Cartilage acidic protein 1  
1a G
 0 0 2 0 0 0 0 0 4 2 0 0 
54 Caspase-14 
1a *
 6 0 0 0 0 0 0 0 0 0 0 0 
55 Catalase 
1a
 3 0 0 0 0 0 0 0 0 0 0 0 
56 Cathelicidin antimicrobial peptide  
1a
 
0 0 2 3 0 0 0 0 2 2 0 0 
57 Cathepsin D 
GS
 2 0 0 0 0 0 0 0 0 0 0 0 
58 Cationic trypsin 2 0 0 0 0 0 3 0 0 0 0 0 
59 CD5 antigen-like  * 0 0 0 2 3 3 0 0 0 4 6 4 
60 Ceruloplasmin  
GS
 0 10 28 33 22 19 0 5 28 34 24 26 
61 Cholinesterase 
1a
 0 0 0 0 0 0 0 0 0 0 2 0 
62 Clusterin 
GS
 0 5 13 19 10 8 0 4 17 18 8 10 
63 Coagulation factor IX 
1a GS
 0 6 8 6 0 0 0 2 12 11 2 0 
64 Coagulation factor V 
1a G
 0 5 0 0 0 0 0 5 2 2 0 0 
65 Coagulation factor VII 
1a
 0 0 0 3 0 0 0 0 0 3 0 0 
66 Coagulation factor X 
1a





67 Coagulation factor XII 
GS
 0 3 4 2 6 2 0 0 6 4 2 2 
68 Coagulation factor XIII B chain 
1a
 21 31 14 7 2 0 20 33 12 14 4 2 
69 Collectin-11 
1a
 0 0 0 0 0 0 0 0 0 2 0 0 
70 Complement C 
GS
 0 0 0 0 27 20 0 0 0 0 2 14 
71 Complement C1r subcomponent  
GS
 
0 9 18 16 13 4 0 0 24 21 7 3 




0 0 0 0 0 0 0 3 2 2 0 0 
73 Complement C1s subcomponent  
GS
 
0 0 17 19 6 2 0 0 14 15 6 2 
74 Complement C2  
G
 0 0 0 0 0 0 0 0 0 0 0 2 
75 Complement C3  
G
 3 15 15 50 82 99 2 4 2 12 58 98 
76 Complement C4 beta chain 
 G
 0 0 0 15 37 36 0 0 0 8 46 36 
77 Complement C4-B  
G
 0 0 0 0 2 2 0 0 0 0 2 3 
78 Complement component C6  
G
 0 3 11 3 0 0 0 0 12 8 0 0 
79 Complement component C7 
G
 0 0 4 0 0 0 0 0 4 4 0 0 




0 0 0 0 0 0 0 0 0 2 0 0 




0 0 0 0 0 0 0 0 0 2 0 0 
82 Complement component C9 
G
 0 0 0 5 2 0 0 0 0 4 0 0 
83 Complement factor B 
G
 0 0 11 13 2 3 0 3 11 13 6 3 
84 Complement factor H 
G
 53 52 30 16 16 19 45 52 36 31 20 24 




2 4 0 0 0 0 4 3 0 0 0 0 




0 2 0 0 0 0 2 2 0 0 0 0 













0 0 0 0 0 0 0 2 0 0 0 0 
89 Complement factor I  
G
 0 10 17 14 5 6 0 3 22 17 9 4 
90 Corneodesmosin  
1a GS
 2 0 0 0 0 0 0 0 0 0 0 0 
91 Cornifin-A  
1a
 0 0 2 0 0 0 0 0 0 0 0 0 
92 Cystatin-A  
1a GS
 2 0 0 0 0 0 0 0 0 0 0 0 
93 Dermcidin
 1a
 2 2 0 0 0 0 2 0 0 0 0 0 
94 Desmocollin-1 
1a GS
 4 0 0 0 0 2 0 0 0 0 0 0 
95 Desmoglein-1  
1a GS
 11 0 0 0 0 0 0 0 0 0 0 0 
96 Desmoplakin 
1a *
 23 0 8 0 3 4 5 0 0 0 0 0 
97 EGF-containing fibulin-like 
extracellular matrix protein 1 
1a  G
 
0 0 0 0 0 0 0 0 0 0 0 2 
98 Elongation factor 1-alpha 1 
1a
 0 0 2 0 0 0 0 0 0 0 0 0 
99 Extracellular matrix protein 1 
 1aG
 2 3 0 0 0 0 3 3 0 0 0 0 
100 Extracellular serine/threonine 
protein kinase FAM20C  
G
 
0 0 0 0 0 0 0 0 2 0 0 0 
101 Fetuin-B 
1a GS
 0 4 7 7 0 0 0 4 8 7 0 0 
102 Fibrinogen alpha chain  
GS
 5 3 3 0 0 0 5 3 4 2 0 2 
103 Fibronectin  
GS
 4 4 3 7 36 41 3 4 2 10 47 40 
104  Fibulin-1 
GS
 0 0 3 3 0 0 0 0 4 4 0 0 
105 Ficolin-2 
1a GS
 0 0 0 0 0 0 0 2 4 4 0 0 
106 Ficolin-3 
1aGS
 0 0 0 3 3 4 0 0 2 3 4 4 
107 Filaggrin-2 
1a
 9 0 0 0 0 3 0 2 0 2 0 0 
108 Galectin-3-binding protein 
1a GS
 0 2 0 0 7 8 0 3 0 0 0 14 
109 Galectin-7 
1a GS
 0 0 3 0 0 0 0 0 0 0 0 0 




0 0 2 0 0 0 0 0 2 2 0 0 





112 Gasdermin-A  3 0 0 0 0 0 0 0 0 0 0 0 
113 Gelsolin 
1a
 0 0 0 0 0 0 0 0 0 3 0 0 
114 Glutathione peroxidase 3  0 0 0 0 0 0 0 0 2 0 0 0 
115 Glutathione S-transferase P 
1a





4 0 5 0 0 0 0 0 0 0 0 0 
117 Haptoglobin 
GS
 8 24 28 28 23 22 3 25 28 28 23 21 
118 Haptoglobin-related protein 
1a *
 0 0 5 5 3 4 0 0 5 5 4 4 
119 Heat shock protein beta-1 
1a
 0 0 2 0 0 0 0 0 0 0 0 0 
120 Heat shock protein HSP 90-beta 
1a
 0 0 2 0 0 0 0 0 0 0 0 0 
121 Hemoglobin subunit alpha 
G
 0 0 3 2 0 2 0 0 7 8 4 4 
122 Hemoglobin subunit beta 
G
 0 0 3 3 0 6 0 3 9 10 7 6 
123 Hemopexin  
GS
 0 12 14 11 5 3 0 13 18 12 5 4 
124 Heparin cofactor 2 
GS
 0 0 0 0 4 3 0 0 0 0 2 2 
125 Histidine ammonia-lyase   2 0 0 0 0 0 0 0 0 0 0 0 
126 Histidine-rich glycoprotein  
GS
 0 20 15 10 5 6 0 19 12 13 7 8 
127 Histone H2A type 1-B/E 
1a 
 0 0 2 0 0 0 0 0 0 0 0 0 
128 Histone H2B type 2-F 
1a
 0 0 2 0 0 0 0 0 0 0 0 0 
129 Histone H4 
1a
 0 0 4 0 0 0 0 0 0 0 0 0 
130 Hornerin 
1a*
 0 0 2 0 0 3 3 0 0 2 0 0 
131 Hyaluronan-binding protein 2 * 0 8 6 2 0 0 0 10 6 4 2 0 
133 Ig alpha-1 chain C region 
G
 0 0 8 11 12 9 0 2 10 11 10 9 
134 Ig alpha-2 chain C region
 G
 0 0 0 2 0 2 0 0 2 2 0 0 
135 Ig delta chain C region  
1aG
 0 0 2 0 0 0 0 0 0 0 0 0 
136 Ig gamma-1 chain C region 
G
 4 3 6 0 2 3 0 2 2 2 2 4 
137 Ig gamma-2 chain C region 
G
 0 0 3 0 0 0 0 0 0 0 0 0 
138 Ig heavy chain V-III region BRO * 0 0 0 2 2 2 0 0 0 0 2 2 






140 Ig kappa chain C region * 3 5 6 7 7 7 3 5 6 7 7 6 
141 Ig kappa chain V-I region EU*  0 0 0 0 0 0 0 0 0 2 0 0 
142 Ig kappa chain V-II region TEW*  0 0 0 0 0 0 0 0 0 2 0 0 
143 Ig kappa chain V-III region B6 * 0 0 0 2 0 0 0 0 0 0 0 0 
144 Ig kappa chain V-III region WOL*  2 2 0 2 2 3 2 2 2 3 3 2 
145 Ig kappa chain V-IV region Len * 0 0 0 0 0 2 0 0 0 2 0 2 
146 Ig lambda chain V-I region HA * 0 2 0 2 2 0 0 0 0 0 2 0 
147 Ig lambda chain V-III region LOI*  0 0 0 2 0 2 0 0 0 2 0 0 
148 Ig lambda chain V-III region SH * 0 0 0 2 2 0 0 0 0 2 0 0 
149 Ig lambda-2 chain C regions * 0 2 0 2 2 2 0 2 2 2 2 2 
150 Ig mu chain C region 
GS
 0 0 4 13 13 14 0 0 7 13 13 13 
151 Immunoglobulin J chain 
GS
 0 0 0 3 3 3 0 0 3 3 3 3 
152 Immunoglobulin lambda-like 
polypeptide 5 * 
2 2 3 5 5 4 2 3 4 4 4 5 
153 Insulin-like growth factor-binding 
protein 3  
0 0 0 0 0 0 2 0 0 0 0 0 
154  Insulin-like growth factor-binding 
protein complex acid labile subunit 
GS
 
2 0 0 0 3 0 0 0 0 0 6 0 




0 2 2 20 24 15 0 0 0 5 26 12 




3 3 3 12 27 14 2 2 0 2 29 17 




0 0 0 2 0 0 0 0 0 0 0 0 




0 4 7 8 18 22 0 4 10 10 24 23 
159 Junction plakoglobin 
1a*







 0 0 0 0 2 3 0 0 0 0 6 3 
161 Keratin, type I cytoskeletal 10 
1a*
 25 20 20 24 26 24 19 22 20 24 23 19 
162 Keratin, type I cytoskeletal 14 
1a*
 24 11 25 15 6 16 17 12 3 10 9 10 
163 Keratin, type I cytoskeletal 15 
1a*
 0 0 3 0 0 0 0 0 0 0 0 0 
164 Keratin, type I cytoskeletal 16  
1a*
 15 5 11 10 0 9 8 8 0 0 2 0 
165 Keratin, type I cytoskeletal 17 
1a*
 7 0 14 2 0 3 2 3 0 0 0 0 
166 Keratin, type I cytoskeletal 9* 23 15 15 18 14 22 17 14 13 19 14 16 
167 Keratin, type II cytoskeletal 1* 36 25 24 29 27 29 27 26 22 29 23 26 
168 Keratin, type II cytoskeletal 1b*  17 0 0 0 0 2 0 5 0 0 0 0 
169 Keratin, type II cytoskeletal 2 
epidermal* 
44 26 24 26 26 40 26 25 19 26 19 23 
170 Keratin, type II cytoskeletal 5 
1a*
 21 6 21 8 6 12 14 7 3 5 4 4 
171 Keratin, type II cytoskeletal 6A * 5 2 5 2 0 3 6 3 0 0 0 0 
172 Keratin, type II cytoskeletal 6B * 25 3 29 15 3 18 20 9 2 3 5 2 
173 Keratin, type II cytoskeletal 78* 7 0 0 0 0 0 0 0 0 0 0 0 
174 Keratin, type II cytoskeletal 80 * 9 0 0 0 0 0 0 0 0 0 0 0 
175 Keratinocyte proline-rich protein  6 0 0 0 2 4 0 2 0 0 0 0 
176  Kininogen-1 
GS
 7 22 20 17 13 15 5 27 22 22 15 11 
177 Leucine-rich alpha-2-glycoprotein  
GS
 





0 0 0 0 0 0 0 0 0 0 0 3 
179 Lumican  
GS
 0 0 4 3 0 0 0 0 7 3 0 0 




0 0 0 0 0 0 0 0 2 3 0 0 
181 Mannan-binding lectin serine 
protease 2  
0 0 0 0 0 0 0 2 0 0 0 0 









0 0 0 3 0 0 0 0 0 0 0 0 
184 Myosin-9  
1a
 0 0 2 0 0 0 0 0 0 0 0 0 
185 N-acetylglucosamine-1-
phosphotransferase subunit gamma 
1a GS
 





0 0 0 3 0 0 0 0 0 2 0 0 
187 Neutrophil defensin 1  0 0 0 0 0 2 0 0 0 0 0 0 
188 Out at first protein homolog  0 0 2 0 0 0 0 0 2 2 0 0 









0 0 0 4 2 0 0 0 0 4 3 3 
191 Phosphatidylinositol-glycan-
specific phospholipase D  
1a GS
 
0 0 0 0 9 12 0 0 0 0 11 17 
192 Phosphoglycerate mutase 2 
1a
 0 0 3 0 0 0 0 0 0 0 0 0 
193 Phospholipid transfer protein  
1aG
 0 0 0 0 3 3 0 0 0 0 0 3 
194 Plasma kallikrein heavy chain 0 0 3 0 4 4 0 0 7 7 5 4 
195 Plasma protease C1 inhibitor 0 0 0 0 9 7 0 0 0 0 11 9 
196 Plasma serine protease inhibitor 
 1a
 0 0 0 0 0 4 0 0 0 0 0 6 
197 Plasminogen 0 30 21 2 2 0 0 36 8 8 2 2 
198 Plectin  
1a
 2 0 0 0 0 0 0 0 0 0 0 0 
199 Plexin domain-containing protein 2 
1a
 
0 0 0 0 0 0 0 0 0 2 0 0 
200 Pregnancy zone protein  
1a GS
 0 0 0 0 17 23 0 0 0 0 0 20 
201 Pregnancy-specific beta-1-
glycoprotein 1  
GS
 
0 0 0 0 0 0 0 7 5 5 0 0 





glycoprotein 2  
GS
 
203 Prenylcysteine oxidase 1 
1a G
 0 0 0 0 0 3 0 0 0 0 0 4 
204 Protein AMBP 
GS
 0 5 7 12 9 7 0 4 7 9 11 5 
205 Protein S100-A11 
1a
 0 0 2 0 0 0 0 0 0 0 0 0 
206 Protein S100-A7 
1a
 0 0 3 0 3 0 0 0 0 0 0 0 
207 Protein S100-A8 
1a
 0 0 2 0 0 0 0 0 0 0 0 0 
208 Protein S100-A9  0 0 5 2 2 3 0 0 2 3 0 0 









7 0 0 0 0 0 0 0 0 0 0 0 
211 Protein-glutamine gamma-
glutamyltransferase K  
3 0 0 0 0 0 0 0 0 0 0 0 
212 Prothrombin  2 6 11 19 4 5 2 6 20 21 6 6 
213 Retinol-binding protein 4 0 4 4 4 3 0 0 4 5 3 4 2 
214 Secreted phosphoprotein 24 
1a
 0 2 0 0 0 0 0 3 0 0 0 0 
215 Selenoprotein P 
1aG
 3 7 2 0 0 0 5 7 5 5 0 4 
216 Semenogelin-1 
1a
 0 2 0 0 0 0 0 0 0 0 0 0 
217 Serotransferrin  
GS
 0 41 31 22 10 13 3 43 46 30 13 14 
218 Serpin B12  3 0 0 0 0 0 0 0 0 0 0 0 
219 Serum albumin 17 45 57 50 41 39 10 29 55 52 42 40 
220 Serum amyloid A-1 protein  
GS
 0 0 0 0 0 0 0 0 3 2 0 0 
221 Serum amyloid A-4 protein 
GS
 0 0 4 6 4 5 0 2 5 5 3 3 
222 Serum amyloid P-component 
 GS
 0 0 6 6 4 5 0 0 6 7 5 5 
223 Serum paraoxonase/arylesterase 1  
GS
 
0 0 0 5 9 7 0 0 3 5 9 8 
224 Serum paraoxonase/lactonase 3 
1a G
 0 0 0 0 2 3 0 0 0 2 3 3 
225 Sex hormone-binding globulin  
1a G





G, glycoprotein; GS, sialylated glycoprotein; 1a, low abundance protein (few ng to sub g/mL level); *, non-glycoprotein.  
226 Small proline-rich protein 2E G 0 0 0 0 2 0 0 0 0 0 0 0 
227 Suprabasin  
1a
 2 0 0 0 0 0 0 0 0 0 0 0 
228 Tetranectin  0 7 5 2 0 0 0 7 4 2 0 0 
229 Thioredoxin 
1a
 3 0 0 0 0 0 0 0 0 0 0 0 
230 Transthyretin 5 8 9 8 6 6 0 8 9 8 4 3 
231 Trypsin 
1a
 4 4 4 3 3 3 4 4 4 4 2 3 
232 Tubulin alpha-1B chain  0 0 5 0 0 0 0 0 0 0 0 0 
233 Tubulin beta-4A chain 
1a
 0 0 3 0 0 0 0 0 0 0 0 0 
234 Ubiquitin* 2 0 0 0 0 0 0 0 0 0 0 0 
235 Vitamin D-binding protein  
GS
 0 0 15 7 0 0 0 0 18 13 0 0 
236 Vitamin K-dependent protein C  
1a
 0 0 7 6 0 0 0 0 8 8 0 0 
237 Vitamin K-dependent protein S  0 0 0 10 6 3 0 0 3 8 6 7 




0 2 0 0 0 0 0 3 0 0 0 0 
239 Vitronectin  
GS
 0 8 11 7 6 4 0 9 12 10 5 5 
240 Zinc-alpha-2-glycoprotein  
GS






PROTEINS IDENTIFIED BY THE LC/MS ANALYSIS OF THE SNA CAPTURED PROTEINS FRACTIONATED ON THE 
RPC COLUMN FROM DISEASE- FREE AND CANCER SERA USING M13 COLUMN. DATA ON GS WERE FROM REFS. 
[6, 14, 15, 24, 26, 32, 34, 39, 42, 48, 56, 62-64, 67, 70, 73, 74] 
 
  Average spectral count for disease-free 
serum 




Fr#2 Fr#3 Fr#4 Fr#5 Fr#6 Fr#1 Fr#2 Fr#3 Fr#4 Fr#5 Fr#6 
1 Actin, cytoplasmic 1 * 0 0 0 0 0 0 0 0 0 0 0 11 
2 Afamin 
GS
 0 32 41 7 0 0 0 23 38 13 0 0 
3 Alpha-1-acid glycoprotein 1  
GS
 12 11 5 2 3 0 15 10 8 5 3 0 
4 Alpha-1-acid glycoprotein 2 
GS
 8 10 0 0 0 0 10 14 0 0 0 0 
5 Alpha-1-antichymotrypsin 
GS
 0 10 44 28 22 22 0 10 24 26 19 12 
6 Alpha-1-antitrypsin 
GS
 28 86 141 107 58 49 13 67 98 100 52 27 
7 Alpha-1B-glycoprotein 
GS
 22 15 4 4 3 3 17 18 6 5 4 0 
8 Alpha-2-antiplasmin 
GS
 3 0 10 14 13 9 0 0 15 24 34 3 
9 Alpha-2-HS-glycoprotein 
GS
 23 21 21 17 17 11 17 21 15 12 14 13 
10 Alpha-2-macroglobulin 
GS
 6 4 17 64 134 161 0 2 11 56 157 115 
11 Alpha-S1-casein 0 0 0 5 0 0 0 0 0 0 0 0 
12 Angiotensinogen 
GS
 0 0 14 18 17 10 0 0 8 20 16 5 
13 Annexin A1  
1a







 0 0 0 0 0 4 0 0 0 0 0 4 
15 Antithrombin-III 
GS
 4 47 27 19 13 11 3 35 21 8 9 4 
16 Apolipoprotein A-I  
GS
 30 92 145 128 88 79 21 91 141 119 99 61 
17 Apolipoprotein A-II * 8 10 18 17 17 17 5 13 17 17 19 10 
18 Apolipoprotein A-IV * 33 42 57 52 43 32 25 38 50 41 48 30 
19 Apolipoprotein B-100 
GS
 17 17 18 81 120 125 5 7 6 17 71 34 
20 Apolipoprotein C-I * 10 16 3 4 4 4 7 14 4 0 7 2 
21 Apolipoprotein C-II * 5 14 6 3 4 3 3 12 4 0 4 4 
22 Apolipoprotein C-III 
G
 10 12 6 3 4 4 7 12 5 0 5 0 
23 Apolipoprotein D 
GS
 6 11 20 11 8 7 2 10 19 13 9 4 
24 Apolipoprotein E 
G
 9 31 25 25 23 23 9 19 20 19 26 11 
25 Apolipoprotein F 
G
 0 0 0 0 0 0 3 0 0 0 0 0 
26 Apolipoprotein L1
 G
 0 11 4 5 6 6 0 10 6 6 13 4 
27 Apolipoprotein M 
GS
 0 13 5 5 5 4 0 14 5 4 5 0 
28 Apolipoprotein(a) 
1a
 3 4 0 0 0 0 3 2 0 0 0 0 
29  Attractin 
1a
 0 9 2 0 0 0 0 12 3 0 0 0 
30 Beta-2-glycoprotein 1 
GS
 37 11 10 6 5 3 38 17 15 8 10 3 
31 Beta-2-microglobulin 
GS
 4 0 0 0 0 0 6 0 0 0 0 0 
32 Beta-Ala-His dipeptidase 
1a
 0 0 0 3 5 0 0 0 0 0 15 0 
33 Beta-casein 0 0 0 0 0 0 0 0 0 3 0 0 
34 
C4b-binding protein alpha chain 
G
 
2 13 14 5 6 0 0 5 2 0 2 2 
35 C4b-binding protein beta chain 
G
 0 3 0 0 0 0 0 0 0 0 0 0 
36 Carboxypeptidase B2  
1a GS
 0 0 4 0 0 0 0 0 7 0 0 0 
37 




0 17 15 4 4 3 0 27 17 4 5 0 
38 Carboxypeptidase N subunit 2 
GS
 0 0 0 4 20 25 0 0 0 8 22 14 








40 Cationic trypsin 3 0 0 0 0 0 0 0 0 0 0 0 
41 CD5 antigen-like * 0 4 10 9 6 3 0 0 10 7 11 3 
42 Ceruloplasmin 
GS
 6 69 65 42 37 36 5 83 65 54 45 30 
43 Cholinesterase 
1a 
 0 0 4 0 0 0 0 0 4 4 4 3 
44 Clusterin  
GS
 11 31 20 16 11 7 9 28 15 8 10 6 
45 Coagulation factor IX 
1a GS
 0 3 0 0 0 0 0 4 0 0 0 0 
46 Coagulation factor V 
1a GS
 3 0 0 0 0 0 0 0 0 0 0 0 
47 Coagulation factor XII 
GS
 4 8 10 10 6 0 4 13 5 0 4 0 
48 




13 0 0 0 0 0 9 0 0 0 0 0 
49 
Complement C1r subcomponent 
GS
 
14 32 24 20 4 0 14 44 16 11 3 0 
50 
Complement C1r subcomponent-
like protein  
1a GS
 
0 5 4 4 0 0 0 7 4 0 0 0 
51 
Complement C1s subcomponent 
GS
 
0 26 11 6 3 0 0 28 12 4 3 0 
52 Complement C2 
G
 0 0 0 2 6 0 0 0 0 7 12 0 
53 Complement C3  
GS
 13 81 154 213 248 196 8 37 153 214 342 148 
54 Complement C4-A  
GS
 0 0 104 82 0 0 0 0 0 0 0 0 
55 Complement C4-B  
GS
 0 33 106 84 67 66 0 25 93 111 91 61 
56 Complement C5  
G
 0 0 2 12 28 28 0 0 0 7 51 20 
57 Complement component C6 
G
 7 12 0 0 0 0 8 20 0 0 0 0 
58 Complement component C7 
G
 0 2 0 0 0 0 0 9 0 0 0 0 
59 




0 18 6 3 4 2 0 9 5 3 3 0 
60 














0 14 8 3 3 2 0 8 3 0 2 0 
62 Complement component C9  
G
 0 2 3 0 0 0 0 3 4 0 0 0 
63 Complement factor B 
G
 5 35 17 8 7 0 10 41 23 12 15 4 
64 Complement factor H  
GS
 173 76 64 55 48 19 153 84 61 36 38 30 
65 Complement factor H  76 0 0 0 0 0 69 0 0 0 0 0 
66 
Complement factor H-related 
protein 1  
GS
 
26 8 8 0 0 0 21 12 6 0 0 0 
67 
Complement factor H-related 
protein 2  
GS
 
15 4 5 0 0 0 17 6 3 2 0 0 
68 




10 0 0 0 0 0 10 0 0 0 0 0 
69 Complement factor I  
G
 23 44 28 22 14 7 25 65 25 18 17 11 
70 Corticosteroid-binding globulin  0 0 0 4 4 2 0 0 0 3 4 3 
71 Cystatin-B  
1a GS
 0 0 0 0 0 0 0 0 0 0 0 5 
72 Dermcidin 
1a
 2 0 3 0 0 0 0 0 0 0 0 4 
73 Desmocollin-1 
1a GS
 0 0 0 0 0 3 0 0 0 0 0 0 
74 Desmoglein-1  
1a GS
 0 0 0 0 0 8 0 0 2 0 0 3 
75 Desmoplakin  
1a*
 6 5 0 0 3 22 0 0 4 0 5 25 
76 Elongation factor 1-alpha 1 
1a 
 0 0 0 0 0 0 0 0 0 0 0 4 
77 Extracellular matrix protein 1G 0 0 0 0 0 0 7 0 0 0 0 0 
78 Fetuin-B 
1a GS
 6 14 10 4 2 0 4 15 6 4 4 0 
79 Fibrinogen alpha chain 
GS
 7 0 0 0 0 0 6 0 0 0 0 0 
80 Fibronectin  
GS
 26 24 92 88 83 66 9 12 50 61 68 61 
81 Fibulin-1 
GS
 0 0 3 0 0 0 0 2 3 0 0 0 
82 Ficolin-2 
1a GS
 0 0 0 0 0 0 0 3 0 0 0 0 
83 Ficolin-3 
1a GS
 0 3 5 7 10 7 0 3 5 8 11 4 
84 Filaggrin-2 
1a





85 Galectin-3-binding protein 
1a
 0 0 0 0 6 5 0 0 0 0 6 9 






0 0 0 0 0 2 0 0 0 0 0 0 
88 Haptoglobin 
GS
 79 96 83 75 68 59 74 96 79 72 65 56 
89 Haptoglobin-related protein
 1a*
 38 48 46 44 43 33 0 52 40 41 38 33 
90 Heat shock protein beta-1 
1a G
 0 0 0 0 0 0 0 0 0 0 0 4 
91 Hemoglobin subunit alpha G 0 9 0 0 0 0 9 32 13 8 7 5 
92 Hemoglobin subunit beta G 0 10 7 4 2 0 10 26 16 14 15 12 
93 Hemoglobin subunit delta  0 0 0 0 0 0 0 14 0 0 0 0 
94 Hemopexin 
GS
 35 53 19 14 11 8 23 56 17 14 16 8 
95 Heparin cofactor 2  
GS
 0 0 17 13 10 7 0 4 17 16 12 9 
96 




6 0 0 0 0 0 0 0 0 0 0 0 
97 Histidine-rich glycoprotein  
GS
 32 33 23 21 12 10 20 26 13 14 13 5 
98 Hornerin 
1a *
 0 3 4 0 0 5 0 3 5 0 2 2 
99 Hyaluronan-binding protein 2 * 6 7 0 0 0 0 7 11 0 0 0 0 
100 Ig alpha-1 chain C region 
G
 11 37 42 40 29 30 11 43 36 42 39 28 
101 Ig alpha-2 chain C region 
G
 0 29 33 35 24 0 0 33 28 30 31 0 
102 Ig delta chain C region 
G
 0 3 0 0 0 0 0 0 0 0 0 0 
103 Ig gamma-1 chain C region 
G
 4 3 10 13 12 7 4 4 7 8 8 8 
104 
Ig heavy chain V-II region ARH-
77 * 
0 0 0 4 3 4 0 0 3 0 4 5 
105 Ig heavy chain V-III region BRO
*
 0 4 2 3 3 3 0 0 3 3 0 4 
106 
Ig heavy chain V-III region GAL 
*
 
0 2 4 0 3 0 0 0 4 3 3 0 
107 Ig heavy chain V-III region TIL * 0 0 3 4 3 3 0 3 3 3 4 3 





109 Ig kappa chain V-I region DEE * 0 0 0 0 0 0 0 0 3 0 0 0 
110 
Ig kappa chain V-II region RPMI 
6410 * 
0 0 3 0 0 0 0 0 0 0 0 0 
111 
Ig kappa chain V-III region HAH 
* 
0 4 4 5 2 0 0 3 4 4 3 4 
112 Ig kappa chain V-IV region Len * 0 3 4 2 3 3 0 3 4 0 2 0 
113 Ig lambda chain V region 4A 
1a *
 0 0 3 3 0 3 0 0 3 3 4 0 
114 
Ig lambda chain V-I region 
NEW*  
0 0 3 0 0 0 0 0 0 0 0 0 
115 
Ig lambda chain V-I region WAH 
*
 
0 0 3 3 0 0 0 2 3 0 0 0 
116 
Ig lambda chain V-III region LOI 
*
 
0 0 4 3 4 0 0 2 3 3 3 0 
117 Ig lambda chain V-III region SH*  0 3 6 2 3 0 0 3 4 0 4 0 
118 Ig lambda-2 chain C regions 
GS
 0 15 18 15 17 15 10 15 17 15 17 15 
119 Ig mu chain C region 
GS
 5 23 35 39 42 28 0 23 37 42 47 28 
120 IgGFc-binding protein  
1a G
 0 0 0 0 0 0 0 0 0 0 3 6 
121 Immunoglobulin J chain 
GS
 3 5 5 6 6 4 0 4 5 7 5 5 
122 
Immunoglobulin lambda-like 
polypeptide 5  
6 11 15 11 13 10 8 10 14 14 12 10 
123 




5 0 0 0 0 0 0 0 0 0 0 0 
124 
 Insulin-like growth factor-










3 33 55 42 27 16 0 13 48 54 39 18 
126 
Inter-alpha-trypsin inhibitor 
heavy chain H2  
GS
 







heavy chain H3 
GS
 
0 5 14 0 0 0 0 2 15 0 0 0 
128 
Inter-alpha-trypsin inhibitor 
heavy chain H4 
1a GS
 
10 45 50 33 35 34 9 48 77 64 68 39 
129 Junction plakoglobin
 1a
 0 0 0 0 0 7 0 0 0 0 0 4 
130 Junction plakoglobin  0 0 0 0 0 38 0 0 0 0 0 0 
131 Kallistatin 
GS
 0 0 10 13 7 3 0 4 9 25 14 4 
132 Keratin, type I cuticular Ha3-II 
1a
 0 0 0 0 0 0 0 0 0 0 9 0 
133 Keratin, type I cytoskeletal 10 
1a
 58 59 64 44 57 83 38 56 64 57 63 57 
134 Keratin, type I cytoskeletal 13 
1a
 0 22 0 0 20 0 0 0 0 16 14 60 
135 Keratin, type I cytoskeletal 14 
1a
 33 38 31 31 31 70 17 22 38 29 36 42 
136 Keratin, type I cytoskeletal 16
 1a
 36 47 25 32 35 77 0 19 34 31 39 50 
137 Keratin, type I cytoskeletal 17 
1a
 24 27 21 20 23 52 0 0 28 21 23 38 
138 Keratin, type I cytoskeletal 9 65 64 52 35 43 111 32 50 48 40 55 53 
139 Keratin, type II cuticular Hb4 0 0 0 0 0 0 0 0 0 0 8 0 
140 Keratin, type II cuticular Hb6 0 0 0 0 0 0 0 0 0 0 5 0 
141 Keratin, type II cytoskeletal 1 83 74 74 49 71 104 42 70 72 71 77 78 
142 Keratin, type II cytoskeletal 1b  0 0 0 0 0 0 0 0 0 5 0 0 
143 
Keratin, type II cytoskeletal 2 
epidermal 
71 59 67 37 57 89 27 54 60 52 74 64 
144 Keratin, type II cytoskeletal 4  0 8 0 0 5 0 0 0 0 0 6 72 
145 Keratin, type II cytoskeletal 5 
1a
 41 37 37 22 32 69 11 26 38 26 40 63 
146 Keratin, type II cytoskeletal 6A  34 36 0 25 33 81 0 0 37 25 43 64 
147 Keratin, type II cytoskeletal 6B 33 36 20 21 31 82 9 18 39 22 45 67 
148 Keratin, type II cytoskeletal 78  0 0 0 0 0 5 0 0 0 0 0 5 
151 Keratinocyte proline-rich protein  0 2 5 0 3 7 0 2 3 5 4 4 
152 Kininogen-1  63 60 42 23 20 16 76 81 52 32 38 23 



















0 0 0 0 0 4 0 0 0 0 3 3 
156 Lumican 
1a GS
 0 3 0 0 0 0 0 10 0 0 0 0 
157 Lysozyme C 
1a
 3 0 0 0 0 2 3 0 0 0 0 4 
158 










0 5 2 0 0 0 0 5 0 0 0 0 
160 Neutrophil defensin 1  0 0 0 0 0 3 0 0 0 3 0 0 
161 Ovalbumin 
GS
 0 0 0 0 0 0 0 0 3 0 0 0 
162 Peroxiredoxin-1 
1a
 0 0 0 0 0 0 0 0 0 0 0 4 
163 Peroxiredoxin-2  
1a






0 0 7 0 0 0 0 0 6 0 0 0 
165 
Phosphatidylinositol-glycan-
specific phospholipase D 
1a GS
 
0 0 0 9 11 4 0 0 0 11 14 16 
166  Phospholipid transfer protein 
1a G






0 0 0 0 0 0 0 0 0 0 2 0 
168 Plasma kallikrein heavy chain 
GS
 0 0 6 4 7 3 0 13 5 4 7 3 
169 Plasma protease C1 inhibitor 
GS
 0 5 18 29 18 18 0 4 14 19 16 15 
170 Plasma retinol-binding protein 
G
 7 23 23 14 6 6 13 22 22 18 15 5 
171 




0 0 0 11 7 6 0 0 0 7 17 0 
172 Plasminogen  
GS
 69 33 9 7 3 0 58 37 5 3 5 0 
173 Pregnancy zone protein 
1a GS










0 0 0 0 0 0 3 4 3 0 0 0 
175 Prenylcysteine oxidase 1
1a G
 0 0 0 0 0 0 0 0 0 0 5 0 
176 Prolactin-inducible protein 
1a G
 0 0 0 0 0 2 0 0 0 0 0 2 
177 Protein AMBP 
GS
 18 21 22 21 17 6 14 20 20 20 17 7 
178 Protein S100-A7 
1a
 0 0 0 0 0 4 0 0 0 9 0 0 
179 Protein S100-A8 
1a
 0 0 0 0 0 0 0 0 0 4 0 6 
180 Protein S100-A9  3 4 4 3 4 6 0 3 3 11 4 9 
181 




0 0 4 0 0 0 0 0 3 2 3 0 
182 
Protein-glutamine gamma-
glutamyltransferase E  
1a
 
0 0 0 0 0 0 0 0 0 0 0 3 
183 Prothrombin  16 16 6 5 5 3 6 8 5 3 5 2 
184 Selenoprotein P
 1a G
 5 0 0 0 0 0 6 0 0 0 0 0 
185 Semenogelin-1 
1a
 0 0 0 0 0 5 0 0 0 0 0 0 
186 Serotransferrin 
GS
 120 85 42 24 19 22 99 95 31 20 24 32 
187 Serpin B12  0 0 0 0 0 2 0 0 0 0 0 0 
188 Serum albumin 0 18 0 0 0 0 0 23 0 0 0 0 
189 Serum albumin 171 240 137 101 92 90 156 258 138 119 129 69 
190 Serum amyloid A-4 protein 
GS
 3 13 8 7 6 5 4 14 7 0 3 2 
191 Serum amyloid P-component  
GS
 0 24 18 15 11 9 8 21 16 14 13 9 
192 
Serum paraoxonase/arylesterase 1 
GS
 
0 7 19 14 12 13 0 10 15 14 14 10 
193 Serum paraoxonase/lactonase 3 
1a G
 0 0 0 0 0 0 0 0 4 5 4 0 
194 Sex hormone-binding globulin 
1a G
 0 3 0 0 0 0 0 3 0 0 0 0 
195 Small proline-rich protein 3 
G
 0 0 0 0 0 0 0 0 0 0 0 4 
196 Sulfhydryl oxidase 1 
1a
 0 0 4 0 0 0 0 0 4 0 0 0 
197 Tetranectin 
GS





G, glycoprotein; GS, sialylated glycoprotein; 1a, low abundance protein (few ng to sub g/mL level); *, non-glycoprotein.
198 Thyroxine-binding globulin  
GS
 0 0 0 5 0 0 0 0 0 3 2 0 
199 Transthyretin * 14 17 13 8 4 4 8 23 11 8 7 0 
200 Trypsin 
1a
 14 12 12 9 11 10 12 13 13 12 12 13 
201 Vitamin D-binding protein  
GS
 2 62 5 6 0 0 4 32 0 0 0 0 
202 Vitamin K-dependent protein C 
1a
 4 14 0 0 0 0 5 16 0 0 0 0 
203 Vitamin K-dependent protein S  0 13 36 13 6 6 0 13 35 16 11 7 
204 Vitamin K-dependent protein Z 
1a GS
 0 0 0 0 0 0 4 0 0 0 0 0 
205 Vitronectin 
GS
 11 17 11 10 11 5 9 18 11 8 10 7 
206 von Willebrand factor 
1a GS
 0 0 3 0 0   0           
207 Zinc-alpha-2-glycoprotein 
GS















































  AACT_HUMAN  48 kDa 








T_HUMAN 47 kDa 






 A1BG_HUMAN 54 kDa 




 A2MG_HUMAN 163 kDa 
Down 55 28 
F3-Up Antithrombin-III 
GS
 ANT3_HUMAN  53 kDa 






N 31 kDa 




 APOE_HUMAN 23 KDa 
Up 5 11 
F4-Down Apolipoprotein B 
100 
GS
 APOB_HUMAN 516 KDa 






N 21 kDa 




 APOH_HUMAN 38 kDa 




 FA9_HUMAN 52 kDa 




 FA12_HUMAN 68 kDa 




 F13B_HUMAN 76 kDa 
Up 7 14 
TABLE 8  
DIFFERENTIALLY EXPRESSED PROTEINS IN THE MAL FRACTIONS FROM 
DISEASE-FREE SERUM (DFS) AND CANCER SERUM (CS) FOR THE COLUMN  
ORDER MAL-II  SNA. DATA ON GS WERE FROM REFS. [14, 22, 34, 56, 62, 












F6-Up Complement C1r 
subcomponent 
GS
 C1R_HUMAN 80 kDa 
Up 16 21 
F3-Down Complement C1s 
subcomponent 
GS
 C1S_HUMAN 77 kDa 
Down 18 12 
F3,F4-Down Complement C3 
G
 CO3_HUMAN 187 kDa Down 65 15 
F5,F6-Up Fibronectin 
1aGS




 HBA_HUMAN  15 kDa 
Up 2 8 
F4,F5-Down Inter-alpha-
trypsin inhibitor 
heavy chain H1 
GS
 ITIH1_HUMAN 101 kDa 





heavy chain H2 
GS
 ITIH2_HUMAN  106 kDa 
Down 45 31 
F2-Up Clusterin 
GS





 PSG1_HUMAN 48 kDa 






 PHLD_HUMAN 92 kDa 
Up 9 17 
F3-Up Plasma kallikrein 
heavy chain  
H0YAC1_HUM
AN 77 kDa Up 3 7 
F2,F3,F4-
Down Plasminogen  PLMN_HUMAN 91 kDa 
Up 53 42 
F2,F6-Up Serotransferrin 
GS
 TRFE_HUMAN  77 kDa Up 72 89 
F4-Up Vitronectin 
GS1a







DIFFERENTIALLY EXPRESSED PROTEINS IN THE SNA FRACTIONS FROM DISEASE-
FREE SERUM (DFS) AND CANCER SERUM (CS) FOR THE COLUMN ORDER MAL-II  




































 AACT_HUMAN  48 kDa 




 A2AP_HUMAN 55 kDa 






N 39 kDa 
Up 6 14 










Down  388 158 
F2,F3-Down C4b-binding 
protein alpha chain 
G
 C4BPA_HUMAN 67 kDa 




 CBPB2_HUMAN 48 kDa 
 5 9 
F4-Down Coagulation factor 
XII 
GS
 FA12_HUMAN 68 kDa Down 10 2 


















G, glycoprotein; GS, sialylated glycoprotein; 1a, low abundance protein (few ng to sub g/mL 




Complement C5  
G
 CO5_HUMAN  
188 
kDa 
Up 67 91 
F3-Down Complement 
component C8 
gamma chain  CO8G_HUMAN 22 kDa 
 14 8 






Up 76 84 
F1,F2,F3,F5
-Down Fibronectin 1GS1a FINC_HUMAN  
240 
kDa 




 HBA_HUMAN  15 kDa 






 HBB_HUMAN  16 kDa 






















 5GWP8_HUMAN 66 kDa 
Down 38 4 
F5-Up Kininogen-1 GS KNG1_HUMAN 48 kDa Up 20 38 





 PHLD_HUMAN 92 kDa 
Up 4 16 
F4-Up Protein S100-A7 1a S10A7_HUMAN 11 kDa Up 6 11 





N 53 kDa 






DEPS UNIQUE TO MAL LECTIN AND SNA LECTIN AND COMMON TO BOTH 
LECTINS FOR THE COLUMN ORDER MAL-II  SNA. DATA ON GS WERE 
FROM REFS. [14, 22, 32, 34, 39, 56, 62, 63, 67, 68, 70, 73, 74] 
DEPs unique to MAL 
lectin 
DEPs common to both 
lectins 



















Apolipoprotein L1G Antithrombin-III 
GS





 Apolipoprotein B 100 
GS





 Coagulation factor XII 
GS
 Carboxypeptidase B2 
GS
 
Coagulation factor IX 
GS1a
 Complement C3 G 
Inter-alpha-trypsin 
inhibitor heavy chain H4 
GS
 



















heavy chain H1 
GS
 Complement C5  G 
Inter-alpha-trypsin inhibitor 















Plasma kallikrein heavy 
chain  Complement factor H G 
Plasma kallikrein heavy 
chain   




















G, glycoprotein; GS, sialylated glycoprotein; 1a, low abundance protein (few ng to sub 









































Protein S100-A9  
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polymerization of methacrylate/acrylate monomers in the presence of adequately chosen 
porogens. The nonpolar monoliths for reversed phase chromatography (RPC) involved the co-
polymerization of  (i) octadecyl acrylate (ODA) and trimethyloyl propane triacrylate (TRIM) with 
or without incorporated multiwall carbon nanotubes (MWCNTs) and (ii) glyceryl methacrylate 
(GMM) and ethylene glycol dimethacrylate (EDMA) incorporated with MWCNTs. The affinity 
monoliths were based on the co-polymerization of GMM and pentaerythritol triacrylate (PETA) 
which were further modified with (i) surface immobilized lectins such as Sambucus nigra 
agglutinin (SNA) or Maakia amurensis lectin (MAL) and (ii) antibodies or microbial proteins for 
the depletion of high abundance proteins, e.g., albumin and immunoglobulins (Igs). These 
columns were assembled in a multi column platform consisting of high precision HPLC pumps 
and switching valves to perform the on line the depletion of albumin and Igs, followed by the 
capturing of sialoglycoproteins from human serum and the subsequent fractionation of these 
captured proteins by RPC. The RPC fractions were analyzed by liquid chromatography – tandem 
mass spectrometry (LC-MS/MS) to identify the sialoglycoproteins and to determine their 
differential expression in breast cancer serum with respect to disease free serum. 
Findings and Conclusions: 
 The major findings and conclusions were as follows: while GMM/EDMA-MWCNTs 
monolith proved useful for RPC separations of small chiral and achiral molecules on the basis of 
hydrophobic and π-π interactions, the ODA/TRIM monoliths with or without MWCNTs were 
very effective is separating proteins with improved selectivity when the monolith has 
incorporated MWCNTs. The lectin monolithic columns specific for sialoglycoproteins captured 
selectively these targeted proteins. These captured proteins, which were further fractionated by 
RPC, were readily identified by LC-MS/MS.  In total, the multi column platform in combination 
with LC-MS/MS facilitated the identification of 71 differentially expressed proteins in breast 
cancer serum with respect to healthy serum, thus representing 71 candidate breast cancer 
biomarkers.  
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